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Foreword 
 
This thesis is formed of two different pieces of work and which represent the 
evolution of my scientific interest during the last three years of studies. The first 
part consists of a clinical follow-up of facio-scapulo-humeral dystrophy patients 
and, in a manner, closes a circle that began long time ago when I visited for the 
first time the same patients for my undergraduate thesis. In the meantime, I started 
to be interested in laboratory work and this led me to do some basic research 
projects. As a first bench experience, under the supervision of Professor Elena 
Pegoraro at my home University of Padova, I selected a cohort of female FSHD 
patients, most of them already included in the previous follow-up study, and tried 
to characterise the chromosome X inactivation pattern in order to analyse its role 
as a genetic modifier for the disease. 
During the last years of my residency in Neurology, I was involved in the 
management of the myasthenia gravis unit of my Department. It was an important 
and formative experience that started my interest in the disorders of the 
neuromuscular junction. This, combined with my desire to explore more basic 
research, led me away from Padova and to Oxford. There, under the expert 
supervision of Professors Angela Vincent and David Beeson, I have carried out 
the second project of this thesis on MuSK myasthenia gravis, studying the in vitro 
activity of a potential new therapy able to counteract the pathogenic effects of 
MuSK antibodies. 
These years have been absolutely amazing as I widened my knowledge and 
perspectives thanks to all the extraordinary people I collaborated with. This thesis 
would not have been possible without their help and support and I am honoured to 
have collaborated with each one of them. 
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Part I 
 
Facio-scapulo-humeral dystrophy: clinical follow-up and role of 
chromosome X inactivation in female patients 
 2 
 
Abstract 
 
Facio-scapulo-humeral dystrophy (FSHD) is an autosomal dominant muscular 
dystrophy characterized by high prevalence and clinical variability. It involves 
facial muscles, shoulder girdle and, in most severe cases, the lower limbs. Over 
95% of patients have a contraction of D4Z4 repeated units on chromosome 4q35 
that causes hypomethylation of the region and the overexpression of a toxic factor, 
DUX4. In about 5% of patients, called FSHD2, D4Z4 hypomethylation is due to 
mutations of SMCHD1, a gene involved in the inactivation of chromosome X 
during embryotic development. The aim of this study was to evaluate the clinical 
progression of FSHD over a 5-year follow-up using the Clinical Severity Score 
(CSS), a scale previously validated by the Italian Network for FSHD. 
Furthermore, considering the role of SMCHD1 in the epigenetic control of the 
chromosome X and the differences in severity between genders, the inactivation 
pattern of the chromosome X was analysed in order to test whether it could 
represent a genetic modifier of the disease. 
The sample consisted of 55 FSHD patients (29 males and 26 females) from the 
Neuromuscular Centre of Padova. All subjects carried a pathological D4Z4 
fragment between 17-40 Kb.  Patients who had been evaluated with CSS at T0 
were re-evaluated after an average period of 5 years (T1). The score of each 
muscle region, the total CSS and the MRC score were recorded and compared 
between T0 and T1.  
Chromosome X inactivation was analysed in 38 FSHD1 and 4 FSHD2 females 
measuring the degree of methylation of the CAG repeated sequence of the 
androgen receptor gene. Genomic DNA was digested with methylation-sensitive 
restriction enzymes (HpAII and HhAI), amplified by PCR and finally genotyped. 
48 healthy individuals were studied as controls and X inactivation patterns were 
correlated to muscle impairment measured by CSS. 
After 6 years of follow-up, the mean CSS difference between T0 and T1, and 
MRC score at biceps, triceps and tibialis anterior reached significance only in the 
probands group. There was no difference at shorter follow-up times or between 
relatives. Disease progression appeared independent of the size of D4Z4 fragment 
and no differences were found between genders. X-inactivation pattern was 
normally distributed in patients and controls. There was a moderate linear 
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correlation between the percentage of X-inactivation and the severity of the 
shoulder girdle involvement, but not with any other muscle groups. 
In conclusion, FSHD symptoms progress slowly over time and, although CSS 
represents a valuable tool for patient assessment, it lacks sensitivity for the 
detection of subtle clinical modifications even over a five-year period. Therefore, 
its use in follow-up appears to be limited. Moreover, the X inactivation pattern in 
FSHD patients mirrors the normal distribution observed in healthy females and 
correlates only modestly with the severity of the disease. These latter findings 
suggest that different genetic regulators are involved in the full phenotypic 
expression of the disease, and make evaluation of potential therapies difficult. 
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 Chapter 1 
Introduction 
  
Facio-scapulo-humeral muscular dystrophy (FSHD – OMIN #158900 - 
#158901) is one of the most common dystrophies of adulthood. It is inherited with 
autosomal dominant transmission with a variable severity in its phenotypic 
expression and clinical severity. The pathological mechanisms that cause FSHD 
have not been completely unravelled yet and only in recent years has a new 
pathogenic molecular model, able to explain the disease course and its clinical 
phenotype, been proposed. These novel insights in the pathogenic pathways of 
FSHD might be able to lead towards a deeper understanding of its 
pathophysiology and, hopefully, to new therapeutic approaches. 
 
1.1) Epidemiology 
Facio-scapulo-humeral dystrophy, known also as Landouzy-Dejerine syndrome 
from the names of the French neurologists who described it firsts in 1885, is one 
of the most common muscular dystrophies of adulthood, second only to myotonic 
dystrophy. Its incidence corresponds to 10 new cases per 100.000 population per 
year (Orphanet), but the variability of its phenotypic expression and the presence 
of paucisymptomatic patients are likely to mean that this is an underestimate. 
 FSHD has an autosomal dominant inheritance with a penetrance of 95% by the 
end of the third decade (Lunt et al, 1989; Padberg et al, 2004) although it varies 
significantly with respect to the genotype of each patient (Ricci et al, 2013). Both 
genders are affected, but females seem to have a slower progression of the 
disease, milder phenotype and a higher incidence of asymptomatic carriers 
compared to males (Zatz et al, 1998; Tonini et al, 2003; Ricci et al, 2013). Most of 
the cases described in the literature are familial and only 10% are sporadic 
suggesting that FSHD does not reduce significantly the fertility of the patients or 
their reproductive function in general. 
 
1.2) Clinical features 
 FSHD involves selectively and asymmetrically the muscles of the face, that 
close the eyelids and move the lips (orbicularis oculi and oris respectively), and 
the proximal scapular girdle. In the most severe cases, there is also an impairment 
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of the lower limb that starts from the distal legs and progresses proximally with 
late involvement of the pelvic girdle. 
 The disease presents a high inter- and intra-family variability with respect to 
onset, progression and severity of the symptoms. Most frequently, the onset is in 
the second or third decade but some rare and most severe cases have symptoms at 
the moment of birth with widespread weakness and hypotonia (congenital FSHD 
forms).  
The orbicular muscles of the face are impaired in the first stage of the disease 
with weakness in closing eyelids, moving lips and puffing up cheeks (Figure 1A). 
Generally, muscles of the inferior part of the face are more frequently involved 
compared to those of the upper part. Symptoms of facial impairment consist of 
lagophthalmos, that causes an incomplete closure of the eyelids during sleep, 
inability to whistle and an overall reduction in facial mimicry. Facial weakness 
affects about 90% of patients but due to mild and symmetrical involvement, 
patients are often not aware of it (Mul et al, 2016). 
The shoulder girdle involvement has been reported in about 80% of FSHD 
patients (Wang and Tawill, 2016) and the first sign of impairment usually consists 
of an asymmetric detachment of the scapula from the back (winging scapula, 
Figure 1B). This is due to the weakness of the trapezius and the dentatus anterior 
and causes a progressive difficulty in the abduction of the arms. The winging 
scapula can be observed in the standing rest posture and enhanced by the 
abduction and flexion of the arm (Figure 1C). The selective muscular hypotrophy 
determines the characteristic “sloping” shape of the shoulders together with the 
straight clavicle. Symptoms related to the impairment of the shoulder girdle 
consists in difficulties to raise the arms above the head and to lift weights. From 
the shoulder girdle, the weakness spreads to the proximal part of the upper limb 
involving the biceps and triceps brachii and sparing the deltoid and the distal 
muscles.  
 Involvement of the legs and the pelvic girdle usually occur during the later 
stages of the disease and affect about 20% of patients (Mul et al, 2016).  These 
have an inverse distribution pattern compared to the upper limbs. The muscular 
weakness starts distally with impairment of the tibialis anterior causing a 
characteristic foot drop during gait (steppage). Only in the most severe forms of 
the disease is the pelvic girdle involved causing anserine gait and hyperlordosis  
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Figure 1. Phenotypic features of FSHD. In A: weakness of orbicularis oculi. In B: severe 
asymmetric winging scapula. In C: asymmetric winging scapula with impairment of arm 
abduction. In D: Beevor’s sign. The flexion of the head on the chest causes the umbilicus to rise 
along the mid-line for at least 1 cm. 
 
 
 
posture. In these patients, there is an important impairment of both balance and 
ambulation with necessity to use a wheelchair in some cases.  
With respect to the trunk muscles, the inferior rectus abdominis is selectively 
involved while the superior is usually spared. This asymmetrical impairment of 
the abdominal muscles causes the characteristic Beevor’s sign: the patient is asked 
to flex his head on the chest from the supine position maintaining, at the same 
time, the shoulders on the bed. In case of abdominal muscle weakness, the 
umbilicus will rise upwards along the median line by at least 1 cm (Figure 1D). 
Respiratory function is generally normal in FSHD. A restrictive respiratory 
deficit has been rarely described in very severe patients with a long lasting history 
of disease and seems to be related to secondary modifications of the shape of the 
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rib cage more than a direct involvement of the respiratory muscles (Kilmer et al, 
1995; Wohlgemuth et al. 2004).  
The extraocular muscles, the bulbar district and the heart are selectively spared 
(Tawill et al. 2006). With respect to cardiac involvement, FSHD patients have 
been reported to have a higher frequency of atrial tachiarrythmia and alteration in 
the conduction system although they rarely cause clinical symptoms (Stevenson et 
al, 1990; Trevisan et al, 2006). 
There are some extramuscular signs that, if present in association with the 
characteristic muscular involvement, could sustain the diagnosis of FSHD. 
Between 25% and 60% of patients have an acoustic neusosensitive deficit that 
involve high frequencies. Patients usually are not aware of this impairment but it 
is easily assessed by an audiometric test (Gieron et al, 1985; Balatsouras et al, 
2007). A severe hypoacusis has been described in some cases with juvenile onset 
(Chen et al. 2013). 
The involvement of the ocular retina has a variable frequency. Up to 40% of 
the patients have retinal microaneurisms and telangiectasia, detectable by 
fluorescent angiography, in the absence of symptomatic visual deficits (Padberg et 
al, 1995). In rare cases, retinal involvement can evolve into an exudative 
retinopathy with characteristica similar to those of Coat’s syndrome. This is a 
severe complication that could result in detachment of the retina and loss of sight 
or even complete blindness (Statland et al. 2013). 
The Central Nervous System can also be affected. Cognitive impairment 
associated with generalised epilepsy has been described in neonatal patients (Chen 
et al, 2013). In the more frequent adult forms, brain MRI scans showed slight not-
specific alterations concerning the white matter together with hypotrophy of the 
primary frontal motor cortex on the left side of the brain. None of these changes 
correspond to detectable signs or symptoms in the patients (Quarantelli et al, 
2006). 
With respect to the prognosis, disease progression is generally very slow and 
there is no reduction in life span. On the other hand, in those patient with an early 
onset, there is relevant impairment of muscle function and, therefore, quality of 
life can be markedly reduced. About 20% of patients require the wheelchair 
before the age of 50 (Statland et al, 2013). 
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The diagnosis is based on the clinical symptoms according to the pattern of 
muscular involvement and it is confirmed by molecular analysis. Blood tests and 
other instrumental and histological examinations are not essential to address the 
correct diagnosis. The blood level of Creatine Kinase (CK) is usually raised by up 
to 3-5 folds of the normal value. A raised CK level over 1000 U/L is unusual in 
FSHD and suggests a different diagnosis (Lunt and Harper, 1991). 
Electromyography shows mild myopathic changes with a concomitant 
polyneuropathy. 
Among all the instrumental tests, muscular magnetic resonance (MR) seems to 
be the most useful for both diagnosis and clinical follow-up. The Relaxation Time 
1 (T1) and Short-tau inversion recovery (STIR) weighted MR images are able to 
highlight the typical asymmetric involvement of the shoulder girdle and the distal 
leg that mirrors the muscular weakness observed during the clinical evaluation of 
the patient. STIR weighted images show that muscle inflammation represents the 
first detectable change before a rapid substitution of the muscle fibres with fibro-
adipose tissue. RMN studies allowed to identify the most involved muscles 
(specifically the semimembranosus, gluteus minimus, biceps femoris, and the 
rectus abdominis) and those which are selectively spared (iliopsoas and obturator) 
(Tasca et al, 2016). Moreover, RMN scans are more sensitive compared to clinical 
evaluation to detect early signs of involvement in previously healthy muscles. 
Therefore, RMN could be helpful in detecting paucisymptomatic carriers of the 
mutations among the population of relatives of the proband (Leung et al, 2015). 
 
 
1.3) Muscular histopathology 
In patients affected by FHSD, the muscle biopsy shows nonspecific and 
chronic myopathic changes. There is an increase of fibre size variability and 
central nuclei, with the concomitant presence of atrophic fibres together with 
normotrophic or hypertrophic ones (Figure 2A). In the most severe cases with 
early onset and long lasting disease, there is a marked increase of the connective 
tissue and adipose substitution typical for dystrophic abnormalities (Figure 2B). 
  Typically, there is no sign of denervation or necrosis, but the expression of 
proteins related to development such as the foetal myosin isoform and MHC class 
I suggests the presence of regenerative fibres among the atrophic ones. The high 
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variability observed within the fibres could be related to the type of muscle 
sampled. However, there is no correlation between the clinical severity and the 
histopathologic changes detectable as muscles with substantial weakness can have 
only minor abnormalities in the muscle biopsy (Dubowitz et al, 2007). 
Up to 40% of the biopsies of FSHD patients have a mononuclear inflammatory 
reaction of the endomysium and, less often, the perivascular areas (Padberg et 
al,1982). In some cases, the severity of this immune reaction could be confused 
with a primary inflammatory myopathy (Rothstein et al. 1971). Usually, the 
immune infiltrate consists mainly of CD8+ T cells and some CD4+ T cells along 
the blood vessels. There is no inflammatory invasion inside the muscle cells and 
immune-mediate necrosis has not been observed (Arahata et al, 1995; Frisullo et 
al, 2011). 
Apoptosis seems to be the main cause of cell death in FSHD pathogenesis and 
could be related to activation of caspase 3, and expression of bax and bcl-2 
(Sandri et al, 2001). 
Nowadays, considering the typical phenotypic features, the existence of highly 
sensitive molecular analysis, and the nonspecific histological findings, the role of 
the muscle biopsy in FSHD diagnosis is limited. Therefore, muscle biopsy should 
be performed only in those cases with atypical clinical characteristics and when 
the molecular test results are negative. 
 
 
 
 
 
Figure 2.  FSHD muscle biopsy features. In A: increased fibre size variability and presence of 
central nuclei. In B: increased fibre size variability with angulated atrophic fibres and fibro-
adipose substitution. H&E x200. 
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1.4) Molecular genetic  
 First linkage studies, performed in the 1990s, showed an association of FSHD 
with the subtelomeric region of the chromosome 4 (4q35) (Upadahyaya et al, 
1990; Wijmenga et al, 1990). This is a highly polymorphic region rich in 
sequences recognised by the restriction enzyme EcoRI. The fragment obtained 
after enzymatic restriction contains the region called D4Z4 that, in healthy 
individuals, has 12-100 copies of a tandem repeat sequence of 3.3 Kbs. Each 
tandem repeat is rich in GC and has strict similarities with LSau sequences that 
are characteristic of heterochromatin. Therefore, under physiological conditions, 
this region is silenced for genetic transcription because of its highly methylated 
status. 
 The molecular probes used to identify the D4Z4 locus in the Fluorescent in situ 
hybridisation (FISH) assay also identified other associations with different 
chromosomes, in particular Chr 10 and Y (Hewitt et al, 1994; Winokur et al, 
1994). Further linkage analyses did not confirm these results suggesting a cross-
reaction of the probes with other sequences similar to the D4Z4 region of 
4q35(Gilbert et al. 1995). 
Inside each tandem repeat of the D4Z4 region there is an open reading frame 
(ORF) for the gene Double Homeobox 4 (DUX4), a retrogene that encodes for a 
transcriptional factor made by two homeobox domains (Hewitt et al, 1994; 
Gabriels et al, 1999). DUX4 is normally expressed during the first stages of the 
embryotic development and then is silenced once the cellular differentiation is 
complete. In the adult, it remains actively expressed only in testicular tissue. The 
physiological role of DUX4 is to regulate the activity of retrotrasposomes and 
other several genes implicated in cellular differentiation and in the regulation of 
the immune system (Geng et al, 2012). The first two exons of DUX4 are inside 
every tandem repeat but the remaining coding sequences are located downstream 
of D4Z4. Therefore, only the DUX4 located in the last tandem repeat is able to 
generate a full functional transcript (Lemmers et al, 2012). 
Additional genetic studies ravelled the presence of two different haplotypes in 
the subtelomeric region of chromosome 4q, called 4qA and 4qB (Lemmers et al, 
2002), evenly distributed among the population. These two variants differ in 
several minor polymorphisms located in different parts of the D4Z4 (either 
proximally, distally and inside the tandem repeats). However, the most important 
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region is the distal one as it contains, in the 4qA haplotype, a pLAM sequence 
with a polyadenylation signal. This sequence is absent in the 4qB variant. A 
strong association with the disease has been confirmed only for the 4qA 
polymorphism (Thomas et al, 2007). In addition to these two main haplotypes, 9 
other minor polymorphisms have been reported, but only a few of them (known as 
159, 161 and 168) seem to be significantly correlated with FSHD and they always 
require the combined presence of the major haplotype 4qA (Lemmers et al, 2007; 
Spurlock et al, 2010). 
Further clues to the likely roles of the different haplotypes in the pathogenic 
mechanisms of the disease come from the translocation analyses between 
chromosome 10 and 4. The D4Z4 tandem repeats of the 4q35 have a high degree 
of homology, up to 98%, with 10q26. These two loci have a high frequency of 
reciprocal translocation but, downstream the tandem repeat, the region in 10q26 
lacks the entire haplotype A, that remains characteristic of the chr. 4q35. 
Mutations of 10q26 are not associated with FSHD. These data suggest that, 
considering the similarities of the two chromosome regions, only the particular 
configuration of the different haplotypes on chromosome 4 is able to trigger the 
pathological mechanisms that cause the disease (van Deutekom et al, 1996; 
Lemmers et al, 1998; Lemmers et al, 2010). 
The homology between the D4Z4 and the region on 10q26 requires a complex 
protocol in order to identify only the sequences of the chromosome 4. Samples 
undergo double digestion with two different restriction enzymes: the first 
digestion is done by EcoRI while the second by BlnI. The latter is able to cut 
specifically the sequences of the chromosome 10q leaving intact the D4Z4 
fragment from 4q (Deidda et al, 1996). After the enzymatic restriction, the final 
stage of the genetic analysis consists of pulse-field electrophoresis (PFGE) to 
identify the size of D4Z4 fragment and the number of tandem repeats.  
95% of FSHD patients carry a D4Z4 fragment shorter than 38 Kb that 
corresponds to a number of tandem repeats lower than 10. A D4Z4 fragment with 
a size between 38 and 41 Kb (10 – 11 tandem repeats) is considered borderline 
(Wijmenga et al, 1994; Van Deutekom et al, 1993; Upadhyaya et al, 1997). 
Monosomy of 4q is not associated with the disease and it is necessary to show at 
least 1 tandem repeat to have a clinical manifestation of FSHD (Tupler et al, 
1996). 
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Initially, the first molecular studies focused on the identification of a specific 
gene located near the D4Z4 region, on the assumption that the depletion of the 
tandem repeat could determine a dysregulated expression. It was observed that in 
the presence of a pathological D4Z4 contraction there was a corresponding 
reduction in the methylation degree of the entire region (de Greef et al, 2007). 
DNA methylation of cytosine residues is one of the most relevant epigenetic 
modification that regulates gene expression. Methylated genes are usually 
silenced due to a closed chromatin conformation (heterochromatin) that avoid the 
binding of the transcription complex to the DNA helix.  In FSHD, the reduction of 
methylation degree due to D4Z4 contraction, is thought to induce a 
conformational change of the chromatin (from heterochromatin to euchromatin) 
with the suppression of gene silencing.  Several genes located upstream of the 
4q35 region, such as FRG1, FGR2 and ANT1, has been identified and proposed as 
potential candidates in the pathogenicity of the disease (Van Deutekom et al, 
1996, Gabellini et al, 2002, Rijkers et al, 2004). However, none of them has been 
confirmed to be dysregulated nor to have a significant pathogenic effect. Although 
the overexpression of FRG1 is associated with the development of a muscular 
dystrophy in an animal model, this activation does not occur in FSHD patients 
compared to the control population (Jiang et al, 2003; Winokur et al, 2003). 
The recent identification of the gene DUX4 inside the D4Z4 tandem repeats 
and the association of the disease with the haplotype 4qA have contributed 
significantly to the formulation of the current and most recognised pathogenic 
hypothesis. The contraction of the D4Z4 fragment determines the reduction in 
methylation of the entire region with a consequent relaxation in the chromatin 
status. Therefore, gene expression is reactivated with an enhanced transcription of 
DUX4, previously silenced. However, in order to allow the correct expression of 
DUX4, the contraction of the D4Z4 fragment is not sufficient but the sequences 
downstream of the tandem repeats must contain also the third exon of DUX4 and 
the pLAM polyadenylation sequence of the 4qA haplotype. Only if all these 
conditions are fulfilled, could the expression of the DUX4 gene of the last tandem 
repeat generate a complete and stable mRNA with an efficient protein translation 
(Lemmers et al, 2010, Lemmers et al, 2012) (Figure 3A, B). 
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Figure 3. Schematic representation of the subtelomeric region 4q35. In A: structure of the 
D4Z4 locus formed by several tandem repeats. Upstream and downstream of the D4Z4 
there are the SSLP polymorphisms and the haplotypes 4qA/B respectively. A number of 
tandem repeats lower than 11 is considered pathological and has been associated with 
FSHD. In B: each tandem repeat contains the first two exons of DUX4. The third DUX4 
exon and the polyadenylation sequence pLAM are present only in the haplotype A and 
they are needed for the expression and stabilisation of the DUX4 transcript. In the 
presence of the permissive haplotype 4qA, the contraction of the D4Z4 fragment seems to 
determine the hypomethylation of the whole region with the consequent overexpression 
of DUX4, leading to toxicity and cell death through apoptosis. 
 
 
The overexpression of DUX4 should cause a toxic effect on the muscle due to 
the activation of different pathways leading to cell damage and apoptosis. Under 
physiological conditions, DUX4 has a role in the differentiation of the muscle 
tissue and its overexpression determines the transcription of several genes 
involved in the post-transcriptional processes of proteins, such as splicing factors 
and ubiquitin ligase, and mediators of the inflammatory response (Geng et al, 
2012). In vitro studies on myoblasts collected from FSHD biopsies showed an 
increase in the expression of the transcriptional factor PITX1 mediated by DUX4 
(Dixit et al, 2007) and p53 induced apoptosis has also been reported (Kowaljow et 
al, 2007; Wallace et al, 2011). The apoptosis phenomenon could be related to the 
induction of the differentiation programme on the adult muscle by DUX4 (Endo et 
al. 1998). Moreover, the alteration of the protein expression pattern caused by the 
abnormal transcription of splicing and ubiquitin proteins could determine protein 
catabolism and muscular atrophy. Finally, the activation of other regulator 
proteins, such as DEFB103, could reduce myoblast regeneration and antigen 
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tolerance with the induction of local inflammatory reaction observed in some 
muscular biopsies (Geng et al, 2012; Semple et al, 2011). 
However, expression studies of DUX4 on muscle biopsies have given 
controversial results. Snider and colleagues reported that DUX4 RNA was 
detected in all individuals carrying a permissive allele, regardless of their clinical 
phenotype. However, only subjects expressing a full length splicing variant of 
DUX4 (DUX4-fl) have been reported to express the phenotype whereas shorter 
splicing variants (DUX4-s) do not seem to be correlated with clinical symptoms. 
In a different study, however, DUX4-fl was not detectable in some FSHD patients 
with full phenotype expression while a minority of unaffected individuals 
expressed DUX4-fl, even though they did not have contracted D4Z4 fragment 
(Jones et al, 2012). 
Other epidemiologic evidences further challenged the supposed indispensable 
role of DUX4 in the pathogenic development of FSHD. The Italian Consortium 
for FSHD have found that the genetic signatures of FSHD (such as the presence of 
a permissive 4qA haplotype and the D4Z4 fragment contraction) are present in 
more than 1% of the unaffected population (Scionti et al, 2012). Moreover, some 
patient with classical phenotypes carry a non-permissive 4qB haplotype whilst 
some relatives of FSHD patients who do not show any clinical sign of the disease, 
still have an increased expression of DUX4. These observations suggest that the 
actual pathogenic model is far from comprehensive and further mechanisms of 
damage, independent of DUX4, are necessary for the development of the disease 
(Jones et al, 2012). 
 
1.5) FSHD2 
 Between 5% and 10% of FSHD patients do not have a pathological contraction 
of D4Z4 fragment. These patients called FSHD2, are phenotypically 
indistinguishable from those who carry the D4Z4 contraction. Most of FSHD2 
patients present as sporadic cases, but both dominant and recessive inheritance 
have been reported in familial cases (de Greef et al, 2010). In FSHD2, the D4Z4 
region has a normal size and number of tandem repeats but, similarly to FSHD1, 
is significantly hypomethylated. (de Greef et al, 2007). As previously described 
above, in addition to the impairment of methylation degree, FSHD2 also requires 
the presence of a permissive 4qA haplotype on at least one chromosome 4 to be 
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manifested. This suggests that both FSHD1 and FSHD2, despite the original cause 
of D4Z4 hypomethylation, have a common final pathogenesis (de Greef et al, 
2009). 
 Next Generation Sequencing analyses in FSHD2 families showed, in some, an 
association with heterozygous mutations on the gene Structural Maintenance of 
Chromosomes Flexible Hinge Domain Containing 1 (SMCHD1) located on the 
chromosome 18p11.32. SMCHD1 is a physiological regulator of CpG methylation 
and plays a significant role in epigenetic silencing of chromosome X during the 
embryogenesis (Blewitt et al, 2008; Gendrel et al, 2012). SMCHD1 is able to bind 
and maintain the heterochromatinic status of the D4Z4 repeats. In FSHD2, 
detrimental mutations of SMCHD1 cause the loss of its binding with D4Z4 
tandem repeats with consequent chromatin relaxation and derepression of DUX4 
(Lemmers et al, 2012). 
Some FSHD patients with a particularly severe phenotype have been reported 
to carry both the contraction of D4Z4 and SMCHD1 mutations. Therefore, 
SMCHD1 could play an important role as a genetic modifier of the disease 
(Sacconi et al, 2013; Larsen et al, 2015). 
 
1.6) Genotype-phenotype correlations 
 Several studies have tried to find correlations between the size of D4Z4 
fragment and the severity of FSHD clinical symptoms. The deletion of the entire 
D4Z4 region from both chromosomes is not lethal and, as mentioned above, the 
presence of at least one tandem repeat is necessary in order to have expression of 
the phenotype (Tupler et al, 1996). Some studies pointed out that the smaller the 
size of D4Z4 fragment, the earlier the age of onset and loss of ambulation (Zatz et 
al, 1995; Lunt et al, 1995). In particular, a number of tandem repeats <3 determine 
an infantile onset of the disease, sometimes just after birth, together with 
extramuscular involvement such as cognitive impairment, epilepsy, Coat’s 
syndrome and severe hypoacusis (Chen et al, 2013). With respect to D4Z4 
fragments with a higher residual number of tandem repeats, the correlation with 
the severity of clinical expression is still controversial, as different studies showed 
incongruous results (Tawill et al, 1996; Butz et al, 2003; Tonini et al, 2003). 
 Although FSHD is inherited with autosomal dominant transmission, there is 
evidence suggesting different expression of the phenotype between males and 
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females. A higher number of asymptomatic females have been reported to carry 
pathological D4Z4 mutations and, in general, females show slower disease 
progression compared to males (Zatz et al, 1998). A recent study showed that the 
differences between the two genders in terms of age of onset and severity of 
symptoms are significant only during the female fertile period. On the other hand, 
males and females have the same phenotype expression during pre-puberty and 
post-menopause, suggesting an important role of female hormones as a protective 
factor in the development of symptoms (Ricci et al, 2013). 
Patients who carry the D4Z4 mutation in mosaic usually have a milder 
phenotype or are completely asymptomatic according to the percentage of muscle 
cells that have inherited the mutation (Lemmers et al, 2004). 
Controversial evidences have been reported regarding the expression severity 
in the presence of compound heterozygous (double fragment). Some studies 
showed that the presence of two pathogenic D4Z4 fragments did not result in an 
increased severity of symptoms (Wohlgemuth et al, 2003; Tonini et al, 2004).   
However, other reports pointed out an increased percentage of symptomatic 
patients and a more severe phenotype in patients who are compound heterozygous 
(Scionti et al, 2012). 
 Conversely to other inherited diseases associated with alterations in tandem 
repeats, FSHD does not show the phenomenon of anticipation. In first studies, this 
phenomenon was suggested on the evidence that the offsprings of FSHD patient 
seemed to be more severe compared to their parents (Zatz et al, 1995). However, 
futther studies did not confirm this preliminary hypothesis (Flaningan et al, 2001) 
and, moreover, there is no evidence of an instability of the D4Z4 tandem repeat 
that could explain anticipation of the symptoms towards generations. 
 
1.7) Therapy 
 There is no pharmacological treatment able to cure or stop the progression of 
FSHD. An early study with prednisolone, performed on patients with an 
inflammatory reaction in the muscle biopsy, showed a brief and unsustained 
benefit with a mild improvement of muscle strength (Munsat et al, 1972). A 
further trial with the administration of steroids for 12 consecutive weeks did not 
show any improvement or significant modification of the symptoms (Tawill et al, 
1997). An oral β2 agonist (albuterol) was tested in two different trials (Kissel et 
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al. 2001, Van der Kooi et al. 2004) but again did not have any significant 
improvement except for a mild increase in the muscular trophism. 
 Following the new insights on the molecular pathogenic mechanisms 
responsible for the development of the disease, there are novel potential molecules 
that could be specifically targeted with a more pharmacological compound in 
order to reduce DUX4 expression. However, at the moment, we do not have any 
drugs able to modify or regulate the conformation of the chromatin required to 
silence the genes overexpressed in FSHD. Moreover, this kind of compound 
would increase significantly the high risk of tumours. On the other hand, the 
pathways downstream of DUX4 are not established enough to develop a specific 
treatment. The development of micro-RNAs able to block the activity of the 
messenger RNA of DUX4, altering its splicing and reducing its stability, appears 
to be the most viable and safe way to achieve a pharmacological treatment (Tawil 
et al, 2014). A recent in vitro study showed that siRNAs directed 
against DUX4 coding region, 3′UTR, and DUX4 promoter were effective in 
reducing both DUX4 and DUX4-target gene expression and in initiating 
epigenetic silencing of DUX4 expression (Lim et al, 2015). Moreover, morpholino 
oligonucleotides that specifically target the pLAM sequence significantly 
decreased expression of several DUX4 target genes (Chen et al, 2016). These 
findings are encouraging and raise the possibility that RNA-based therapies may 
be effective in future FSHD treatment. 
 Physiotherapy remains one of the most important therapeutic approaches for 
FSHD patients, due to its effectiveness in slowing down disease progression and 
in maintaining muscular trophism. There is evidence that a mild aerobic exercise, 
if performed regularly, is able to reduce fatigue and prolong physical tolerance 
(Olsen et al. 2005). Other therapies include orthopaedic aids, useful in 
ameliorating ambulatory performance and, only in a few selected cases, the 
fixation of the scapula in order to reduce the limitation of arms abduction. 
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Aims of the study 
 
Facio-Scapulo-Humeral muscular dystrophy is characterised by a high 
variability in its phenotype expression. Moreover, despite its inheritance through 
autosomal dominant transmission that would imply a similar expression in both 
genders, important differences have been reported in disease severity between 
males and females. 
Considering the variability in phenotypic expression and the lack of reliable 
tools to predict the progression of the disease, in the first part of the study, the 
FSHD cohort of Padova was evaluated at 5 years from the first visit. A clinical 
evaluation scale, named CSS (Clinical Severity Score), created and validated in 
2007 by the Italian Network for FSHD, was used to test and quantify the muscular 
involvement of the patients in both the first (T0) and second evaluations (T1). 
Therefore, the first aim of my study was to quantify the progression and the 
residual muscular function of FSHD patients and, at the same time, to verify the 
sensitivity and the utility of the CSS as a reliable tool in the clinical follow-up. 
The second part of the study was focused on the identification of possible 
genetic modifiers of the disease. SMCHD1 mutations have been proven to be 
responsible for a large proportion of FSHD2 cases and to increase FSHD1 
severity in patients who carry a concomitant D4Z4 contraction. SMCHD1 is also 
known to play a significant role in the epigenetic silencing of chromosome X in 
the early phases of female embryonic development. For these reasons, I tested for 
SMCHD1 mutations in the patients who were negative in a previous D4Z4 
analysis to study the inactivation pattern of chromosome X in FSHD1 and FSHD2 
females in order to see whether it could represent a genetic modifier of the 
disease. 
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Chapter 2 
Materials and Methods 
 
2.1) Patient population 
For the follow-up study, FSHD patients were selected among those who were 
first evaluated between 2008 and 2013. 55 cases were identified, including 23 
probands (42%) and 32 relatives (58%). All of them carried a pathological D4Z4 
fragment, ranging between 19 and 40 Kbs. The probands consisted of 14 males 
(41%) and 9 females (39%) while, in the relatives, there were 15 males (47%) and 
17 females (53%). The relatives group was further subdivided between 
“symptomatic” (n=13; 40.6%) and “asymptomatic” (n=19; 59%). Both the first 
(T0) and the follow-up (T1) evaluations were performed by the candidate 
minimising the inter-observer bias. 
SMCHD1 mutations and D4Z4 methylation analyses were performed in 9 
patients (4 males and 5 females) presenting typical FSHD features and previously 
found negative for the D4Z4 contraction. 
With respect to the chromosome X inactivation study, the 42 FSHD female 
patients whose DNA was available were studied.  38 of them were FSHD1, 
carrying a D4Z4 fragment with a range between 19 and 40 Kbs. Two patients 
were compound heterozygous with a reduced D4Z4 fragment in both alleles. The 
remaining 4 patients were FSHD2 with pathogenic mutations in SMCHD1. The 
average age of FSHD1 patients were 51 ± 15 years, while FSHD2 patients were 
49 ± 21 years. 48 healthy individuals, with an average age of 38 ± 14, were used 
as controls. 
 
2.2) Clinical evaluation of the patients 
 The Clinical Severity Score (CSS), a scale created and first validated by the 
Italian Network for FSHD in 2007 (Lamperti et al, 2010), was used to quantify 
disease severity and to compare the two clinical evaluations in a standardised 
manner. 
 The CSS consists in an objective clinical examination of the patient and 
evaluates all the 6 major muscular districts involved in FHSD (face, shoulder 
girdle, proximal arm, pelvic girdle, distal leg and abdominal muscles) in a 
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quantitative and functional way. The strength of each muscle is quantified by the 
Medical Research Council (MRC) score. 
 The function of the facial muscles is evaluated asking the patient to perform 
specific facial movements such as closing eyes, puff out cheeks and protrude lips. 
The ability of the patient to do all the different actions is classified as “normal”, 
“partial” or “abolished” depending on the degree of complete the movement 
required in the presence and in the absence of the examiner’s resistance. 
 The function of the shoulder girdle is evaluated through the patient’s ability to 
abduct the upper limbs in the frontal plane with a complete extension of the arms. 
The function is considered normal if the patients are able to clap their hands over 
their head. A complete but abnormal function is defined by the necessity to use 
compensatory actions to fulfil the task such as flexing the elbows or rotating 
forward the shoulders. If the patient is not able to complete the movement, the 
score would depend on the degree of arm abduction (higher or lower than 45°). 
 The ability to rise from a chair and to climb 4 steps are the movements 
evaluated for the pelvic girdle function. The score will be given according to the 
necessity of support and to the time needed (cut-off of 12 seconds) to complete 
the different actions. 
The function of the lower limbs is evaluated through the observation of the 
gait, the ability to walk on both tiptoes and heels and the necessity to use the 
wheelchair with either manual or electric control. 
The strength of several muscles is tested by the MRC score. The following 
muscles of upper and lower limbs are evaluated: biceps and triceps brachii, arm 
extrarotators, fingers’ flexors and extensors, wrist’s flexors and extensors, 
quadriceps femoris, and tibialis anterior.    
The involvement of the abdominal musculature is evaluated by the presence or 
absence of the Beevor’s sign (upward movement of the umbilicus on the median 
line when the patient rises his head on the chest in supine position). 
 Finally, the presence of winging scapula, asymmetrical hypotrophy, sloping 
shoulders, and straight clavicula are considered in the final evaluation of the 
patient. 
The results of the score of each muscule region are then added together in 
order to obtatin a final comprehensive mark corresponding to the Clinical Severity 
Score - CSS. Thus the final score is calculated as following:  
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1) facial waekness: 
0: no weakness; 
1: partial ability to do at least one of the following tasks: 
- to close eyes 
- to protrude lips 
- to puff out cheeks 
2: severe weakness. Unable to do at least one of the previous tasks. 
 
2) Scapular girdle involvement: 
 0: no invovement 
 1: mild involvement with no limitation of arm abduction 
 2: arm abduction > 45 
 3: arm abduction ≤45° 
 
3) Upper limbs involvement: 
0: no involvement 
1: at least two muscles affected with MRC >3 
2: at least two muscles with MRC ≤3 
 
4) Legs involvement 
 0: no involvement 
1: unable to walk on tiptoes or heels (only one task impaired) 
 2: unable to walk on tiptoes and heels (two tasks impaired) 
 
5) Pelvic girdle involvement 
 0: no involvement 
1: able to walk and to climb stairs without support but abnormally/ because 
of posterior leg muscle hypotrophy 
 2: able to walk unaided, to climb stairs or to stand up from a chair with 
support 
 3: able to walk unaided but unable to stand up from a chair or to climb stairs 
without support/ more than 12 seconds 
 4: able to walk with support 
5: wheelchair bound 
 22 
 
6) Abdominal muscle involvement 
0: no involvement 
1: presence of Beevor's sign 
 
The final score varies from 0 to a maximum of 15 points. A score equal to 0 
corresponds to the complete absence of symptoms. A score between 1 and 4 
indicates a mild form of the disease while a score between 5 and 10 is consistent 
with a moderate impairment. Finally, a severe disease reaches a CSS of 11-15.  
The CSS was used to standardise the evaluation of all the patients of the study.  
 
2.3) Molecular analyses 
 Genetic analyses for the detection and methylation degree of D4Z4 fragment, 
4qA and 4qB haplotypes, and for SMCHD1 mutations were performed by the 
Miogen laboratory at the University of Modena and Reggio Emilia by the group 
of Professor Rossella Tupler, and at the Centre de référence des maladies 
neuromusculaires of Nice by the group of Professor Sabrina Sacconi. The 
following methods were previously described (Scionti et al 2012; Lemmers et al, 
2012) and are reported here in order to provide the laboratory details underlying 
the clinical follow-up and the characterization of FSHD2 patients of this study.  
Genomic DNA from each patient was extracted from peripheral blood 
leucocytes using standard techniques and then digested by the restriction enzymes 
EcoRI, EcoRI/BlnI and XapI (p13E-11 probe). Digested DNA samples were 
separated using pulse-field gel electrophoresis (PFGE) in a 1% agarose gel. To 
estimate the dimension of the D4Z4 fragment size, 7 µg of digested DNA were 
hybridised with the probe p13E-11 and subjected to electrophoresis in 0.4% 
agarose gel for 45-48 hours at 35 V together with a marker of 8-48 Kb (Bio-Rad). 
In order to identify the chromosomal origin of D4Z4 (chr. 4 vs chr. 10), DNA 
samples underwent a second enzymatic digestion with the restriction enzyme NotI 
and were then hybridised with the probe B31. The digested fragments were then 
identified by autoradiography or the Typhoon Trio® system (GE Healthcare). 
 The haplotypes 4qA and 4qB were studied by PFGE followed by Southern blot 
and hybridisation of 7 µg DNA, previously digested with the restriction enzyme 
HindIII, with radioactive probes for the sequences of 4qA/4qB. The chromosome 
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attribution of the two haplotypes was performed evaluating the dimension of the 
fragment after enzymatic digestion with EcoRI, as previously described. 
 For the identification of the simple sequence length polymorphisms (SSLPs) 
and the pLAM SNP (AT(T/C)AAA) sequence, adjacent to the D4Z4 tandem 
repeats, the single D4Z4 alleles, separated by linear electrophoresis from DNA 
samples, were digested by EcoRI. The SSLP sequence was then determined by 
PCR amplification using specific oligonucleotides (forward primer 5’-
GGTGGAGTTCTGGTTTCAGC-3’ marked with hexachlorofluorescein [HEX], 
reverse primer 5’-CCTGTGCTTCAGAGGCATTTG-3’). 
 The pLAM sequence analysis was performed through PCR amplification using 
specific oligonucleotides (forward primer 5’-ACGCTGTCTAGGCAAACCTG-
3’, reverse primer 5’-TGCACTCATCACACAAAAGATG-3’). The differences 
between the size of SSLPs and pLAM sequences were determined using the 
program ABI Prism 3130 Genetic Analyzer. 
 To study the degree of methylation of the D4Z4 region, genomic DNA 
underwent double enzymatic digestion by restriction enzymes EcoRI and BglI, run 
overnight at 37ºC and finally purified through specific PCR column extraction. 
Once the purified DNA sample was obtained, it was further digested with the 
enzyme FseI for 4 hours, separated by 0.8% agarose gel and probed with a 
radioactive p13E-11 probe on Southern blot. The radioactive signal of the probes 
was quantified by Image Quant software. The % ratio of the radioactive signal 
values between the methylated fragments of 4061 bps and the non-methylated 
fragments of 3387 bps corresponds to the proportion of methylated FseI sites. 
 SMCHD1 analysis was performed using either Sanger mutational analysis or 
Southern blot deletion assay. The mutational analysis was done by performing the 
Sanger sequencing on all the 48 exons of the gene using intronic primers and 
annealing sequences of at least 50 nucleotides from donator or acceptor splice 
sites. 5’ and 3’ non-coding sequences were not included. The genomic sequence 
of SMCHD1 was obtained by Ensemble (build 37) 
[GRCh37:18:2655286:2805615]. The pathogenicity of SMCHD1 mutation was 
predicted by SIFT and GVGD Align software. 
 Deletions of the SMCHD1 gene were studied using a hybridisation method 
based on the Southern blot technique. 5 µg of genomic DNA were digested by the 
restriction enzymes EcoRV o BamHI (MBI ferments) followed by 2 cycles of 
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PFGE on 0.85% agarose gel at 8.5V for 16 hours. The time-lapse between the 
cycles was increased progressively from 1 second to 2 seconds in the final stages. 
PFGE was performed in 0.5xTBE buffer supplemented with 150 ng/ml ethyl 
bromide at 20°C. Southern blot was hybridised overnight at 65°C with a cDNA 
probe of SMCHD1 that binds all the 48 exons of the gene, and then washed three 
time for 10 minutes in SSC and 0.1% SDS at 65°C. The blots were finally 
developed and analysed with Image Quant® software (Molecular Dynamics).  
 
2.4) Chromosome X inactivation analysis 
This part of the study and the related laboratory techniques were performed 
and developed directly by the candidate. The methylation status of the CAG 
repeated sequences of the androgen receptor (AR) gene was used to determine the 
pattern of chromosome X inactivation as it correlates with the methylation of the 
entire chromosome (Allen et al, 1992). 
About 15 ml of blood were collected in EDTA tubes from the patients and 
DNA was extracted from peripheral leucocytes by phenol-chloroform method. An 
equivalent amount of lysis buffer (0.77 M NH4Cl, 46 mM KHCO3) was added to 
the samples and then spun at 4000 rpm for 15 min in order to lyse the 
erythrocytes. Supernatant was discharged and the whole procedure was repeated 
other two times until the pellet became clearer. In order to lyse the leucocytes, the 
pellet was incubated with to a second lysis buffer (100 mM NaCl, 25 mM EDTA, 
500 µl 20% SDS, 1 mg/ml Proteinase K) and mechanically destroyed by pipetting. 
After overnight incubation at 37ºC, an equal volume of phenol, saturated with 0.1 
M TrisHCl, was added to the samples and followed by mixing and spinning at 
4000 rpm for 15 min. The surpernant was removed and another equal volume of 
phenol was added repeating the last steps 5 times. Two times of the original 
volume of 100% ethanol were added to the solution together with 1 μl of 4 M 
ammonium acetate, followed by gently shaking to precipitate the DNA. After 
spinning at 3000 rpm for 5 min, the 100% ethanol was carefully removed and 500 
μl of 70% ethanol were added to the DNA. Finally, after the last spinning at 4000 
rpm for 15 min, the 70% ethanol solution was removed and the DNA pellet left to 
air-dry before dissolve it in 500 μl of sterile water. 
The methylation analyses were performed on two DNA samples of 100 ng/μl. 
One DNA sample was restricted for 2 hours at 37°C with 10 U of two different 
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methylation sensitive restriction enzymes, HpAII and HhAI. The second sample 
was incubated under the same condition without the restriction enzymes. In order 
to stop the action of the restriction enzymes, samples were incubated at -20ºC for 
at least one hour. Finally, in order to purify the DNA, 30 µl of phenol-chloroform 
were added to the samples, spun at 15000 rpm for 2 minutes and then washed 
twice with 80 µl of ether. Purified DNA samples were amplified through semi-
quantitative PCR (forward primer 5’-TCCAGAATCTGTTCCAGAGGCGTG-3’, 
reverse primer 5’-GCTGTGAAGGTTGCTGTTCCTCAT-3’). Efficacy of PCR 
amplification was tested by electrophoresis of the samples in 2% agarose gel. 
Finally, the samples were genotyped with capillary electrophoresis (ABI 3100 
DNA Sequencer, Applied Biosystems, Foster City, CA). Peak Scanner® software 
was used to analyse genotyping results. 
To obtain the methylation degree of the two X chromosomes, the ratio 
between the height of the peaks of each restricted alleles was compared to those of 
the non-restricted alleles. Chromosome X inactivation was considered skewed if 
the ratio between the peaks was greater than 80% (Amos-Landgraf et al, 2006).  
 
2.5) Statistical analysis 
In the follow-up study, Student’s t was used to compared independent groups 
with variables with normal distribution while ANOVA multiple comparison was 
used when the groups were more than two. Ordinal variables were analysed by 
Mann Whitney U test while non-correlated variables by χ2. For repeated values 
with normal distribution (T0 – T1), repeated measures ANOVA analysis was 
performed in ordert to compare the three different groups (probands, 
asymptomatic and symptomatic relatives). One-way ANOVA was used to test the 
difference between ordinal variables at T0 and T1 among the three groups. In case 
of positivity, single group couples were further analysed by Mann-Whitney U test. 
Correlations between the D4Z4 size and all the other variables were tested 
through Spearman’s rho as the dimension of D4Z4 did not show a normal 
distribution. The Saphiro-Wilk test was used in the chromosome X inactivation 
study to analyse whether the population of patients and controls were normally 
distributed. Correlations between the percentage of X inactivation, total CSS and 
the scores of each muscle district were tested through Spearman’s rho. Statistical 
significance was set at p<0.05.  
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Chapter 3 
Results 
 
3.1) Clinical follow-up 
 A total of 55 patients were recruited for the follow-up study. They were 
divided in 23 probands (42%) and 32 relatives (58%), all of them carrying a 
pathological D4Z4 fragment. The number of males (29) was not significantly 
different from those of the females (26) (p=0.31). At the first visit, the average 
age of the probands was 45.5±15 years and it was comparable to the age of the 
relatives (44±17 years). The whole population was subdivided into three groups: 
probands, symptomatic and asymptomatic relatives. 
We compared the MRC score of every muscle, and the partial and total 
Clinical Severity Score (CSS) at the time of the first (T0) and the second (T1) 
evaluation between each patients’ groups. Differences between genders and 
possible correlations between the size of D4Z4 were also analysed.  
At the first visit, conducted at T0, all the 23 probands were symptomatic by 
definition. In the group of relatives, 13 (40.63%) showed clinical signs of FSHD 
and this difference between the two groups was statistically significant 
(p<0.0001). The size of D4Z4 fragment were uniformly distributed and no 
significant difference were found between the probands and the relatives (p=0.61) 
(Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. D4Z4 fragment size distribution in the groups of probands and their relatives. 
 
D4Z4 fragment size (Kb) Probands Relatives Tot 
 
N % N % 
 
19 1 4.3% 1 3.1% 2 
21 2 8.7% 1 3.1% 3 
23 1 4.3% 3 9.4% 4 
24 1 4.3% 2 6.2% 3 
26 2 8.7% 8 25.0% 10 
27 1 4.3% 2 6.2% 3 
30 3 1.3% 0 0.0% 3 
32 1 4.3% 1 3.1% 2 
33 5 21.7% 3 9.4% 8 
35 2 8.7% 2 6.2% 4 
36 1 4.3% 3 9.4% 4 
38 2 8.7% 3 9.4% 5 
40 1 4.3% 3 9.4% 4 
Tot 23 42% 32 58% 55 
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The average age at onset in the probands (29.7±17.15 years) was lower 
compared to the symptomatic relatives (31.6±14 years), but this difference did not 
reach significance (p=0.73) (Figure 4). As expected, the average duration of 
disease was higher in the probands (15.7±15 years) compared to the symptomatic 
relatives (5.6±5.4 years) (p<0.05) (Figure 5). 
At T0, the average CSS was 5.4, 2.6, and 0.8 in the groups of probands, 
symptomatic, and asymptomatic relatives respectively. The result of the Kruskal-
Wallis test showed that the CSS was significantly higher in the probands’ group 
compared to both groups of relatives (p<0.0001), and as expected, symptomatic 
relatives had a higher CSS than the asymptomatic relatives (p<0.01) (Figure 6). 
 
 
 
 
Figure 4. Distribution of the age of disease onset in the groups of probands and their relatives. 
Probands had an earlier onset on average compared to their relatives, but this difference did not 
reach significance (p=0.73; Mann Witney test). 
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Figure 5. Distribution of disease duration in the groups of probands and their relatives. Probands 
had a significantly longer disease compared to their symptomatic relatives (p<0.05; Mann Witney 
test). 
 
 
 
 
 
Figure 6. Total CSS values in the groups of probands, asymptomatic, and symptomatic relatives. 
Total CSS was significantly higher in the probands compared to both groups of relatives 
(p<0.0001; One-way ANOVA). Within the relatives, as expected, the symptomatic individuals had 
a higher CSS compared to the asymptomatic subjects (p<0.01; One-way ANOVA). 
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Figure 7. Correlations between D4Z4 size, age of onset and total CSS. In A: significant correlation 
between D4Z4 fragment size and age of onset of the symptoms among all the symptomatic patients 
(probands and relatives) (Spearman’s rho=0.36, p<0.05). In B: analysing separately the probands from 
the symptomatic relatives, the onset-D4Z4 correlation was maintained only in the group of probands 
(Spearman’s rho=0.58, p<0.01). In C: significant inverse correlation between D4Z4 size and total CSS 
only within the groups of symptomatic relatives (Spearman’s rho= -0.72, p<0.01). 
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Considering all the symptomatic patients, the age of onset of the disease 
proportionally correlated with the size of D4Z4 fragment (Rho=0.36, p<0.05) 
(Figure 7A), ie. early onset corresponded to a smaller D4Z4 fragment. However, 
once the analysis was repeated separating the probands from the symptomatic 
relatives, the onset-D4Z4 correlation was maintained only within the probands 
(Rho=0.58, p<0.01) (Figure 7B). Finally, within the group of symptomatic 
relatives there was an inverse correlation with smaller D4Z4s associated with 
higher scores (Rho= -0.72, p<0.01) (Figure 7C). 
All the patients were evaluated after 5.35 ± 1.27 (median value: 5.8; range 3-7 
years). Figure 8 shows patients’ distribution according to the time lapse between 
the evaluations at T0 and T1. The majority of patients (31) were re-evaluated after 
6 or 7 years from the first visit. 
 
 
Figure 8. Distribution of the average follow-up period between T0 and T1 in the patients’ cohort. 
The highest number of patients (31/55) were re-evaluated between 6 and 7 years after the first 
visit. 
 
 
With respect to the whole cohort of patients, the CSS worsened significantly 
during the two evaluations starting from a score of 3.2 ± 2.5 at T0 and reaching 
3.9 ± 3.2 at T1 (p<0.01). However, analysing separately the three groups, the 
significance was maintained (p<0.001) only among the probands while the 
relatives did not show any significant worsening (p=0.29) (Figure 9A). Then, the 
analysis was restricted to the 31 patients with the longest interval between the two 
evaluations (6-7 years) and, as seen before, only in the probands’ group the 
disease showed a significant progression (p<0.05) (Figure 9B). 
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Figure 9. Disease progression measured by total CSS at T0 and T1 in the groups of probands 
(blue), symptomatic (green), and asymptomatic (red) relatives. In A: analysing the whole 
population (n=55) for the entire period of follow-up, the CSS worsened significantly between T0 
and T1 only within the probands while the relatives did not show any significant worsening 
(p<0.001; repeated measures ANOVA).  In B: a similar result was observed analysing separately 
the subjects (n=31) with the longer follow-up period (p<0.05; repeated measures ANOVA). In C: 
no significant differences were found analysing the cohort of patients (n=24) with a follow-up of 
3-5 years in each group (p=0.78; repeated measures ANOVA). 
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The separate analysis of the remaining 24 patients with a time interval between 
T0 and T1 of 3-5 years did not show any significant difference among the three 
groups (p=0.78) (Figure 9C). No correlation was found between the size of the 
D4Z4 fragment and the degree of worsening, measured as the difference between 
the total CSS at T0 and T1 (Rho= -0.15, p=0.26) (Figure 10).  
Correlation analysis was performed also between the values at T0 and T1 of the 
MRC score of each muscle tested (biceps brachii, triceps brachii, fingers flexors 
and extensors, wrist flexors and extensors, quadriceps, tibialis anterior) and the 
CSS of every muscle group included in the evaluation protocol (face, upper and 
lower limb girdles, distal legs and abdomen). The MRC scores of triceps brachii, 
biceps brachii and tibialis anterior were weaker at T1 compared to T0. Tables 2 
and 3 show the MRC and CSS values for each muscle group tested at T0 and T1. 
On the other hand, only the pelvic girdle was significantly more impaired in the 
analysis of the single muscular districts evaluated by CSS. Consistently with the 
previous findings, only the group of the probands resulted worsened in the 
correlation analysis on tibialis anterior and pelvic girdle compared to the groups 
of relatives (Table 4 and Figure 11). 
No significant differences were found between the progression of the disease 
between males (14) and females (9) in the probands’ group (Table 5).  
 
 
 
 
Figure 10. Correlation analysis between D4Z4 fragment size and progression of the disease. No 
correlation was found between the D4Z4 fragment size and the progression of the disease 
measured by the difference between the total CSS at T1 and T0 (Spearman’s rho= -0.15, p=0.26). 
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Table 2. Mean MRC scores of each muscle and mean CSS values for each muscle group measured 
in the groups of probands, asymptomatic, and symptomatic relatives at T0.  
 
 
 
 
 
 
Muscle 
Probands 
(mean MRC score) 
Asymptomatic 
relatives 
(mean MRC score) 
Symptomatic relatives 
(mean MRC score) 
Triceps brachii 
(left) 
4.65 ± 0.411 4.92 ± 0.25 4.76 ± 0.388 
Triceps brachii 
(right) 
4.58 ± 0.51 4.86 ± 0.32 4.80 ± 0.38 
Biceps brachii 
(left) 
4.84 ± 0.35 5.0 ± 0.00 4.88 ± 0.21 
Biceps brachii 
(right) 
4.82 ± 0.32 4.97 ± 0.11 4.96 ± 0.13 
Quadriceps 
(left) 
4.89 ± 0.52 5.00 ± 0.00 4.92 ± 0.27 
Quadriceps 
(right) 
4.78 ± 0.65 5. 00 ± 0.00 5.00 ± 0.00 
Tibialis anterior 
(left) 
3.97 ± 1.00 4.81 ± 0.41 4.50 ± 0.95 
Tibialis anterior 
(right) 
3.93 ± 1.24 5.00 ± 0.00 4.57 ± 0.75 
Extensor digitorum 
(left) 
4.95 ± 0.20 4.89 ± 0.31 4.96 ± 0.13 
Extensor digitorum 
(right) 
4.93 ± 0.31 4.89 ± 0.31 4.96 ± 0.13 
Extensor carpi 
(left) 
5.00 ± 0.00 5.00 ± 0.00 5.00 ± 0.0 
Extensor carpi 
(right) 
5.00 ± 0.00 5.00 ± 0.00 5.00 ± 0.00 
Flexor digitorum 
(left) 
4.95 ± 0.20 5.00 ± 0.00 5.00 ± 0.00 
Flexor digitorum 
(right) 
5.00 ± 0.00 5.00 ± 0.00 5.00 ± 0.00 
Flexor carpi 
(left) 
4.97 ± 0.10 5.00 ± 0.00 5.00 ± 0.00 
Flexor carpi 
(right) 
4.96 ± 0.10 5.00 ± 0.00 5.00 ± 0.00 
Muscular group Mean CSS value Mean CSS value Mean CSS value 
Face 0.95 ± 0.36 0.47 ± 0.51 0.92 ± 0.27 
Scapular girdle 1.73 ± 0.54 0.05 ± 0.22 0.53 ± 0.51 
Upper arms 1.00 ±0.42 0.15 ± 0.37 0.38 ± 0.50 
Distal leg 0.69 ± 0.70 0.10 ± 0.31 0.23 ± 0.438 
Pelvic girdle 0.69 ± 0.63 0.10 ± 0.45 0,30 ± 0.63 
Abdomen 0.43 ± 0.50 0.00 ± 0.00 0.23 ± 0.43 
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Table 3. Mean MRC scores of each muscle and mean CSS for each muscle group measured in the 
groups of probands, asymptomatic, and symptomatic relatives at T1.  
 
 
 
 
 
 
Muscle 
Probands 
(mean MRC score) 
Asymptomatic 
relatives 
(mean MRC score) 
Symptomatic relatives 
(mean MRC score) 
Triceps brachii 
(left) 
4.19 ± 0.63 4.78 ± 0.41 4.65 ± 0.42 
Triceps brachii 
(right) 
4.19 ± 0.44 4.76 ± 0.42 4.53 ± 0.51 
Biceps brachii 
(left) 
4.54 ± 0.39 4.97 ± 0.11 4.76 ± 0.33 
Biceps brachii 
(right) 
4.56 ± 0.52 4.94 ± 0.15 4.84 ± 0.31 
Quadriceps 
(left) 
4.69 ± 0.73 5.00 ± 0.00 5.0 ± 0.00 
Quadriceps 
(right) 
4.76 ± 0.65 5.00 ± 0.00 5.00 ± 0.00 
Tibialis anterior 
(left) 
3.28 ± 1.35 4.81 ± 0.47 4.42 ± 0.90 
Tibialis anterior 
(right) 
3.19 ± 1.34 4.92 ± 0.25 4.34 ± 1.14 
Extensor digitorum 
(left) 
4.97 ± 0.10 4.89 ± 0.31 4.96 ± 0.13 
Extensor digitorum 
(right) 
5.00 ± 0.00 4.89 ± 0.31 5.00 ± 0.00 
Extensor carpi 
(left) 
5.00 ± 0.00 5.00 ± 0.00 5.00 ± 0.00 
Extensor carpi 
(right) 
5.00 ± 0.00 5.00 ± 0.00 5.00 ± 0.00 
Flexor digitorum 
(left) 
5.00 ± 0.00 5.00 ± 0.00 5.00 ± 0.00 
Flexor digitorum 
(right) 
5.00 ± 0.00 5.00 ± 0.00 5.00 ± 0.00 
Flexor carpi 
(left) 
4.97 ± 0.10 5.00 ± 0.00 5.00 ± 0.00 
Flexor carpi 
(right) 
4.97 ± 0.10 5.00 ± 0.00 5.00 ± 0.00 
Muscular group Mean CSS value Mean CSS value Mean CSS value 
Face 1.13 ± 0.344 0.52 ± 0.51 1.00 ± 0.40 
Scapular girdle 1.78 ± 0.51 0.10 ± 0.31 0.61 ± 0.50 
Upper arms 0.95 ± 0.36 0.26 ± 0.45 0.53 ± 0.51 
Distal leg 1.00±0.67 0.15 ± 0.50 0.30 ± 0.48 
Pelvic girdle 1.34±1.22 0.10 ± 0.45 0.38 ± 0.76 
Abdomen 0.56 ± 0.50 0.00 ± 0.00 0.30 ± 0.48 
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Table 4. Differences of MRC scores and CSS between T1 and T0 for each muscle in the groups of 
probands, asymptomatic, and symptomatic relatives. In red are highlighted the muscles that showed a 
significant worsening during the period of follow-up. 
 
 
Muscle Probands 
Asymptomatic 
relatives 
Symptomatic 
relatives 
One-way 
ANOVA 
Mann Whitney 
 
Mean SD Mean SD Mean SD 
 
P vs A P vs S A vs S 
Triceps brachii 
(left) 
-0.45 0.58 -0.13 0.32 -0.11 0.36 0.034 0.045 0.08 1.00 
Triceps brachii 
(right) 
-0.39 0.47 -0.10 0.31 -0.26 0.43 0.045 0.014 0.40 0.36 
Biceps brachii 
(left) 
-0.30 0.36 -0.02 0.11 -0.11 0.21 0.007 0.003 0.18 0.40 
Biceps brachii 
(right) 
-0.26 0.54 -0.02 0.11 -0.11 0.30 0.04 0.017 0.27 0.62 
Quadriceps 
(left) 
-0.19 0.55 0.00 0.00 0.07 0.27 0.03 0.06 0.25 0.73 
Quadriceps 
(right) 
-0.02 0.10 0.00 0.00 0.00 0.00 0.50 
   
Tibialis 
anterior 
(left) 
-0.69 0.71 0.00 0.28 -0.07 0.34 0.0001 0.0006 0.006 0.90 
Tibialis 
anterior 
(right) 
-0.73 0.63 -0.07 0.25 -0.23 0.63 0.0003 0.0002 0.02 0.76 
Extensor 
digitorum 
(left) 
0.02 0.23 0.00 0.00 0.00 0.00 1.00 
   
Extensor 
digitorum 
(right) 
0.06 0.31 0.00 0.00 0.03 0.13 0.52 
   
Extensor carpi 
(left) 
0.00 0.00 0.00 0.00 0.00 0.00 1.00 
   
Extensor carpi 
(right) 
0.00 0.00 0.00 0.00 0.00 0.00 1.00 
   
Flexor 
digitorum 
(left) 
0.04 0.20 0.00 0.00 0.00 0.00 0.45 
   
Flexor 
digitorum 
(right) 
0.00 0.00 0.00 0.00 0.00 0.00 1.00 
   
Flexor carpi 
(left) 
0.00 0.00 0.00 0.00 0.00 0.00 1.00 
   
Flexor carpi 
(right) 
0.00 0.00 0.00 0.00 0.00 0.00 1.00 
   
Muscular 
group           
Face 0.17 0.38 0.05 0.22 0.07 0.27 0.42 
   
Shoulder 
girdle 
0.04 0.20 0.05 0.22 0.07 0.27 0.91 
   
Upper arms -0.04 0.20 0.10 0.31 0.15 0.37 0.11 
   
Distal legs 0.30 0.55 0.05 0.22 0.07 0.27 0.09 
   
Pelvic girdle 0.65 0.88 0.00 0.00 0.07 0.27 0.0004 0.0008 0.04 0.73 
Abdomen 0.13 0.34 0.00 0.00 0.07 0.27 0.26 
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Figure 11. Percentages of variation of the scores for each muscle (on the right of the diagram) and 
muscle group (on the left of the diagram) between T0 and T1 for each group (proband: in blue; 
asymptomatic relatives: in red; symptomatic relatives: in green). Probands had the highest 
variations among the three groups in the strength of triceps brachii, biceps brachii, and tibialis 
anterior (p<0.05, p<0.05 and p<0.0001 respectively; One-way ANOVA) and an increase in the 
scores of distal leg (NS) and pelvic girdle (p<0.001; One-way ANOVA) measured by CSS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Differences of MRC scores and CSS between T1 and T0 of all the patients divided 
according to their gender. 
Muscle 
Mean 
(difference between T1 e T0) 
P SD 
 
F M 
 
F M 
Triceps brachii (left) -0.50 -0.42 0.781 0.43 0.67 
Triceps brachii (right) -0.33 -0.42 0.650 0.35 0.54 
Biceps brachii (left) -0.38 -0.25 0.380 0.33 0.37 
Biceps brachii (right) -0.50 -0.10 0.089 0.66 0.40 
Quadriceps (left) -0.33 -0.10 0.355 0.82 0.28 
Quadriceps (right) -0.05 0.00 0.220 0.16 0,00 
Tibialis anterior (left) -0.66 -0.71 0.880 0.43 0.87 
Tibialis anterior (right) -0.55 -0.85 0.277 0.46 0.71 
Extensor digitorum (left) 0.00 0.03 0.733 0.00 0.30 
Extensor digitorum (right) 0,00 0.10 0,435 0.00 0.40 
Extensor carpi (left) 0.00 0.00 
 
0.00 0.00 
Extensor carpi (right) 0.00 0.00 
 
0.00 0.00 
Flexor digitorum (left) 0.00 0.07 0.435 0.00 0.26 
Flexor digitorum (right) 0.00 0.00 
 
0.00 0.00 
Flexor carpi (left) 0.00 0.00 
 
0.00 0.00 
Flexor carpi (right) 0.00 0.00 
 
0.00 0.00 
Muscular group 
     
Face 0.22 0.14 0.642 0.44 0.36 
Shoulder girdle 0.00 0.07 0.435 0.00 0.26 
Upper arms 0.00 -0.07 0,435 0.00 0.26 
Distal legs 0.11 0.42 0.189 0.33 0.64 
Pelvic girdle 0.77 0.57 0.596 0.97 0.85 
Abdomen 0.11 0.14 0.834 0.33 0.36 
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3.2) Methylation status of the D4Z4 alleles and SMCHD1 mutational analyses in 
patients with normal D4Z4 fragment size. 
Molecular analyses of SMCHD1 mutations, and the size and methylation 
degree of the D4Z4 fragment were performed at the Centre de référence des 
maladies neuromusculaires of Nice by the group of Professor Sabrina Sacconi. 
Eight patients (4 males and 4 females) with normal D4Z4 fragment size and 
typical FSHD clinical features were investigated for the methylation status of both 
D4Z4 alleles and for mutations on SMCHD1 gene. In addition, the analysis of the 
dimension of the D4Z4 fragment was repeated in order to avoid false negative 
results in the first molecular analysis. Indeed, three patients were positive in the 
second test showing a pathogenic D4Z4 fragment. Among the other 6 patients, 2 
had normal D4Z4s (in size and methylation) and no mutations were detected in 
SMCHD1. In the remaining 4 patients (1 male and 3 females), the D4Z4 fragment 
was significantly hypomethylated (Fse < 25%) and different pathogenic mutations 
were identified in SMCHD1. Moreover, the haplotype analysis showed the 
presence of the permissive haplotype 4qA161 in all the FSHD2 patients studied. 
 Clinical features of these 4 patients differed in clinical severity and course of 
disease. Patient 1 (V.R.) had the onset of her symptoms at the age of 45 with a 
progressive impairment of the shoulder girdle. The course of her disease has been 
mild with a very slow progression of the weakness. In fact, at the time of the 
evaluation, 12 years from the onset, she had only a mild involvement of the facial 
and proximal upper limb muscles (CSS=3). A missense SMCHD1 mutation 
(chr18:2760707G>A; p.Met1468Ile) was identified. Patient 2 (C.D.) had a more 
severe course with earlier onset (26 years) at the shoulder girdle and a more 
aggressive progression of muscle weakness. At the time of the evaluation he was 
66 (40 years of disease history) and showed severe impairment during ambulation 
and arm abduction (CSS=10). This patient was found to carry a deletion of 
SMCHD1 (chr18:2732494_2732497delAGTA) that caused a splicing alteration 
with the formation of an abnormal final transcript. Patient 3 (B.M.) had onset at 
25 years with impairment of the shoulder girdle followed by a slow progression of 
symptoms. At the time of this study, 25 years from the onset, the patient showed 
moderate weakness of the proximal upper limb muscles and initial ambulatory 
impairment (CSS=6). In this patient a single base pair deletion in SMCHD1 
(chr18:2775841_2775841delG; Arg1762Leu fs*53), causing the formation of an  
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  Table 6. Clinical and genetic features of FSHD2 patients. 
 
 
 
 
 
 
 
 
 
 
Figure 12. Genealogical tree patient #1’s family. In red are highlighted the pathological findings for each 
member of the family. Only in the proband (II;2 - arrow) the mutation of SMCHD1 is inherited together 
with a permissive haplotype 4qA161 and, consequently, the disease is expressed. All the other relatives 
lack of at least one pathogenic feature (II;3 and II;4 have the mutation in SMCHD1 and a non-permissive 
haplotype while III;1 and III;2 have the permissive haplotype but not the mutation in SMCHD1) 
preventing the expression of the phenotype. 
 
 
Proband Gender 
Disease 
duration 
(years) 
CSS 
score 
SMCHD1 mutation 
D4Z4 
fragment 
1 (V.R.) F 11 3 chr18:2760707G>A normal 
2 (C.D.) M 40 10 chr18:2732494_2732497delAGTA normal 
3 (B.M.) F 27 6 
chr18:2775841_2775841delG ; 
Arg1762Leu fs*53 
normal 
4 (M.R.) F 10 9 chr18:2718234G>T 36 kb 
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early stop codon after 53 triplets, was detected. Finally, the forth patient (M.R.) 
differed from the other four as she carried a splicing mutation in SMCHD1 
(chr18:2718234G>T) combined with a pathological contraction of D4Z4 (36 Kb). 
This patient had a late onset of the disease (60 years) but the progression was 
particularly fast as, just after 10 years, her impairment was severe and widespread 
(CSS=10).  
Table 6 summarises the clinical features and the SMCHD1 mutations identified 
in the patients described above. 
The methylation status of the D4Z4 alleles and SMCHD1 mutational analyses 
were also performed in all the first-degree relatives (1 brother, 2 sisters and 2 
daughters) of patient 1 (V.R.). Her relatives were completely asymptomatic at the 
evaluation. One of the sisters and both the daughters of the patient inherited the 
permissive haplotype 4qA161 but none of them were positive for SMCHD1 
mutations nor for D4Z4 hypomethylation. The brother and the other sister of the 
patient had the same SMCHD1 mutation (chr18:2760707G>A; p.Met1468Ile) and, 
consequently, showed D4Z4 hypomethylation. However, both of them had a non-
permissive 4qB163 haplotype. Figure 12 shows the genealogical tree of patient 
1’s family and the corresponding results of the molecular analysis.  
 
3.3) Chromosome X inactivation pattern in the female FSHD population 
The 41 females were from the FSHD cohort of Padova. 38 of them were 
FSHD1, carrying a D4Z4 fragment with a range between 19 and 40 Kbs. Two 
patients were compound heterozygous presenting a reduced D4Z4 fragment in 
both 4qA regions. The remaining three patients, were the FSHD2 females who 
carried pathogenic mutations in SMCHD1, already identified in the previous part 
of the study. The average age of FSHD1 patients was 51 ± 15 years, while FSHD2 
patients were 49 ± 21. 48 healthy individuals, with an average age of 38 ± 14, 
were used as a control population. All patients were clinically evaluated, at the 
moment of the sample, using the FSHD Clinical Severity Score (CSS). Table 7 
shows the clinical features of the patients included in this part of the study. 
The methylation status of the CAG repeated sequences of the androgen 
receptor (AR) gene was used to define the pattern of chromosome X inactivation, 
because it correlates with the methylation degree of the entire chromosome. 
Genomic DNA sequence of the AR gene was digested by two different restriction 
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enzymes (HpAII and HhAI). These enzymes selectively cut the methylated 
cytosines on the AR gene. After digestion, according to the methylation degree of 
the AR alleles, DNA was not able to be amplified by PCR. Therefore, the 
methylation degree of the AR gene has an inverse correlation with the PCR 
amplification. As a control, a non-digested DNA was used. To verify the efficacy 
of PCR amplification, DNA samples were run on 2% agarose gel (Figure 13). 
 
 
 
Figure 13. Electrophoresis in 2% agarose gel of the DNA samples of patients 1-9 after restriction 
and PCR amplification. The gel was done to verify the effectiveness of PCR amplification in order 
proceed to genotype sequencing. R = restricted sample; NR= non restricted sample. 
 
 
The amplified samples were genotyped with capillary electrophoresis and 
analysed by Peak Scanner® software. The area of each peak calculated by the 
software corresponds to the amplification of the single allele and, therefore, it is 
inversely correlated to the methylation degree of that allele. Raw data were 
normalised to the genotyping results from the alleles of genomic DNA not 
exposed to enzymatic digestion. The inactivation pattern was considered skewed 
if the ratio between the percentage inactivation of each AR gene was greater than 
80%. Methylation degree and X inactivation pattern were then related to the 
severity of muscle impairment according to the scores of the single muscle groups 
and to total CSS. Figure 14 shows three different examples of the results of 
genotype peak analysis with the pattern of a skewed X inactivation (A), a random 
inactivation (B) and two homozygous AR alleles (C). The results of the genotype 
analyses of AR alleles (with and without enzymatic restriction) of each patient 
and control are shown in table 8 and 9 respectively. 
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Figure 14. Genotype analyses of the CAG repeats in the first exon of the androgen receptor (AR) 
gene. On the left are shown the two AR alleles not digested by the restriction enzymes: on the right 
DNA was digested with the methylation-sensitive HpaII and HhaI restriction enzymes prior PCR 
amplification. PCR products, both before and after digestion, were electrophoresed on an ABI 
automated sequencer, and peak heights and area were analysed. In A: skewed X inactivation 
pattern where a peak of one allele is almost completely digested and therefore not amplified by 
PCR. The remaining peak corresponds to the inactive, methylated allele. In B: random X 
inactivation pattern where the ratio between the height of the two peaks is similar before and after 
enzymatic digestion. In C: homozygous (CAG)n in the AR gene where the two peaks overlap with 
each other. 
 
 
 
 
 
Figure 15. Distribution of the X inactivation pattern in patients (A) and controls (B). Both populations 
have a normal distribution of the values of the percentages of chromosome X inactivation (patients: 
W=0.95906, p=0.3311; controls: W=0.96008, p=0.1487; Saphiro-Wilk test). 
 
 42 
 
6 controls and 5 patients were homozygous for AR and were excluded from the 
analysis as it is impossible to distinguish the methylation degree between the two 
homozygous alleles. 28 patients presented a random inactivation pattern while the 
remaining 9 were skewed. Of those, one patient was affected by FSHD2. 35 
controls were randomly inactivated whilst 7 were skewed. Both populations of 
patients (W = 0.95906, p = 0.3311) and controls (W = 0.96008, p = 0.1487) 
showed a normal distribution of X chromosome inactivation pattern with skewed 
values corresponding to the tail of the curve (Figure 15). 
Finally, it was important to assess whether the X inactivation pattern correlated 
with the severity of the phenotype among the patient populations. A moderate 
linear correlation (rho = 0.574) was found between the percentage of X 
inactivation and the severity of the shoulder girdle involvement; the group with a 
skewed X inactivation had a shoulder girdle score significantly lower than the 
random X inactivation group (p< 0.01) (Figure 16A). No further significant 
differences were found in the other muscle groups although a trend was emerging 
between the abdominal muscle involvement, the total CSS scores and the 
percentage of X inactivation (Figure 16B, C). A significant inverse correlation 
(rho = -0.405) was found between the total CSS and the size of D4Z4 fragment 
(Figure 16D). The FSHD2 patients were not analysed in a covariate analysis due 
to the low number of individuals but their degree of inactivation was randomly 
distributed. 
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Figure 16. Correlations among the percentages of X inactivation, the CSS in different muscular 
districts and the D4Z4 size. In A: moderate linear correlation (Spearman’s rho=0.574) between the 
percentage of X inactivation and the severity of the shoulder girdle involvement. In the patients 
with a skewed X inactivation, the CSS of the shoulder girdle was significantly lower compared to 
the patients with a random inactivation (p<0.01; Mann Witney test). In B and C: linear correlation 
trend among the abdominal muscle involvement, the total CSS and the percentage of X 
inactivation. In D: significant inverse correlation (Spearman’s rho= -0.405) between the total CSS 
and the size of D4Z4 fragment. 
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Table 7. Clinical features of FSHD female patients included in the chromosome X inactivation 
study. Age of onset, age at the sample, scores of each muscle group and total CSS are shown. 
 
 Clinical Severity Score (CSS) 
Patients 
Age 
of 
onset 
Age at 
the 
sample 
Face 
Arm 
abduction 
Proximal 
upper 
limb 
Distal 
leg 
Pelvic 
girdle 
Abdo-
men 
Total 
1 asympt. 63 0 0 0 0 0 0 0 
2 35 73 2 1 2 2 5 1 13 
3 52 57 1 2 1 1 1 1 7 
4 13 29 2 3 1 1 3 1 11 
5 31 52 1 1 1 2 2 0 7 
6 59 63 0 1 2 1 0 0 4 
7 50 60 1 2 1 2 2 0 8 
8 39 45 1 1 0 0 1 1 4 
9 48 51 1 1 0 0 1 0 3 
10 60 67 1 1 1 1 2 1 7 
11 21 46 1 2 1 2 1 1 8 
12 23 54 1 2 1 0 0 0 4 
13 29 30 1 0 0 0 0 0 1 
14 asympt. 45 1 0 0 0 0 0 1 
15 60 67 1 1 1 1 1 0 5 
16 14 27 2 2 1 0 0 0 5 
17 57 65 0 1 1 1 0 0 3 
18 37 41 1 0 1 0 0 0 2 
19 16 42 1 2 1 1 1 1 7 
20 asympt. 38 0 0 0 0 0 0 0 
21 83 84 1 0 0 1 3 0 5 
22 18 33 1 0 1 0 0 0 2 
23 55 63 1 0 1 0 0 1 3 
24 asympt. 70 0 1 0 0 2 0 3 
25 asympt. 35 1 1 0 0 0 0 2 
26 53 63 2 2 1 1 2 0 8 
27 49 69 1 2 1 2 2 1 9 
28 40 65 1 1 1 1 2 0 6 
29 50 79 1 3 2 1 2 0 9 
30 29 35 0 0 1 0 0 0 1 
31 asympt. 14 0 0 0 0 0 0 0 
32 66 67 1 0 1 0 0 0 2 
33 10 24 0 3 2 2 4 1 12 
34 25 51 1 3 1 1 2 0 8 
35 60 65 1 2 2 2 2 0 9 
36 45 56 1 0 1 0 0 0 2 
37 11 18 1 2 1 0 0 0 4 
38 18 64 1 2 0 0 1 0 4 
39 67 72 2 2 2 1 4 0 11 
40 asympt. 53 0 0 0 0 0 0 0 
41 27 32 1 2 1 0 1 1 6 
42 61 62 1 0 0 1 0 0 2 
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 Restricted Non restricted  
Patients D4Z4 (Kb) 
AR 
allele 
1 
height 
AR 
allele 
2 
height 
AR 
allele 
1 
height 
AR 
allele 
2 
height 
Inactivation 
of one AR 
alleles (%) 
X 
inactivation 
pattern 
1 33 743 1687 1200 1056 28 Random 
2 19 2288 1217 2051 1811 62 Random 
3 33 1315 889 943 798 56 Random 
4 21 2454 1731 1053 780 51 Random 
5 33 1208 4500 4384 1964 11 Skewed 
6 28 523 223 1167 981 66 Random 
7 32 1275 855 1620 1206 53 Random 
8 28 856 786 854 733 48 Random 
9 35 1219 1039 1838 1393 47 Random 
10 24 5714 2880 1597 1183 60 Random 
11 33 3120 3503 3216 2413 40 Random 
12 34 2707 2311 949 636 44 Random 
13 32 1380 2393 2218 1710 31 Random 
14 21 508 1815 1255 496 10 Skewed 
15 35 2276 676 1216 1440 80 Random 
16 26 2564 2723 7112 5800 43 Random 
17 33 1747 1592 1490 1224 47 Random 
18 33 1788 1845 2252 1479 39 Random 
19 24 482 597 254 194 38 Random 
20 36 418 1274 2535 1902 20 Random 
21 36 831 236 2646 2439 76 Random 
22 35 651 919 901 838 40 Random 
23 27 1803 798 2448 2292 68 Random 
24 38 3459 694 2107 2452 85 Skewed 
25 28 701 939 830 774 41 Random 
26 20 772 3127 2623 2296 18 Skewed 
27 33 2526 1834 2057 1980 57 Random 
28 23 326 1040 2076 1662 20 Random 
29 38 751 0 1825 2056 100 Skewed 
30 35 725 3092 5690 4027 14 Skewed 
31 33 168 1538 1527 1240 8 Skewed 
32 36 and 38 257 1840 815 744 11 Skewed 
33 30 and 36 2893 1472 1261 1208 65 Random 
34 SMCHD1 353 264 275 154 43 Random 
35 SMCHD1 + 36 5871 1416 2065 1922 79 Random 
36 SMCHD1 227 2909 1994 1716 6 Skewed 
37 25 4349 5421 homozygous N.D. 
38 35 5403 3497 homozygous N.D. 
39 40 6932 5230 homozygous N.D. 
40 36 1239 156 homozygous N.D. 
41 36 2459 1117 homozygous N.D. 
 
Table 8. Results of the genotype analysis of AR alleles performed on restricted and non-restricted 
DNA samples from 41 FSHD female patients. When the ratio between the percentage inactivation 
of each AR allele was greater than 80%, the X inactivation pattern was considered skewed. 5 
patients were homozygous for AR alleles and, therefore, was not possible to determine the 
percentage pattern. 
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Table 9. Results of the genotype analysis of AR alleles performed on restricted and non-restricted 
DNA samples from 48 healthy controls. When the ratio between the percentage inactivation of 
each AR allele was greater than 80%, the X inactivation pattern was considered skewed. 6 
individuals were homozygous for AR alleles and, therefore, was not possible to determine the 
inactivation pattern. 
 Restricted AR Non restricted  
Controls 
AR 
allele 
1 
height 
AR 
allele 
2 
height 
AR 
allele 
1 
height 
AR 
allele 
2 
height 
Inactivation 
of one AR 
alleles (%) 
X 
inactivation 
pattern 
1 2218 209 260 324 93 skewed 
2 1067 348 1512 1406 74 random 
3 516 975 354 230 26 random 
4 620 1143 592 413 27 random 
5 53 139 1398 1145 24 random 
6 155 292 1974 3037 45 random 
7 246 182 2102 1888 55 random 
8 150 205 2167 1815 38 random 
9 330 2482 2514 1941 9 skewed 
10 1835 605 433 459 76 random 
11 1368 2104 1074 619 27 random 
12 1031 1558 122 57 24 random 
13 2223 2076 312 270 48 random 
14 2241 1072 5021 3937 62 random 
15 510 905 457 517 39 random 
16 1843 1325 553 418 51 random 
17 339 827 624 528 26 random 
18 760 303 753 517 63 random 
19 301 290 446 293 41 random 
20 1507 827 865 688 59 random 
21 1069 1661 596 560 38 random 
22 187 361 420 236 23 random 
23 1168 560 505 422 64 random 
24 1593 391 393 444 82 skewed 
25 426 560 447 351 37 random 
26 404 735 2546 1912 29 random 
27 1311 325 318 308 80 random 
28 2334 1291 1654 1518 62 random 
29 4185 690 2177 2194 86 skewed 
30 935 699 1280 1154 55 random 
31 1157 255 1146 1058 81 skewed 
32 330 1057 289 237 20 random 
33 1482 545 642 332 58 random 
34 196 106 734 857 68 random 
35 592 588 745 620 46 random 
36 431 1668 1586 776 11 skewed 
37 263 175 1451 702 42 random 
38 507 522 358 359 49 random 
39 940 1349 756 528 33 random 
40 619 119 509 455 82 skewed 
41 219 282 232 169 36 random 
42 657 621 990 357 28 random 
43 1378 2324 homozygous N.D. 
44 2957 3204 homozygous N.D. 
45 5432 4396 homozygous N.D. 
46 945 734 homozygous N.D. 
47 7047 861 homozygous N.D. 
48 2373 3842 homozygous N.D. 
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Chapter 4 
Discussion 
 
Facio-scapulo-humeral dystrophy is a complex disease characterised by high 
variability in phenotype expression that challenges our ability to foresee its 
course. A comprehensive pathogenic model, able to explain all the several 
discrepancies reported in literature, is still missing and, therefore, genotype-
phenotype correlations are hard to estimate. The overexpression of DUX4, due to 
the contraction of D4Z4 and its selective hypomethylation, undoubtedly plays a 
significant role in disease pathogenesis but, at the same time, there is evidence 
suggesting that other alterations are required to trigger the process that leads to the 
manifestation of the disease. 
Considering the variability in phenotypic expression and the lack of reliable 
tools to predict the progression of the disease, a clinical follow-up of the FSHD 
cohort of Padova was performed re-evaluating 55 patients, visited from 2008 to 
2013, after an average time lapse of 5 years. The Clinical Severity Score (CSS) 
was used for the clinical assessment of the patients. The CSS is a specific scale 
validated in 2007 by the neuromuscular centre of Padova, in collaboration with 
the Italian Consortium for FSHD, a nation-wide network established to set up an 
Italian registry of FSHD patients and to investigate its genotype-phenotype 
correlations and pathogenic mechanisms. The CSS was created with the intent to 
provide a reliable and standardised protocol to use in clinical trials and 
epidemiological studies in which a uniform evaluation of the patients was 
required. However, its reliability and sensitivity were not previously tested in the 
follow-up of the patients. 
  The whole population was split into probands and relatives and the latters 
were further subdivided between symptomatic and asymptomatic subjects. At the 
time of the first evaluation (T0), less than half of the relatives (40%) had clinical 
symptoms although they carried the D4Z4 fragment of the probands. As expected, 
probands showed a more severe involvement, measured by CSS, and a lower age 
of onset compared to their relatives while the penetrance of the disease decreases 
among the relatives. As the degree of kinship increases, each relative carries a 
genetic background progressively less close to the proband. Therefore, although 
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relatives and probands have in common the same D4Z4 mutation, different 
genetic factors largely modulate the phenotypic expression of the disease. 
The higher age of onset within the relatives could be partially explained by the 
fact that the proband, being more affected, was the first member of the family to 
be diagnosed. The other relatives usually have only mild involvement and tend to 
underestimate their symtpoms causing a delay in their detection and making it 
difficult to determine the correct date of onset.  
With respect to the whole cohort of patients, the D4Z4 fragement showed a 
normal distribution ranging between 19 Kb and 40 Kb. Analysing the genotype-
phenotype correlations, in the probands’ group, the D4Z4 size was inversely 
correlated with the severity of the symptoms as the most affected patients carried 
the smallest D4Z4 fragment. On the other hand, this correlation was lost within 
the relatives. This could be due to the fact that the probands’ CSS was more 
uniformely distributed and clustered around a score of 6. Conversely, in the 
relatives group, the phenotype expression was more variable with the consequent 
dispersal of CSS values and the loss of correlation between the severity and the 
D4Z4 fragment size. 
The comparison of the CSS values between T0 and T1 showed that only the 
probands had a significant worsening of the disease. Disease progression was 
definitely slower within the relatives, and the CSS was not able to detect any 
significant differences. Noteworthy, those individuals who were asymptomatic at 
T0 did not express the disease over the entire period of the follow-up. The slow 
progression of the disease is further confirmed by the fact that, once the patients 
were clustered according to different follow-up periods, significant differences 
were found only in those subjects with the longest time lapse between T0 and T1 
(more than 5 years). Males and females showed a similar pattern of disease 
progression. 
With respect to the MRC scores of each muscle, there was a significant 
worsening in the strength of the biceps brachii, triceps brachii and tibialis anterior. 
However, in the CSS functional scale, only the pelvic girdle showed a significant 
progression of the impairment while arm abduction and involvement of facial and 
abdominal muscles were unchanged. It is worth noting that the worsening 
measured by the MRC score did not correlate with the loss of function measured 
by the CSS due to the lack of sensitivity of the latter. In fact, for the upper limb, a 
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MRC score > 3/5 or ≤ 3/5 represents the cut-off between a CSS of 1 and 2 where a 
score of “2” is the highest achievable. Therefore, for every MRC scores < 3/5, the 
CSS lack a corresponding level of worsening with a consequent loss of sensitivity. 
A similar threshold effect happens also when the MRC scores of the distal leg are 
compared to the function measured by the CSS. When the patients loose their 
ability to walk on both the heels and the tiptoes, any further worsening of the 
muscle strength measured by the MRC score does not modify any further the 
functional CSS value. 
According to these results, the CSS seems to provide a detailed picture of the 
general impairment of the patient but the results are not reliable in the detection of 
subtle modification during the follow-up. Moreover, neither the size of the D4Z4 
fragment nor gender were relevant in predicting the course of the disease. 
It is likely that the contraction of the D4Z4 fragment is necessary to initiate the 
pathological mechanisms underlying FSHD but other, yet unknown, factors (both 
genetic and environmental) play a role in modulating disease progression. 
Moreover, although females have been reported to have a milder phenotype, they 
do not differ from males in disease progression suggesting that the genetic or 
hormonal factors that protect females from developing symptoms are no longer 
effective once the disease is triggered. 
The second part of this study aimed to identify possible genetic modifiers that 
modulate the phenotypic expression of FSHD. The identification of FSHD2 
patients with mutations in SMCHD1 was particularly relevant. SMCHD1 
mutations have been reported to cause D4Z4 hypomethylation regardless of 
fragment contraction (Lemmers et al, 2012) and to be associated with more severe 
phenotypes when inherited together with an abnormal D4Z4 (Sacconi et al, 2013). 
Among the FSHD population of Padova, 9 subjects with typical FSHD 
phenotype and a normal D4Z4 fragment were identified to be tested for SMCHD1 
mutations. The analysis of D4Z4 fragment size is not straightforward and, 
therefore, it was repeated in order to avoid false negatives. Indeed, 3 subjects 
among the 9 tested carried a previously undetected pathological D4Z4 fragment. 
Of the remaining 6 patients, 4 of them carried SMCHD1 mutations and all the 
mutations detected showed pathogenic potential as they were associated with 
hypomethylation of the D4Z4 region. However, the molecular analyses of the 
first-degree relatives of one proband showed that mutations in SMCHD1 are not 
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alone sufficient to cause the disease. In the family studied, the only member 
affected was the proband that carries the SMCHD1 mutation combined with a 
permissive 4qA161 haplotype. All the other relatives, who were positive for the 
4qB haplotype, were asymptomatic despite the presence of the same SMCHD1 
mutation and consequent D4Z4 hypomethylation. These results are consistent 
with the pathogenic model proposed by Lemmers and colleagues in 2010; they 
proposed that the D4Z4 hypomehtylation needs to be combined with a permissive 
4qA haplotype to cause the toxic overexpression of DUX4 and, therefore, the 
phenotypic expression of the disease. FSHD2 patients showed a similar 
phenotypic expression to the more common FSHD1, with similar variability 
among severity of symptoms, age of onset and disease progression. Of particular 
interest is the case of patient 5 who carried both D4Z4 fragment contraction and 
SMCHD1 mutation. She had a late onset of the disease after menopause that could 
suggest a protective role of female hormones as previously hypothesised in recent 
reports (Ricci et al, 2013). However, the patient showed a fast progression 
reaching a high CSS (9) in less than a decade.  It is reasonable to think that this 
unusal course of the disease is due to the combined action of the SMCHD1 
mutation and the D4Z4 fragment contraction. Although the number of the patients 
studied were not sufficient to make any statistical inference, these data are in 
agreement with reports in the literature and suggest that SMCHD1 plays a 
significant role in the phenotype expression of FSHD. Therefore, its mutations 
should be searched for in all the patients negative for D4Z4 contraction and in 
those with a severe and fast progressive phenotype. 
Considering that the impairment of genome methylation is one of the main 
causes of the disease, that SMCHD1 is implied in chromosome X inactivation 
during embryogenesis, and that phenotypic differences have been frequently 
reported between genders, it was reasonable to suspect that some genetic 
modifiers could be located on chromosome X and their function impaired by an 
inbalanced inactivation of the chromosome itself. Therefore, the last part of the 
study focused on the assessment of chromosome X inactivation pattern in the 
FSHD female population. 
The inactivataion of chromosome X is distributed as a continuous value, such 
as height and weight, and happens randomly in the healthy population. 
Consequently, a variable proportion of healthy individuals have a skewed X 
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inactivation that corresponds to different percentiles of the curve. The threshold at 
which the inactivation is considered skewed is arbitrary and, frequently, is set at 
80% of the cells (Amos-Landgraf et al, 2006). 
The FSHD female cohort of the study showed a normal distribution of the 
chromosome X inactivation and did not differ to the distribution observed in the 
healthy control population. Moreover, once the distribution of X inactivation was 
studied among the patient population, it did not correlate with the severity of the 
phenotype measured by the total CSS. Only the score of the shoulder girdle was 
lower among the patients with a skewed X inactivation compared to those with a 
random pattern. Both FSHD1 and FSHD2 cases were included in the analyses. 
The patients with SMCHD1 mutations were only 4 and, although the number was 
not sufficient to reach any statistical significance, X inactivation was randomly 
distributed. 
These results suggest that the impairment of methylation, in the pathogenesis 
of FSHD, is confined to the 4q35 region, further confirming that local 
rearrangements of the D4Z4 fragment are mainly involved. Therefore, the control 
of chromosome X methylation seems to be unaffected and inactivation happens 
randomly as in the healthy individuals. Moreover, it is important to note that 
SMCHD1 acts in the final stages of the inactivation process (Blewitt et al, 2008) 
presumably once the chromosome to be inactivated has already been selected. The 
differences found in the symptom severity between patients with skewed and non-
skewed inactivation are subtle although a slight trend is detectable, suggesting a 
more severe phenotype among those individuals with a chromosome X random 
inactivation. A higher number of patients is needed, however, to reach a final and 
more reliable conclusion regarding the possible role of the chromosome X 
inactivation as a genetic modifier of phenotype expression. 
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Conclusions 
 
 
Although the diagnosis of facio-scapulo-humeral dystrophy is usually 
straightforward considering the characteristic clinical features, the prediction of 
the clinical course is hard to define due to the high variability of its phenotype 
expression. This should be taken into account in the evaluation of the prognosis 
and during the genetic counselling. 
The follow-up study performed in the FSHD patients of Padova confirmed that 
the disease has, usually, a long slow progression over the years, independent of 
gender and of the D4Z4 fragment size. The proximal muscles of the upper limbs 
and the distal leg are the regions where the disease shows the greatest progression. 
The evaluation scale used, the Clinical Severity Score, was not sensitive enough 
in the detection of minor changes of muscle strength and, therefore, is not reliable 
for the follow-up of the patients. More sensitive tools, either clinical, instrumental 
or biochemical, or combined, are required in order to monitor the progression of 
the disease over time. 
The identification of genetic modifiers represents another major aim for the 
understanding the phenotype expression and clinical course of FSHD. Mutations 
in SMCHD1 were pathogenic in all the patients studied and also actively 
contributed to determine a more severe phenotype when inherited together with a 
D4Z4 fragment contraction. Moreover, the haplotype analyses of the FSHD2 
patients further confirmed that a permissive genetic background is needed for the 
full development of the disease. 
Finally, the chromosome X inactivation pattern appeared not to differ between 
healthy and affected females suggesting that the pathogenic mechanisms 
underlying the disease do not include? The methylation process of chromosome X 
during embryogenesis. Nonetheless, female patients with a skewed inactivation of 
chromosome X seem to have a milder phenotype, in particular regarding the 
involvement of the shoulder girdle. Therefore, a greater number of patients is 
needed to reach final conclusions for the role of chromosome X inactivation as 
genetic modifier of the disease. 
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Part II 
 
SHP2: a novel therapeutic target in MuSK-myasthenia 
 54 
 
Abstract 
 
Muscle Specific Kinase antibody myasthenia gravis (MuSK-MG) is an 
autoimmune disease that impairs neuromuscular transmission leading to 
widespread muscle weakness and fatigability. Under physiological conditions, 
agrin activates the LRP4-MuSK complex, initiating a phosphorylation cascade 
that culminates with the clustering of acetylcholine receptors (AChRs). SH2 
domain-containing phosphatase (SHP2) is a negative regulator of AChR 
clustering that inhibits MuSK phosphorylation. In MuSK-MG, (auto)antibodies 
against MuSK, mainly of the IgG4 subclass, block MuSK interaction with LRP4 
and, therefore, its activation. The smaller population of MuSK IgG1-3 appear to 
act by a different mechanism. Although MuSK-MG is a treatable disease, a 
therapy that targets specifically its pathogenic mechanisms is still not available. 
The aim of this study was to confirm and extend preliminary findings that 
demonstrated the in vitro effects of a specific SHP2 inhibitor, NSC-87877, as a 
potential specific treatment for MuSK-MG.   
Total IgG and IgG subclasses (IgG1-3, IgG4) were purified from plasma of 3 
MuSK-MG patients. MuSK-Ab titres were measured by radioimmunoassay. To 
test the effects of NSC-87877 on MuSK phosphorylation and AChR clustering, 
C2C12 myotubes were used.  The myotubes were incubated with increasing 
concentrations of NSC-87877 at different time intervals (from 15 to 360 minutes) 
using agrin and DMEM as positive and negative controls respectively. To test 
whether the drug was able to reverse the pathogenic effects of MuSK-Abs, 
myotubes were then exposed to agrin either with MuSK total IgG, IgG1-3 or 
IgG4, in the presence or absence of NSC-87877. MuSK expression and tyrosine 
phosphorylation were detected by western blotting, and the phosphorylation 
expressed as the ratio of the densitometry values of phospho-tyrosine MuSK to 
total MuSK. For AChR cluster quantification, myotubes were labelled with α-
bungataroxin-594 followed by image acquisition and analysis with ImageJ 
software.  For all experiments 20 images were scanned, coded, and the number of 
clusters > 5 µm counted using ImageJ. 
In the absence of agrin, NSC-87877 caused a dose-dependent increase in both 
MuSK phosphorylation and AChR clustering, reaching a maximum at 100 µM, 
after 40 minutes of incubation. 100 µM NSC-87877 enhanced MuSK 
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phosphorylation in the presence of MuSK total IgG and purified IgG4 while no 
significant change was observed with purified IgG1-3. Nevertheless, MuSK total 
IgG and both subclass fractions caused the dispersal of AChR clusters (see also 
Koneczny et al, 2013), and NSC-87877 was able to reverse their pathological 
effects in all samples. 
SHP2 inhibition by NSC-87877 induced MuSK phosphorylation and increased 
AChR clustering regardless of direct stimulation by agrin. Moreover, NSC-87877 
effectively induced MuSK activation despite the inhibitory effects of MuSK IgG4 
antibodies, and enhanced AChR clustering in the presence of all the different IgG 
subclasses. Therefore, irrespectively of the MuSK IgG subclass, SHP2 inhibition 
represents a potential therapeutic strategy in MuSK myasthenia and further studies 
should access its efficacy and reliability in vivo. 
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Chapter 1 
Introduction 
 
Myasthenia gravis is an autoimmune disease that impairs transmission at the 
neuromuscular junction. It is a heterogeneous disorder with respect to its clinical 
manifestations and pathogenic mechanisms. From a clinical point of view, its key 
features are distinct as they consist of fluctuating weakness in skeletal muscles 
which deteriorates during effort and improves with rest. On the other hand, the 
range of severity is wide, from mild and inconstant involvement of the ocular 
muscles to life-threatening respiratory impairment. 
The disease is caused by antibodies directed against various proteins expressed 
at the neuromuscular junction. Symptoms and response to treatment vary partially 
according to which antibody is responsible for the disease. Therefore, identifying 
the antibody is a fundamental step not only for correct diagnosis but also to 
choose and administer the most effective therapy. 
Myasthenia gravis is usually a treatable disease and the therapeutic options 
include steroids, immunosuppressant and immunomodulatory drugs. Although 
these treatments are often effective to control the symptoms, they lack specificity 
and might cause important side effects as they target the whole immune system. 
The purpose of this thesis was, therefore, to analyse the in vitro effects of a novel 
therapeutic strategy that could provide an additional and specific treatment for 
patients. 
 
1.1) Epidemiology  
 Due to its heterogeneity in clinical and immunological aspects, it is difficult to 
make a precise estimation of the prevalence and incidence of myasthenia. If we 
consider the disease as a whole, a recent meta-analysis that pooled 55 studies 
performed between 1950 and 2007 in different countries around the world, 
showed an overall incidence rate of 5.3:1000000 population-year and a prevalence 
rate of 77.7 cases/1000000 population (Carr et al, 2010). It is worth noting that the 
prevalence has been rising over the last 40 years. This could be due to a more 
accurate diagnosis following the introduction of the radioimmunoassay to detect 
antibodies titres, to better health care of the patients and, finally, to more precise 
statistical analyses. There is also evidence that the incidence is increasing among 
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elderly people and this seems to be due only partially to a prolonged life 
expectancy (Pakzad et al, 2011; Phillips et al, 1996; Vincent et at, 2003; Matsui et 
al, 2009; Somnier et al, 2005). 
 The incidence of myasthenia differs significantly between males and females. 
Males present the peak of incidence after the age of 60, whilst females have a 
bimodal distribution with two different peaks, one during the fertile period 
between the second and third decade, the second after the menopause, at a similar 
age to men (Vincent et al, 2003; Carr et al, 2010; Heldal et al, 2009). 
 The variations in incidence and prevalence rates observed between the studies 
of the meta-analysis represent evidence of the heterogeneous background of 
myasthenia. Age of onset, gender and geographical distribution vary significantly 
according to HLA genotypes, thymus involvement and type of antibodies that 
sustain the disease. For example, in North America and Europe, HLA-DR3 and B8 
alleles are strongly associated with early onset of the disease with thymic 
hyperplasia (Compston et al, 1980; Janer et al, 1999) while late-onset cases are 
weakly associated with HLA-DR2 and B7 (Giraud et al, 2008). HLA-DR9 allele 
represents a risk factor for Asian people and they seem to have a higher incidence 
of infantile cases (onset <15 years) particularly in China and Japan (Chen et al, 
1993; Matsuki et al, 1999; Yu et al, 1992; Zhang et al, 2007). With respect to the 
type of antibodies, myasthenia with antibodies against Muscle Specific Kinase 
(MuSK) often presents at a younger age with female predominance and its 
frequency decreases with distance from the equator (Sanders et al, 2003; Evoli et 
al, 2003; Guptil et al, 2011; Vincent et al, 2008).  
 
1.2) Clinical features 
 Myasthenia gravis was first described as a distinct clinical entity in 1672 by 
Thomas Willis who reported the case of a woman with a fluctuating palsy of her 
limbs and tongue (Hughes, 2005). In his book “De anima Brutorum”, Willis 
draws an accurate picture of the basic symptoms that characterise myasthenia 
writing that “those who be in trouble with a scarcity of spirits, are able at first 
rising in the morning to walk, move their arms this way and that, or to lift up a 
weight with strength; but before noon, the stores of spirits which influenced the 
muscles being almost spent, they are scarce able to move hand or foot”.  
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The name myasthenia gravis was coined in late 19th century fusing the Greek 
words “μῦς” (muscle) and “ἀσθένεια” (weakness). The Latin adjective “gravis” 
was added in order to highlight the severity that in the past characterised the 
prognosis of the disease, almost inevitably fatal, when no treatment was available 
(Keesey, 2002). 
Patients present a typical fluctuating weakness that involves different skeletal 
muscle groups. Muscle fatigue worsens with exercise and improves with rest, 
sometimes with full recovery. Therefore, symptoms are usually mild or even 
absent during the first hours after awakening and tend to worsen during the day 
with a characteristic circadian pattern. In over 85% of patients, the onset of the 
disease involves the extraocular muscles that control gaze movements (Grob et al, 
2008). This causes diplopia and ptosis of the eyelids, often asymmetrical, 
exacerbated by activities that imply focus of the gaze such as reading, watching 
television or driving. 
Within two years from an ocular onset, between 50% and 80% of the patients 
have generalisation of the weakness with limb and/or bulbar involvement 
(Antonio-Santos et al, 2008). If the symptoms remain confined to the ocular 
muscles for more than two years, is very unlikely that the disease will spread to 
other muscles (Kerty et al, 2014). In the generalised form, muscle weakness 
usually is symmetrical and more proximal than distal, although cases with 
prevalent distal and asymmetrical involvement have been reported (Rodolico et al, 
2003; Nations et al, 1999). In a small percentage of cases (up to 15%), the 
impairment of the bulbar muscles represents the first manifestation of the disease 
causing life-threatening symptoms like dysphagia, dysarthria, dysphonia and 
dyspnea (Meriggioli et al, 2009). A quick diagnosis and prompt treatment are 
fundamental in these cases.   
Myasthenia has a relapsing-remitting course. Exacerbations of the symptoms 
are due mainly to intermittent infections, concomitant treatments for other 
diseases (such as antibiotics, anticonvulsants, statins, anaesthetics, and 
antihypertensives), unplanned or too quick withdrawal of the therapy, pregnancy, 
or surgeries. A severe exacerbation that requires a prompt intubation of the 
airways due to the failure of respiratory muscles defines the myasthenic crisis 
(Bedlack et al, 2002). About 10-20% of the patients experience this kind of crises 
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at least once during their illness and up to 20% of them have a crisis as the first 
manifestation of myasthenia (Wendell et al, 2011).  
The disease tends to progress to highest severity during the first 5 years after 
the onset and, in this period, crises are also more frequent. After this initial period, 
myasthenia usually stabilises in terms of of general symptomatology and 
exacerbations while permanent and spontaneous remission occurs in about 10% of 
the cases (Grob et al, 2008). 
 
1.3) Quantification of clinical severity 
According to the severity and distribution of muscle weakness, myasthenic 
patients are divided into the following five classes: 
 
 Class I: Any ocular muscle weakness. May have weakness of eye closure. 
All other muscle strength is normal; 
 Class II: Mild weakness affecting other than ocular muscles; may also 
have ocular muscle weakness of any severity; 
- IIa: Predominantly affecting limb, axial muscles, or both. May also 
have lesser involvement of oropharyngeal muscles;  
- IIb: Predominantly affecting oropharyngeal, respiratory muscles, or 
both. May also have lesser or equal involvement of limb, axial 
muscles, or both; 
 Class III: Moderate weakness affecting other than ocular muscles; may 
have ocular muscle weakness of any severity; 
- IIIa: Predominantly affecting limb, axial muscles, or both. May also 
have lesser involvement of oropharyngeal muscles;  
- IIIb: Predominantly affecting oropharyngeal, respiratory muscles, or 
both. May also have lesser or equal involvement of limb, axial 
muscles, or both; 
 Class IV: Severe weakness affecting other than ocular muscles; may have 
ocular muscle weakness of any severity; 
- IVa: Predominantly affecting limb, axial muscles, or both. May also 
have lesser involvement of oropharyngeal muscles;  
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- IVb: Predominantly affecting oropharyngeal, respiratory muscles, or 
both. May also have lesser or equal involvement of limb, axial 
muscles, or both; 
 Class V: Defined by intubation, with or without mechanical ventilation, 
except when employed during routine postoperative management. The use 
of a feeding tube without intubation places the patient in class IVb. 
 
This classification was introduced and validated by the Myasthenia Gravis 
Foundation of America (Jaretzki et al, 2000) and represents a quick and reliable 
system to categorise the patients for therapeutic research trials and, nowadays, is 
broadly used in the clinical practise.  
 
1.4) Clinical subtypes 
 As mentioned above, myasthenia is a heterogeneous disease sustained by 
different pathogenic mechanisms. The classification of its different subtypes 
reflects this heterogeneity and takes into account epidemiology, thymic pathology 
and type of antibodies detected. 
 
1.4.1) AChR-MG 
 The most common myasthenia subtype (80% of all cases) is caused by 
antibodies (abs) directed against the acetylcholine receptor (AChR). AChR-Ab 
positive myasthenia is usually classified into the following groups according to 
the age of onset and to the associated thymic pathology: 
- Early-onset myasthenia: the onset is set before the age of 40-50, and females 
are more affected than males with a ratio of 3:1 (Meriggioli et al, 2009). 
Thymic follicular hyperplasia is a common feature and patients usually 
respond well to thymectomy. There is a strong association with HLA-DR3, 
HLA-B8 and with other autoimmune diseases, especially thyroiditis 
(Compston et al, 1980; Klein et al, 2013) both in the patient and their 
families. 
- Late-onset myasthenia: the age of onset is usually considered after 50 years, 
although this threshold could vary between different studies. Males are more 
affected than females (approx 1.5:1) and thymic pathology is rare (Aarli, 
2008; Marx et al, 2013). Therefore, thymectomy is usually not indicated in 
 61 
 
these patients. There is a weak association with HLADR2, HLA-B7, and HLA-
DRB1*15:01 (Compston et al, 1980). 
- Thymoma-associated myasthenia: in this case the disease is considered 
paraneoplastic as it is sustained by the tumour that affects the thymus. It 
accounts for about 10-15% of all myasthenic patients (Grob et al, 2008) and 
virtually all of them have AChR antibodies. Frequently, antibodies against 
other muscle intracellular antigens (titin, ryanodine receptor) have been 
reported (Aarli et al., 1998, Marx et al., 1998) and antibodies against voltage-
gated K+ channel (Kv1.4) have been associated with concomitant diagnosis 
of myocarditis (Suzuki et al, 2014). Antibodies against titin or ryanodine 
receptor are a frequent finding in late onset myasthenia while they have been 
detected rarely in early-onset forms. Therefore, the presence of these 
antibodies in young patients is highly suggestive for the presence of thymoma 
(Buckley et al, 2001). However, these antibodies are also found in late-onset 
MG with no detectable thymoma. The incidence of thymoma reaches the 
peak at the age of 50 and there is no gender predominance (Marx et al, 2013) 
while the presentation tends to be more severe compared to non-thymomatous 
forms. 
 
1.4.2) MuSK-MG 
MuSK is a transmembrane tyrosine kinase located at the muscular sarcolemma 
that is indispensable for the correct development and the maintenance of the high 
density of AChRs at the neuromuscular junction. Its role will be described in 
some detail below. Antibodies directed against MuSK were first described in a 
population of seronegative myasthenic patients by Hoch and colleagues in 2001. 
The original study suggested that MuSK-Abs were responsible for about 70% of 
all the seronegative cases, but more recent findings showed that this percentage 
depends greatly on the population studied with significant variations among the 
different cohorts (Vincent et al, 2005). 
MuSK-MG represents an important subgroup and differs from the more 
common form with AChR-Abs in terms of epidemiology, muscle involvement 
and response to treatment. The disease affects mainly females in the third decade 
(Gutpill et al, 2011; Evoli et al, 2003) and is not commonly reported in elders or 
children (Pasnoor et al, 2010; Skjei et al, 2013). Considering the higher frequency 
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of the disease in the populations that live closer to the equator (Vincent et al, 
2008), together with the HLA-DQ5 association which is the same in different 
European centres (Niks et al, 2006, Bartoccioni et al, 2009; Alahgholi-Hajibehzad 
et al, 2013), environmental factors and genetic background both appear to play a 
significant role in the pathogenesis of MuSK-MG. From a clinical point of view, 
ocular muscles and limbs are often mildly affected compared to the bulbar 
muscles that are often severely impaired with high frequency of respiratory crises 
(Evoli, 2006; Gutpill et al, 2011). No association with thymic pathology has been 
reported so far and, therefore, thymectomy is not indicated (Marx et al, 2013). 
 
1.4.3) LRP4-MG 
 Antibodies against the Low-density-lipoprotein Receptor-related Protein 
4 (LRP4) have been detected in a variable proportion (2-27%) of patients without 
AChR or MuSK-Abs (Higuchi et al, 2011; Zhang et al, 2012; Pevzner et al, 2012). 
Different tests, including cell-based assay (CBA) and ELISA, were used to 
estimate the level of antibodies and this could explain part of the reason for the 
incidence variability in seronegative patients. 
LRP4 is upstream MuSK in the AChR clustering pathway (see below) and 
mediates MuSK activation, but the pathogenicity of LRP4-antibodies in 
myasthenic patients is still a matter of debate. However, in vitro experiments 
showed that LRP4-antibodies are able to reduce agrin-dependent AChR clustering 
(Zhang et al, 2012; Pevzner et al, 2012) and a passive immunisation model had 
clinical and neurophysiological myasthenic features (Shen et al, 2013). Patients 
with detectable levels of LRP4-antibodies are usually females presenting with 
ocular symptoms or mild generalised involvement while the most severe cases 
often have double positivity with MuSK-Abs (Higuchi et al, 2011). 
 
1.4.4) Seronegative myasthenia  
 Seronegative myasthenia (SNMG) is defined always by the absence of 
antibodies against well characterised antigens such as AChR, MuSK or LRP4 in 
patients who have clinical and neurophysiological features consistent with the 
diagnosis of myasthenia. Seronegative cases count for about 15% of all the 
patients and for roughly 50% of the pure ocular forms (Kerty et al, 2014). The 
introduction of a cell-based assay with rapsyn-induced clusters of the 
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acetylcholine receptor improved detection of AChR-Abs in patients who 
otherwise were negative in the traditional radioimmunoassays for AChR or MuSK 
antibodies (Leite et al, 2008; LRP4 was unknown at this time). Up to 66% of 
SNMG patients present these “low-affinity” AChR antibodies. 
Subsequent to the definition of ACHR, MuSK and LRP4 as relevant antigens, 
several other proteins of the neuromuscular junction, such as agrin, cortactin or 
collagen Q, have been proposed as potential targets for antibodies in seronegative 
patients (Cossins et al, 2012; Gasperi et al, 2014; Gallardo et al, 2014, Zoltowska 
Katarzyna et al, 2015) and low titres of antibodies against agrin have been 
reported, but often co-existing with AChR or MuSK-Abs (Zhang et al, 2014). 
Despite the increasing number of reports, the specificities of these antibodies are 
unclear and their potential pathogenic effects unexplored.  
 
1.5) Structure and physiology of the neuromuscular junction 
 The different subtypes of myasthenia gravis have in common an initial 
dysregulation of the immune system that leads to the production of autoantibodies 
against different antigens of the neuromuscular junction. AChR-Abs have been 
proven to be pathogenic causing the destruction and dispersal of the acetylcholine 
receptor clusters located on the muscle membrane in correspondence of the nerve 
terminal. In order to understand the pathogenic mechanisms that cause each form 
of myasthenia, is important to describe first the normal structure, development and 
physiology of the neuromuscular junction. 
 
1.5.1) Principles of development of the neuromuscular junction and the agrin-
LRP4-MuSK pathway 
 The neuromuscular junction is a chemical synapsis between the second motor 
nerve and the surface of skeletal muscle, using acetylcholine as the main 
neurotransmitter. Due to its accessibility and to the apparent simplicity of its 
connections, the neuromuscular junction represents a very well-studied and 
understood model of synaptic transmission. 
The formation of the junction requires a complex signalling process, both 
spatially and temporally, between the motor neuron and the muscle myotubes. The 
end of this process results in the clustering of acetylcholine receptors on the 
postsynaptic side and a differentiated nerve terminal on the presynaptic one 
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(Burden, 2002). During embryonic development, the motor nerve, sprouting from 
the spinal anterior columns, targets the muscle fibres and starts the innervation 
preferentially where pre-patterned AChR clusters are expressed (Panzer et al, 
2006; Flanagan-Steet et al, 2005). The axon of a single motor nerve innervates 
multiple muscle fibres generating large motor units. The final dimension of each 
motor unit is then determined by the intensity of the neural activity Wyatt et al, 
2003; Chung et al, 2009). 
Several proteins are involved in the maturation process and in the maintenance 
of the structure of the neuromuscular junction. Synaptic laminins are responsible, 
for example, for the correct relative positioning of each synaptic element 
(Nishimune et al, 2008). However, the most important role in both pre- and post-
synaptic development of the synapsis is played by the agrin-LRP4-MuSK 
pathway that leads to the clustering of the AChR receptors (Figure 1). Agrin is a 
heparan-sulfate proteoglycan secreted into the synaptic cleft by the motor nerve 
terminal. Its receptor, LRP4, is located on the muscular sarcolemma (Glass et al., 
1996; Zhang et al, 2008) and has specific effects on both sides of the junction. At 
first, LRP4 contributes to the pre-synaptic maturation of the nerve terminal 
increasing the clustering of acetylcholine vesicles through a retrograde signalling 
(Yumoto et al, 2012). Most importantly, LRP4 is the key intermediary protein that 
induces MuSK activation following agrin stimulation (Zhang et al, 2011). Both 
LRP4 and MuSK are transmembrane proteins that form a heteromeric tetramer on 
the muscular sarcolemma. LRP4 interacts with MuSK even in the absence of agrin 
and this basal interaction is sufficient to partially activate MuSK causing the pre-
patterning of acetylcholine receptors in myotubes prior to innervation (Arber et 
al., 2002; Kummer et al., 2006). Since the innervation process starts where the 
pre-pattered AChR are located, the secretion of agrin by the motor nerve 
represents a fundamental step to strengthen the connection between the two sides 
of the junction, leading to the formation of mature AChR clusters and the 
establishment of a fully-operational neuromuscular synapse.  
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Figure 1. Schematic representation of the agrin-LRP4-MuSK-Dok7 clustering pathway. On the 
muscle sarcolemma, LRP4 and MuSK form a loose tetramer and AChRs are disperse (A). Once 
agrin is secreted by the motor nerve terminal into the synaptic cleft, it interacts with LRP4 
inducing a conformational change in the LRP4-MuSK tetramer. MuSK is activated and starts an 
autophosphorylation loop (B). Finally, through the mediation of Dok7, the phosphorylation 
cascade is triggered and culminates in the activation of rapsyn and AChRs clustering (C). 
Aggregation of AChRs in clusters is fundamental for a fast and effective response to acetylcholine 
stimulation and, therefore, for the correct signalling at the neuromuscular synapsis. 
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Figure 2. LRP4-MuSK-Dok7 structures and interactions. MuSK consists of an extracellular 
domain, a transmembrane helix, and an intracytoplasmic region. The extracellular part has three 
immunoglobulin-like domains (Ig1-3) and a cysteine-rich frizzled domain. The first 
immunoglobulin-like (Ig1) domain mediates the interaction with the extracellular region of LRP4. 
MuSK tyrosine kinase domain is located in the intracytoplasmic part of the protein and its 
juxtamembrane tyrosine residue 533 (Tyr533) starts the autophosphorylation of MuSK dimer. 
Other three tyrosine residues (Tyr750, Tyr754 and Tyr755) are then phosphorylated in an 
activation loop. To sustain MuSK activation, Dok7 is recruited and binds to Tyr 533 through its 
PTB domain. The PH domain mediates the dimerization of Dok7 and stabilises also MuSK dimer. 
MuSK and Dok7 activates each other this reciprocal activation starts the intracellular 
phosphorylation cascade that causes the clustering of the acetylcholine receptors. 
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The binding of agrin to the N-terminal of LRP4 induces a conformational 
change in the structure of the whole LRP4-MuSK tetramer that tightens the 
interaction of two molecules of MuSK (Zhang et al., 2011; Zong et al., 2012). 
This causes the autophosphorylation of the tyrosine residues located on the  
intracytoplasmic part of MuSK and the beginning of a phosphorylation cascade 
that determines the clustering of the acetylcholine receptors (Figure 1B, C). 
MuSK is a complex protein consisting of three main parts: an extracellular 
domain, a transmembrane helix, and an intracytoplasmic region (Figure 2). The 
extracellular part has three immunoglobulin-like domains (Ig1-3) and a cysteine-
rich frizzled domain. The first immunoglobulin-like (Ig1) domain is essential as it 
mediates the interaction with LRP4 and, together with the Ig2 domain, forms a 
dimer with another MuSK molecule (Zhang et al., 2011; Stiegler et al., 2006). A 
hydrophilic transmembrane helix connects the extracellular domains to the 
intracytoplasmic region that contains the tyrosine kinase. Within the first 
cytoplasmic juxtamembrane segment, there is a tyrosine residue 533 (Tyr533) 
which starts the autophosphorylation process that activates MuSK (Herbst and 
Burden, 2000). Three other tyrosine residues located in the kinase domain 
(Tyr750, Tyr754 and Tyr755) are then phosphorylated in an activation loop (Till 
et al, 2002).  
In order to sustain MuSK activation, however, it is necessary to recruitan 
additional adaptor protein, docking protein 7 (Dok7). Dok7 presents two main 
consecutive domains, the N-terminal PH and the PTB, followed by a long 
unstructured region that contains two sites of tyrosine phosphorylation (Figure 2). 
The PTB domain binds directly to phosphorylated Tyr553 of MuSK while the PH 
domain mediates the dimerization of Dok7 and stabilises also MuSK dimer in 
order to promote trans-phosphorylation of Tyr750, Tyr754 and Tyr755 (Bergamin 
et al, 2010). The role of Dok7 is essential as it operates both upstream and 
downstream of MuSK. MuSK and Dok7 activate each other and this reciprocal 
activation starts the intracellular phosphorylation cascade that causes the 
clustering of the acetylcholine receptors. 
  
1.5.2) Clustering of the acetylcholine receptors and transmission of the signal 
The downstream parts of the pathway have been only partially defined. 
Following MuSK-Dok7 activation, several other adaptor proteins are 
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phosphorylated and activated, in particular Crk and Crk-L (Hallock et al, 2010), as 
well as other kinases, such as Abl (Finn et al, 2003), Scr (Mittaud et al, 2001), and 
GTpases of the Rho family (Weston et al, 2003). The whole cascade converges on 
the phosphorylation of the AChR subunits and rapsyn (Figure 1C), a structural 
protein that self-aggregates making a scaffold where the AChRs could anchor to 
the actin cytoskeleton and form mature dense clusters (Borges et al, 2001; Zuber 
et al, 2013; Lee et al, 2009).   
The clustering of the acetylcholine receptors in a pretzel-like shape, that 
resembles the form of the nerve terminal, represents the final result of the 
activation of agrin-LRP4-MuSK-Dok7 pathway. Only clustered receptors are able 
to respond appropriately to the signal transmitted by the motor nerve terminal and 
determine muscle contraction. The acetylcholine receptor located on the muscular 
sarcolemma is a nicotine type ligand-gate ion channel. The adult receptor is 
formed by 5 subunits with a stoichiometry of α2-β-δ-ε, while the fetal form 
presents a γ subunits instead of the ε one (Mishina et al, 1986). The subunits are 
disposed in a circle in order to create a central pore for the passage of the ions. 
Each subunit carries an extracellular domain, four transmembrane domains 
(TMD1-4) linked together with intracellular or extracellular loops, and an 
intracytoplasmic C-terminal end. The binding sites for acetylcholine are in the 
interface between the extracellular domains of the α−δ and α−ε subunits (Lee et 
al, 2009; Mukhtasimova et al, 2009). 
The neurotransmitter acetylcholine is secreted in quantal amount into the 
synaptic cleft, as firstly suggested by Bernard Katz in 1966, as the nerve action 
potential reaches the nerve terminal causing the exocytosis of the ACh vesicles. 
Acetylcholine diffuses into the synaptic cleft and interacts with the receptors on 
the postsynaptic muscle membrane. When two acetylcholine molecules bind to the 
AChR, the receptor undergoes a conformational change that opens the channel 
allowing the entrance of cations, in particular Na+, into the cell. The influx of 
cations causes a local depolarisation of the membrane, called the end plate 
potential (EPP) which then, if the stimulus is enough to reach the threshold of -50 
mV (Slater, 2015), leads to the generation of an action potential. To ensure a fast 
and efficient transmission through the synapse, the AChR clustering pathway 
concentrates the receptors (up to 10000 AChRs per micron) on the muscle 
membrane opposed to the motoneuron terminal. AChRs density drops to less than 
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10 per micron just a few micrometers away from the junction. At this 
concentration, AChR receptors are too disperse and, therefore, are not able to 
sustain the transmission of the signal after the binding with the ACh. On the other 
hand, once the action potential is generated in an area wiht high AChRs density, 
the signal propagates along the sarcolemma, determining the release of calcium 
from the intracytoplasmic reticulum and, consequently, muscle contraction. The 
action of acetylcholine is terminated by the enzyme acetylcholinesterase that is 
located close to the AChR and hydrolyses ACh into its two basic components 
(choline and acetyl-CoA).  
 
1.5.3) Negative regulation of AChR clustering 
It is worth noting that the continuous muscle stimulation by the release of 
acetylcholine from the nerve is the main negative regulator of AChR clustering. 
Prolonged Ca++ influx, due to sustained ACh stimulation, activates calpain, a 
protease constitutively inhibited by rapsyn. Once activated, calpain induces AChR 
cluster dispersal through Cdk5 activation (Lin et al, 2005; Chen et al, 2007) 
Muscle contraction also leads to a suppression of AChR expression (Tang et al, 
2004) and promotes the dispersal of AChR clusters (Lin et al, 2005; Misgeld et al, 
2005). This represents a protective mechanism to reduce the risk of a tetanic 
contraction caused by an overstimulation of the muscle. Moreover, negative 
regulators and controllers of AChR play a fundamental role avoiding an 
uncontrolled and scattered localisation of AChRs on the muscular sarcolemma 
and addressing the clusters next to the nerve terminal where the functional 
junction should properly develop. In this scenario, one of the most important 
regulators the pathway is SRC homology 2 domain containing phosphotyrosine 
phosphatase 2 (SHP2). This phosphatase is activated by MuSK through the 
intermediate action of Src and SIRPα1 proteins and, in a negative feedback loop, 
it reduces MuSK phosphorylation. Therefore, SHP2 is able to induce AChRs 
dispersal in extrasynaptic sites, in particular during the early stages of the junction 
development (Qian et al, 2008). 
  
1.6) Pathophysiology of myasthenia gravis 
For several reasons, myasthenia gravis is considered a paradigm of antibody-
mediated diseases. The pathogenic mechanisms underlying the symptoms have 
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been studied intensely over the last 50 years and have provided a wide 
understanding of the role of the different IgG subclasses and how they cause 
impairment of the neuromuscular transmission. In particular, important 
differences have emerged in the pathogenesis of AChR- and MuSK-MG, the two 
most frequent and best characterised forms of the disease, and they will be 
described in detail in the following paragraphs. 
 
1.6.1) AChR-MG 
Role of antibodies 
 Myasthenia gravis is associated in more than 80% of the cases with antibodies 
directed against the acetylcholine receptor and there is much evidence supporting 
a pathogenic cause of the damage and destruction of the postsynaptic muscle 
membrane. AChR antibodies target an epitope formed around aa 67-76 on each α 
subunit of the AChR, which are termed the “main immunogenic regions” (MIR). 
The antibodies are mainly of the IgG1 and IgG3 subclasses and, therefore, they 
activate the classic complement cascade following their binding to the AChRs 
(Aharonov et al., 1975; Lennon and Lambert, 1981; Vincent, 2002). The final 
effect of the complement activation causes a rapid calcium influx into the muscle 
cytoplasm and the consequent destruction of the adjacent membrane together with 
loss of the AChRs and voltage-gate sodium channels which are concentrated at 
the bottom of secondary folds of the sarcolemma (Tüzün et al, 2013; Ruff and 
Lennon, 1998). These latter events determine the reduction in acetylcholine 
response and also the increase of the threshold necessary to trigger the action 
potential. Another mechanism of action of the AChR-Abs is related to their ability 
to bind two different AChR molecules, mainly through the two main 
immunogenic regions. This divalent binding causes the internalisation of the 
receptors increasing their turnover and lysosomal degradation inside the muscle 
cell (Heinemann et al, 1977; Drachman et al, 1978). Finally, a third and 
apparently less important pathogenic effect of the antibodies, described in a 
minority of patients’ sera, is the direct block of AChR channel function (Burges et 
al, 1990). 
 There are two main adaptive mechanisms actuated by the nerve and the muscle 
to compensate the effects of antibody mediated damage to the junction. First, in 
the presynaptic terminal, the number of acetylcholine vesicles rise in order to 
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reinforce the amount of neurotransmitter realised into the synaptic cleft. 
Furthermore, on the other side of the junction, the muscle increases the 
transcription of AChR subunits genes trying to replace the receptors that have 
been lost (Weidoff et al, 1981; Plomp et al, 1995. The efficacy of these 
compensatory mechanisms could have a significant impact in the variability and 
distribution of the symptoms.  
 
Role of the thymus  
Although the pathogenic effects of the antibodies on the neuromuscular 
junction are quite well understood, the very first stages of the aetiology of the 
disease concerning the loss of tolerance for the self antigen are still a matter of 
speculations. In AChR-Ab myasthenia, pathological changes on the thymus play a 
significant role in the future development of the disease but the association with 
thymic pathology is not found with other subtypes of myasthenia, especially in the 
MuSK-MG. 
Some evidence regarding how the self-tolerance for the AChR is lost come 
from a study on the tymic expression of the gene that encodes for the AChR α 
subunit, CHRNA1. A polymorphism of the CHRNA1 promoter been associated 
with early onset of myasthenia in French and UK populations (Giraud et al, 2007). 
This variant of the CHRNA1 promoter prevents binding of interferon regulatory 
factor 8 (IRF8) and reduces the promoter activity in thymic epithelial cells. 
Therefore, IRF8, together with the AutoImmune REgulator (AIRE), modulates the 
expression of the AChR α subunit and regulates a subtle balance (plays a tug of 
war) between self-tollerance and autoimmunity. 
In early-onset myasthenia, the thymus usually presents lymphofollicular 
hyperplasia with an increased number of germinal centres and lymphoid follicles. 
MHC-class II expressing thymic epithelial cells present the unfolded AChR 
subunits and activate auto-reactive CD4+ T cells (Marx et al, 2013). The theory is 
that T cells sustain the formation of early AChR antibodies that are able to 
recognise and attack the properly folded AChRs expressed on the membrane of 
the myoid cells of the thymus. The consequent inflammation, complement 
activation and release of AChR-Ab/immune complexes cause the activation of 
other professional antigen presenting cells and initiate an activation loop of 
CD4+ T cells and the expansion of auto-reactive B cells. Finally, the maturation of 
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B cell receptors leads to the production of high-affinity AChR-Abs and eventually 
result in spreading of the autoimmune process to peripheral lymph nodes (Willcox 
et al, 2008; Thiruppathi et al, 2012). However, this is still largely speculative, and 
whether the autoimmune reaction in the thymus is the primary event or a 
secondary expansion is not yet clear. 
 In thymoma related myasthenia, the pathogenic thymic tissue has many 
features that could impair self tolerance. The neoplastic epithelial cells express a 
variety of striatal antigen epitopes, including sequences of the AChR subunits and 
titin. The theory here is that concomitant reduced expression of both AIRE 
immune regulator and MHC-class II (Strobel et al, 2008) interfere with the correct 
maturation of regulatory T cells resulting in development of naïve and pre-primed 
autoreactive T cells in the peripheral blood that further activate autoimmune B 
cells (Hoffacker et al, 2000).   
 
1.6.2) MuSK-MG 
 As mentioned above, MuSK-MG differs in several ways from the more 
common AChR-MG. MuSK-Abs are mainly of the IgG4 subclass (McConville et 
al, 2004) and, consequently, they do not activate the complement cascade like the 
IgG1-3 subclasses. Moreover, IgG4 are functionally monovalent as they exchange 
their antigen binding fragment (Fab) with other IgG4 antibody Fabs, 
independently of antigen specificity (Koneczny et al, 2016). For these reasons, the 
main pathogenic effect of MuSK-Abs is thought to be interference with the 
physiological function of MuSK rather than complement-mediated damage or 
internalisation of the protein. 
Evidence of the pathogenicity of MuSK-Abs come from different animal 
models created by both passive and active immunization. All these models 
showed clinical myasthenic features and/or impaired neuromuscular transmission, 
with reductions in endplate AChR and in EPP amplitudes (Shigemoto et al, 2006; 
Cole et al, 2010, Klooster et al, 2012; Viegas et al, 2012). In vitro experiments on 
C2C12 myotubes provided further insights on the effects and role of MuSK-Abs 
showing their ability to inhibit MuSK phosphorylation and disperse AChR 
clustering (Koneczny et al, 2013; Huijbers et al, 2013). The first Musk Ig-like 
domain, located in its extracellular part, is the main epitope recognised by the 
antibodies. This particular segment mediates the interaction between LRP4 and 
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MuSK and, therefore, the binding of the antibodies prevents agrin-induced LRP4-
MuSK dimerization (Huijbers et al, 2013). MuSK is not therefore activated and, 
consequently, the whole pathway that leads to AChR clustering is inhibited at the 
beginning. The effect of Ach which is to disperse the clusters, then dominates 
with impairment of neuromuscular signalling.   
The role of the small proportion of IgG1-3 is still controversial. Like MuSK 
IgG4, IgG1-3 antibodies have also been reported to inhibit agrin-induced AChR 
clustering in C2C12 myotubes indicating that all four subclasses have pathogenic 
potential (Koneczny et al, 2013). Moreover, a mouse model knockout for murine 
IgG1 (equivalent to human IgG4) developed a full myasthenic symptomatology 
once immunised against MuSK, and the immune response was sustained by the 
murine equivalent of human IgG1-3 subclasses (Küçükerden et al, 2016). Finally, 
all MuSK IgG subclasses were able to disperse the clusters in Dok7 
overexpressing myotubes, that form spontaneous AChR clusters independently of 
agrin (Koneczny et al, 2013). This suggests that MuSK-Abs have different 
mechanisms of action and their pathogenic effects are not confined to the block of 
LRP4-MuSK interaction. 
 It is worth noting that the in vivo models of MuSK myasthenia lack the 
presynaptic adaptive increase of ACh release observed in the AChR-Ab models 
(Mori et al, 2012; Patel et al, 2014; Viegas et al, 2012). An effective explanation 
of this observation has not been proposed yet. However, it is likely that MuSK-
Abs are able to disrupt retrograde signalling that compensates for the loss of 
AChRs in the AChR-Ab disease. The absence of this adaptive mechanism could 
partially explain the higher severity and resistance to treatment observed in MuSK 
patients.  
 
1.6.3) LRP4-MG 
 AChR and MuSK related myasthenia are the only two subtypes of the disease 
for which the pathogenic role of antibodies has been proven. Nevertheless, LRP4-
Abs are mainly of the IgG1 and IgG2 subclasses and could have pathogenic 
potential. They bind complement and, moreover, they could interfere with LRP4-
MuSK interaction similarly to the way already described for MuSK-Abs. Both in 
vitro and in vivo experiments (Zhang et al, 2012; Pevzner et al, 2012; Shen et al, 
2013) have provided some important clues for their pathogenic effects but the 
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high variability in the incidence of LRP4 antibodies in different studies, often 
using less reliable techniques (eg. ELISA) and the concomitant detection of 
MuSK-Abs in a significant proportion of cases suggest that further studies are 
needed in order to determine the true clinical relevance of these antibodies.  
 
1.7) Diagnosis 
 The diagnosis of myasthenia is based on clinical symptomatology, 
electromyographic recording and antibody characterisation. Clinical suspicion 
arises when the patient describes fluctuant weakness, without concomitant sensory 
impairment, that improves with rest and that affects skeletal muscles, particularly 
the ocular and those of the proximal limbs. 
 Further proof is usually provided by electromyography (EMG) with repetitive 
stimulation of the peripheral nerve. In myasthenic patients, there is a typical 
decrement of about 10% in the amplitude of the muscle action potential while 
stimulating the nerve at 2–5 Hz. The sensitivity of this test reaches its maximum if 
performed in generalised forms on proximal or facial districts (up to 90% of 
sensitivity) but it drops dramatically in the pure ocular forms (30-60%) and when 
tested on distal muscles such as the abductor digiti quinti (about 60%) (Zambelis 
et al, 2011). To increase the sensitivity and specificity of the test, it is possible to 
perform repetitive stimulation on a single muscle fibre (Single Fiber 
ElectroMyoGram - SFEMG) although it requires a high skilled electromyographer 
together with a collaborative patient and it is available only in specialised centres. 
SFEMG analyses the variation of inter-potential interval (jitter) between different 
muscular fibres. A prolonged jitter value (55 µs for a 55 µs for an individual value 
and 36 µs for a mean value, although the threshold varies among different muscles 
at different ages and have been defined in a collaborative multicentre study by 
Bromberg and Scott 1994) is considered abnormal and diagnostic for impairment 
of neuromuscular transmission. A properly performed SFEMG on a proximal 
muscle reached a very high sensitivity (up to 99%) in the detection of myasthenia 
gravis (Sarrigiannis et al, 2006; Sanders et al, 1996). Despite its sensitivity, 
SFEMG has a lower specificity as abnormal jitter values can be found in other 
diseases such as myopathies and neuropathic disorders (Sarrigiannis et al, 2006). 
Therefore, its results should be interpreted carefully considering the whole clinical 
picture of the patient, and the differential diagnoses considered. 
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 Laboratory tests have become progressively more and more important over the 
years and, nowadays, antibody detection and characterisation represent a 
necessary step during the diagnostic process. Different antibodies sustain the 
diagnosis of specific forms of the disease and their pathogenic mechanisms 
influence which therapeutic strategy is the most appropriate for the correct 
treatment of the patient. 
 The radio immunoprecipitation assays (RIA) represent the most available and 
specific tests for detection of AChR and MuSK-Abs. In AChR generalised 
myasthenia, RIA sensitivity is above 85% and reaches almost 100% in patients 
with thymoma while it is positive in only 50-60% of ocular forms (Oger et al, 
1987). On the other hand, RIA specificity approaches 100%, regardless of 
distribution of the deficit and, therefore, a positive test is sufficient to confirm the 
diagnosis of AChR-MG. The radioimmuno assay was first introduced by 
Lindstrom in 1973. The acetylcholine receptor is mixed with 125I-α bungarotoxin 
(a radioactive-labelled snake toxin that binds selectively to the nicotine AChR) 
and after incubation with the patient serum, a second antibody is added to 
precipitate the 125I-α bungarotoxin-AChR-Ab complex. The radioactive counts are 
measured and results are compared to healthy control sera. A similar assay that 
uses the same principles of AChR RIA, is available for the detection of MuSK-
Abs, where the whole extracellular domain of MuSK is labelled with 125I and used 
as radioactive antigen (Matthews et al, 2004). The specificity of MuSK RIA 
reaches 100% but its sensitivity is hard to estimate as the proportion of MuSK 
patients varies among the different populations studied. Despite the sensitivities of 
these two assays, there are always seronegative patients (see above) and the 
introduction of cell-based assay (CBA) in the last decade has increased the 
sensitivity of both AChR and MuSK-Ab detection. In the CBAs, human 
embryonic kidney-293 (HEK) cells are transfected with the DNA of the gene to 
express the protein on the cell surface together with a fluorescent tag. For the 
AChR assay, all five of the genes of the AChR subunits (adult type) are 
transfected together with rapsyn in order to express a full clustered AChR and 
mirror a more physiological condition compared to the RIA. The AChR CBA is 
able to identify up to 66% of patients resulted previously negative in the 
conventional RIA, including 50% of the ocular forms and is particularly useful in 
differentiating SNMG from genetic forms of myasthenia (Jacob et al, 2012; 
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Rodriguez Cruz et al, 2015). Also in the case of MuSK, a CBA has increased by a 
small amount detection of antibodies in a further 8% of previously seronegative 
patients. The MuSK patients who were positive only in the CBA, presented a 
milder phenotype and less effective clustering inhibition in in vitro experiments 
compared to the patients positive in the RIA (Huda et al, 2017). 
In respect of LRP4 antibodies, CBA and ELISA are the main tests used for 
their detection (Zhang et al, 2012; Pevzner et al, 2012; Zisimopoulou et al, 2014) 
but their comparability, sensitivity and specificity have not been determined yet. 
A commercial and reliable assay to detect LRP4 antibodies is therefore needed in 
order to better understand the real incidence and significance of LRP4 antibodies. 
 
1.8) Therapy 
 Among neurological and neuromuscular diseases, myasthenia gravis is one of 
the few that can be successfully treated providing a complete and stable remission 
in a significant proportion of patients; in paralleladvances in therapy have 
markedly reduced both mortality and morbidity. Due to our growing 
understanding of the pathogenic mechanisms that sustain the disease, a variety of 
treatments has been developed during the last decades spreading from 
symptomatic drugs, that improve neuromuscular transmission, to specific 
immunomodulatory therapies that inhibit the production of antibodies. 
 
1.8.1) Acetylcholinesterase inhibitors 
 Acetylcholinesterase inhibitors represent the first known treatment for 
myasthenia. Their efficacy was discovered thanks to the intuition of a Scottish 
clinical fellow, Mary Walker, in 1935. Recognising that myasthenic symptoms 
were similar to those caused by curare poisoning, Dr. Walker administered an 
intravenous dose of physostigmine to a patient with generalised myasthenia 
producing a partial and temporary improvement of her symptomatology (Pearce, 
2005). The discovery of Mary Walker not only provided the first safe therapy for 
myasthenic patients but also suggested, for the first time, that the disease was 
caused by an impairment of the neuromuscular junction. Oral acetylcholinesterase 
inhibitors (pyridostigmine) are still broadly used as a first line symptomatic 
treatment in AChR-Ab myasthenia. Acting inside the synaptic cleft, they reduce 
the enzymatic cleavage of ACh molecules, increasing the total amount of the 
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neurotransmitter and prolonging the time during which ACh can stimulate its 
receptor. Considering its half-life, oral pyridostigmine should be administered 
about every 4 hours. Generally, most common side effects appear during the first 
weeks of treatment and are consistent with muscle cramps and muscarinic 
stimulation of autonomic nervous system. Long-term treatment is generally safe 
and addiction or cumulative side effects have not been reported. 
Acetylcholinesterase inhibitors are usually less effective and tolerated in MuSK 
myasthenia (Evoli et al, 2003; Guptill et al, 2011). The reason underneath this 
phenomenon is not known yet but an explanation could be related to the inhibition 
of the whole AChR clustering pathway by MuSK-Abs. This hypothesis is 
supported by the evidence that a passive immunised animal model of MuSK 
myasthenia, treated with pyridostigmine, showed increased endplate AChR loss, 
probably due to increased dispersal of AChRs by the prolonged action of 
acetycholine (Morsch et al, 2013). 
 
1.8.2) Corticosteroids 
 In most cases, acetylcholinesterase inhibitors are not able to control completely 
the symptoms and, therefore, steroids (prednisone and prednisolone in particular) 
are introduced as first-line immunosuppressant drug. Corticosteroids affect the 
immune system in several different ways. They inhibit inflammation suppressing 
and modulating the expression and release of TNF-α and IL-1, they reduce 
leucocyte proliferation inhibiting the transcriptional factor NF-KB and some 
evidence suggest that they can impair T cell maturation in the thymus (reviewed 
by Coutinho and Chapman, 2011). Steroids are usually efficient in controlling 
symptoms and preventing relapse of the disease and their effect is usually evident 
within 3 weeks after the beginning of treatment. However, an initial and 
temporary deterioration of muscle strength can occur during the first days 
especially when the treatment is started at high dose without a gradual increase 
(Skeie et al, 2010; Benatar et al, 2012). Some studies have also suggested that 
steroid treatment can reduce the risk of generalisation in pure ocular forms (Kerty 
et al, 2013; Benatar et al, 2012). The major issue of long-term administration of 
steroids concerns the occurrence of serious side effects such as increased blood 
pressure, diabetes, increase in weight, osteoporosis and muscular atrophy. For 
these reasons, once control of the symptoms is achieved, steroids should be 
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decreased gradually in order to achieve the lowest dose able to maintain 
pharmacological remission. 
 
1.8.3) Immunosuppressive drugs 
 Immunosuppressive drugs are introduced with the purpose of “sparing” 
steroids and prevent the need for long-term high doses. Azathioprine is usually the 
first choice in a plethora of other immunosuppressant possibilities (Bromberg et 
al, 1997; Palace et al, 1998) and its mechanism of action leans on the inhibition of 
purine synthesis and the consequent reduction in T and B lymphocytes replication. 
Azathioprine requires several months (up to more than one year) before showing 
its effect and, in the meanwhile, the dose of steroids can only be cautiously 
decreased (Palace et al, 1998). The most important side effect of the drug involves 
the bone marrow inhibitionwith the risk of medullary aplasia, together with 
toxicity of the liver, where azathioprine is metabolized by the enzyme thiopurine 
S-methyltransferase. Some isoforms of this enzyme can modify significantly its 
activity, therefore their detection in patients’ samples should be done before 
starting the treatment.  
 Second line immunosuppressants include cyclosporine and mycophenolate 
mofetil. Both of them are efficient in the treatment of myasthenia gravis in clinical 
trials (Tindall et al, 1993; Meriggioli et al, 2003) but they are mosts appropriate if 
azathioprine can not be tolerated or fails to achieve steroid sparing. They present 
major and more severe side effects compared to azathioprine including 
nephrotoxicity, increased risk of infections and tumours. Methotrexate is also 
commonly used in myasthenia despite the fact that clinical trials have never been 
performed to justify its use. Nevertheless, justification for its application in 
myasthenia comes from its effectivness in other autoimmune diseases. 
For those severe myasthenic patients that do not respond to any other 
treatments, there is an increasing number of reports regarding the potential 
benefits of rituximab, a monoclonal chimeric IgG1 that depletes B lymphocytes 
through specific binding to the CD20 transmembrane antigen (Benveniste and 
Hilton-Jones D, 2010; Maddison et al, 2011). Despite the fact that controlled 
studies have not been done yet, early evidence showed that about two thirds of 
patients with insufficient response to other immunosuppressive treatments had a 
significant improvement following rituximab administration. This seems to be 
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particularly true for MuSK myasthenia (Keung et al, 2013; Yi et al, 2013). 
However, only selected patients should undertake rituximab treatment as it 
implies several risks, in particular the development of JC-virus-related progressive 
multifocal leukoencephalopathy as reported during the treatment of other 
autoimmune disorders (Tan and Koralnik, 2010) and it is expensive. 
 
1.8.4) Thymectomy 
 In myasthenic subtypes associated with thymic pathologies (early-onset 
myasthenia with thymic hyperplasia and in case of thymomas), there is a strong 
indication to proceed with the removal of the gland. Although thymectomy has 
been practiced since 1941 in myasthenic patients (Blalock et al, 1941), only a 
recent randomized trial study has finally provided the evidence that the procedure 
gives substantial clinical benefits compared to the use of steroids alone (Wolfe et 
al, 2016). In early-onset myasthenia (<50 years old), thymectomy should be 
performed soon after the diagnosis as it has its highest effectiveness within 5 years 
from onset (Gronseth and Barohn, 2000). All thymic tissue should be removed 
and less invasive video- and roboti-assisted thoracoscopic approaches are quickly 
overtaking the classical sternotomy (Ye at al, 2013). 
Obviously, in case of malignancy, thymectomy represents a necessary 
therapeutic procedure in order to avoid the spreading of the neoplasia and local 
thoracic compression. With respect to myasthenic symptoms, the removal of 
thymoma usually does not correspond to a significant improvement of muscle 
weakness as the autoimmune process has already triggered and sustained by 
peripheral cells (Hoffacker et al, 2000; Buckley et al, 2001).   
 Thymectomy is not indicated in MuSK- and LRP4-myasthenia nor in late-onset 
forms as there is little evidence of thymic involvement and no therapeutic effect 
has been reported.  
   
1.8.5) Plasmapheresis and intravenous immunoglobulins 
 In severe relapses of myasthenia and myasthenic crises that require a rapid and 
effective treatment, both plasmapheresis and administration of intravenous 
immunoglobulins (IVIG) have shown to provide quick and reliable action. The 
level of their effectiveness is comparable (Ronager et al, 2001) and their effects 
usually last about 4-6 weeks. 
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Plasmapheresis consists in the removal of pathogenic autoantibodies and other 
pathogenic factors, such as complement proteins, from the blood stream through 
the exchange of 20–50 mL/kg of plasma every alternate day. The whole procedure 
is repeated five times, but has been performed chronically in rare cases (Gajdos et 
al, 2002). Adverse effects include risk of infection, hypocalcemia, hypotension, 
and thrombocytopenia. 
IVIG are less invasive and better tolerated than plasmapheresis and present 
slightly fewer side effects (Ronager et al, 2001; Zinman et al, 2007). The 
procedure consists in the injection of 2g/kg/day of concentrated immunoglobulins, 
mainly IgG, for 5 consecutive days. The mechanism of action is not fully 
understood but implies cytokine and complement inhibition, competition with 
autoantibodies, interference with Fc receptor binding or antigen recognition by 
sensitized T cells. Most common side effects are flu-like symptoms while 
anaphylaxis reaction can happen in patients with congenital deficiency of IgA 
(Qureshi et al, 1999). Therefore, IgA level should be determined before beginning 
IVIG administration. 
 
1.8.6) A new potential therapeutic target: SHP2 
 As described above, there are several efficient treatments for myasthenia gravis 
and most patients can now live their lives without significant impairment. 
Nowadays, several clinicians pointed out that the adjective “gravis” should not be 
used anymore to describe myasthenia as its mortality rate has dropped 
dramatically over the last decades. Nevertheless, none of the drugs available at the 
moment are specific as they involve the immune system as a whole. This leads to 
a variety of side effects, especially when the severity of symptoms requires long 
lasting immunosuppressive therapy. In this scenario, a treatment able to target and 
counteract specifically the pathogenic mechanisms of the disease would be 
important in order to achieve a better and stable control of the symptoms and to 
decrease the risk of side effects. 
Targeting the intracellular regulators of the acetylcholine receptor pathway 
represents one of the possible therapeutic strategies that could be considered. In 
particular, SRC homology 2 domain containing phosphotyrosine phosphatase 2 
(SHP2) acts as a negative regulator that reduces MuSK phosphorylation and 
inhibits the AChR clustering pathway (Qian et al, 2008). SHP2 is a nonreceptor 
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protein tyrosine phosphatase that consists of two SH2 domains, a catalytic protein 
tyrosine phosphatase (PTP) domain, a c-terminal tail with tyrosyl phosphorylation 
sites (Y542 and Y580), and a proline-rich motif. SHP2 is basally inactive as the n-
terminal SH2 region inhibits the catalytic PTP domain, but upon stimulation by 
tyrosine-phosphorylated docking proteins, SH2 undergoes a conformational 
change to facilitate phosphatase activation (Neel et al, 2003; Alonso et al, 2004; 
Cunnick et al, 2001).  
Apart from its specific role AChR clustering pathway, SHP2 also mediates and 
enhances growth cell signalling in different tissues. SHP2 is involved in activation 
of Erk1/2 MAP kinase by EGF (Deb et al, 1998), and gain of function mutations 
of its gene, PTPN11, are associated with Noonan’s syndrome, juvenile 
myelomonocytic leukemia, and several types of human malignancies (Bentires-
Alj et al, 2004; Tartaglia and Gelb, 2005). For these reasons, SHP2 inhibition has 
been studied with the aim to understand better tumorigenesis and to develop new 
antineoplastic drugs (Schneeberger et al, 2015; Grosskopf et al, 2015; Bunda et al, 
2015).  
Of particular interest is NSC-87877, a SHP 1/2 inhibitor that binds to the 
catalytic cleft of SHP2 through hydrogen bonds inhibiting its phosphatase activity 
(Figure 3A, B) (Chen et al, 2006). For the aim of our study, it is important to 
highlight that the inhibition of SHP2 by NSC-87877 has already been shown to 
increase AChR clustering in C2C12 mouse myotubes independent of agrin 
stimulation (Zhao et al 2007). This is an important first evidence of the potential 
role of SHP2 as a specific target in the treatment of myasthenia, in particular the 
form associated with MuSK-Abs. 
 
 
Figure 3. Structure of NSC-87877 and its binding site on SHP2. In A: chemical structure of NSC-
87877. In B: Molecular model of NSC-87877 binding to the SHP2 PTP domain. Positively 
charged areas are coloured in blue, and negatively charged areas coloured in red. For NSC-87877, 
carbon atoms are coloured in grey, oxygen in red, nitrogen in blue, hydrogen in white, and sulphur 
in yellow (from Chen et al, Discovery of a novel SHP2 protein tyrosine phosphatase inhibitor, 
Mol Pharmacol, 2006) 
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Aims of the study 
 
Targeting the intracellular regulators of the acetylcholine receptor (AChR) 
pathway represents a novel therapeutic strategy in myasthenia gravis. The 
development of a specific treatment would be important in order to achieve a 
better and stable control of the symptoms and to decrease the risk of side effects. 
SH2 domain-containing phosphatase (SHP2) represents a potential target because 
of its role as a key regulator of the AChR clustering pathway. Through a negative-
feedback loop, SHP2 reduces the phosphorylation of Muscle Specific Kinase 
(MuSK), and thus controls MuSK activation by neural agrin. Its selective 
inhibition by the drug NSC-87877 has been shown to increase AChR clustering in 
C2C12 myotubes in either the presence or absence of agrin (Zhao et al 2007). This 
work started by confirming these preliminary observations and aimed to evaluate, 
in in vitro condition, whether the inhibition of SHP2 by NSC-87877 is able to 
counteract the pathogenic effects of MuSK-Abs. Therefore, this study tried to 
answer the following questions: 
 Is NSC-87877 able to enhance MuSK phosphorylation level and AChR 
clustering independently by agrin and which dose causes the highest 
increase? 
 What is the time-course of MuSK phosphorylation after agrin stimulation 
in vitro, and how would it differ after exposure to NSC-87877? 
 Is NSC-87877 able to increase MuSK phosphorylation and AChR 
clustering in the presence of MuSK-Abs? 
 Is there any difference in the pathogenic effects between MuSK IgG4 and 
MuSK IgG1-3 subclasses and, if so, is NSC-87877 effective with all the 
different IgG subclasses? 
 
Assessing the first two questions allowed us to understand the kinetics of 
NSC-87877 and its action on the AChR clustering pathway and to set the basic 
parameters to use in the final experiments aimed to test the efficacy of the drug in 
the presence of MuSK-Abs. 
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Chapter 2 
Materials and Methods 
 
2.1) MuSK-MG plasma samples 
Plasma samples from three different patients affected by MuSK-MG were 
used for all the following experiments. A diagnosis of MuSK-myashtenia was 
confirmed on the basis of characteristic clinical features, detection of MuSK-Abs 
by radioimmunoassay (RIA) and beneficial response to immunotherapy. 
 
2.2) Tissue culture 
Human embrionic kidney 293 (HEK 293) cells and C2C12 mouse myoblasts 
were purchased from ATCC. HEK 293 cells were maintained in 5% CO2 at 37ºC 
in Dulbecco-modified essential medium (DMEM) (Sigma-Aldrich) supplemented 
with 10% of Foetal Calf Serum (FCS - TCS Cellworks Ltd) together with 100 
units/ml each of penicillin G and streptomycin (PS - Invitrogen). C2C12 
myoblasts were grown in growth medium (DMEM supplemented with 15% FCS 
and 1% PS) and differentiated for 5-6 days in fusion medium (DMEM containing 
2% FCS – 2% Horse Serum and PS, DM) at 37°C in an atmosphere of 8% CO2.  
 
2.3) Preparation of agrin plasmid and transfection 
To generate soluble agrin, cDNA encoding the full-length human neural agrin 
was cloned into pcDNA3.1hygro(+). The GFP-tag was also inserted at the C-
terminus of the agrin. The recombinant protein contains its own signal peptide, 
which allows agrin to be secreted as a soluble form. HEK 293 cells were seeded at 
3.5 x 106 cells per T125 tissue culture flask and then transfected using 
polyethyleneimine (PEI) with 18µg of full-length agrin. Following 48 hours of 
transfection, conditioned media were harvested. 
 
2.4) Agrin titration 
C2C12 myoblasts were seeded at 1.5 x 105 per well in 6-well plates and were 
allowed to fuse to form myotubes. C2C12 myotubes were incubated with seriate 
dilutions of agrin (1:50, 1:100, 1:200, 1:400, 1:800, 1:1600) at 37 ºC for 16 hours. 
C2C12 myotubes exposed to DMEM only were used as negative control. The 
following day, the cells were incubated with Alexa Flour 594-conjugated α-
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bungaratoxin (Invitrogen) diluted at 1:1000 in fusion medium for 1 hour at 37ºC. 
Myotubes were washed 3 times with 500 µl fusion medium, fixed with 3% 
formaldehyde, and stored in PBS at 4ºC. Images (20 random fields at 20x 
objective) were captured using Olympus IX71 fluorescence microscope with 
Simple PCI (Digital Pixel). The number of AChR clusters was counted and 
analysed using a macro for the ImageJ software. 
 
2.5) IgG and IgG subclasses purification 
According to the amount of plasma available, samples from patients 1 and 2 
were used to purify total IgG, IgG4 and IgG1-3 subclasses while samples from 
patient 3 were sufficient to perform only the purification of the IgG subclasses. 
For the purification of total IgG, 10 ml of plasma were filtered using 0.2 μm 
syringe filters, diluted 1:2 in PBS and incubated overnight with 2.5 ml of Protein 
G Sepharose Fast-Slow (Sigma) at 4°C with gentle shaking. The bead slurry was 
packed into a column, washed 3 times with 5 ml PBS, and bound IgG were eluted 
with 0.1 M glycine, pH 2.3. 20 fractions of 1 ml were collected into eppendorf 
tubes containing 150 μl Tris-HCl pH 8.0 to neutralise the pH, and analysed for 
protein content by measuring the OD280 with nanodrop. The fractions with the 
highest OD280 were pooled and dialysed overnight against 200 volumes of 
DMEM. 
For the IgG subclass purification, IgG4 affinity matrix (CaptureSelect™ IgG4 
Hu Affinity Matrix – Thermofisher) was used in a similar way as protein G 
sepharose. 10 ml of plasma were filtered using 0.2 μm syringe filters and diluted 
1:2 with PBS, then incubated for 1h at 4°C with 1 ml of IgG4 affinity matrix and 
packed into a column. After washing 3 times with 5 ml PBS, IgG4 were eluted 
with 0.1 M glycine pH 2.3. 20 fractions of 1 ml were collected into eppendorf 
tubes containing 150 μl Tris-HCl pH 8 to neutralize the pH. The flow-through 
containing IgG1-3 was loaded a second time onto the IgG4 affinity matrix to 
ensure complete depletion of IgG4. The second flow-through was then incubated 
overnight with 2.5 ml protein G sepharose and eluted as previously described for 
total IgG purification. The fractions with the highest OD280 of IgG 4 and IgG1-3 
were pooled and dialysed overnight against 200 volumes of DMEM. The fractions 
with a lower OD280 were pooled and concentrated using Centriprep® 30K 
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centrifugal filter units (Millipore) in order to reach a similar concentration of the 
other fractions. 
It is worth noting that protein G sepharose has a binding capacity for human 
IgG of 17 mg/ml while average IgG concentration in the plasma is about 8-18 
mg/ml. Therefore, using 10 ml of plasma and 1 ml of matrix, it is possible to 
obtain only about 1/10 of the total amount of IgG of the original sample. 
Conversely, IgG4 matrix has a binding capacity of 6 mg/ml. The normal 
concentration of IgG4 in the plasma is usually between 6-10% of the total IgG 
(about 0.8-1.8 mg/ml). Therefore, from 10 ml of plasma using 1 ml of matrix, 
about 1/2- 1/3 of the original IgG4 were purified. 
Prior to use the purified samples in the following experiments, the samples 
were sterile-filtered with Ultrafree®-CL centrifugal devices (Millipore) and then 
heated at 55ºC for 30 minutes for the inactivation of any residual complement 
proteins. 
 
2.6) Cell-based assay  
 In order to verify the effectiveness of IgG subclasses purification, purified 
samples were tested on a cell-based assay with HEK 293 cells expressing MuSK 
on their surface. HEK 293 cells were seeded at 1.5 x 104 per well in 24-wells 
plates. The wells were pre-treated with PBS 0.01% poly-L-lysine (PLL) in order 
to enhance the attachment of the cells to the surface. The following day, cells 
were transfected overnight with a solution of 0.6 µg pcDNA 3.1 hygro MuSK 
mCherry, 0.3 µg polyethylenimine (PEI), 0.4 µg 20% glucose, 0.15 µl water per 
well. 24 hours later, successful transfection was confirmed by visualising 
mCherry expression using an Olympus IX71 fluorescence microscope. MuSK 
transfected HEK cells were then incubated with serum, total IgG, IgG4 and IgG1-
3 samples at 1:20 dilution for 1 hour at room temperature. Cells were then washed 
3 times with 500 µl DMEM and then probed with anti-human IgG, anti-human 
IgG4, -IgG1, -IgG2, -IgG3 monoclonal mouse antibodies (Sigma) at 1:50 dilution 
for 1 hour at room temperature. After washing 3 times 500 µl DMEM, cells were 
fixed with 3% formaldehyde for 20 minutes and then washed again 3 times with 
500 µl PBS. Finally, cells were incubated with Alexa Fluor 488 goat anti-mouse 
IgG (Invitrogen) at 1:200 dilution for 1 hour at room temperature in the dark. 
Cells were washed 3 times with 500 µl PBS and stored in PBS at 4ºC. Images 
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were captured using Olympus IX71 fluorescence microscope with Simple PCI 
(Digital Pixel). 
 
2.7) Radioimmunoassay 
MuSK-Ab concentrations were determined by radioimmunoassay (RIA) as 
previously described (McConville et al, 2004).  Plasma samples, purified IgG or 
IgG subclasses were serially diluted 5-fold in PTX (0.02M PBS, 0.1% Triton X) 
to a total volume of 50 μl and incubated with 50 μl of 125I labelled MuSK 
overnight at 4°C. 50 μl anti-human IgG and 5μl of healthy control serum were 
added and incubated at room temperature until precipitation was visible 
(approximately 60 minutes). After addition of 500 μl PTX, the samples were 
centrifuged 5 min at 10000 rpm at room temperature, washed 3 times with 500 μl 
PTX and then cpm were measured with a Wallac Wizard counter. MuSK-Ab 
concentrations were calculated using the following equation: 
 
                             (cpm sample – cpm control) x decay factor 
x nM =       __________________________________________________________ 
 (Vol. sample (µl) x specific activity) (Ci/mmol) x counter efficiency x 2.22 
 
assuming a counter efficiency of 0.815. 
 
2.8) Effects of NSC-87877 on MuSK phosphorylation 
C2C12 myoblasts were seeded at 1.5 x 105 per well in 6-well plates and were 
allowed to form myotubes after 5-6 days in fusion medium. Myotubes were then 
starved for 3 hours with DMEM-1% PS to reduce basal phosphorylation levels.  
Cells were incubated with increasing concentration of NSC-87877 (Tocris®) (1 
µM, 10 µM, 100 µM, 200 µM) for 40 minutes at 37°C while myotubes exposed to 
a non-saturating agrin dilution (1:800) and DMEM were used as positive and 
negative controls respectively. 
The time-course of MuSK phosphorylation was studied incubating the 
myotubes with NSC-87877 100 M at different time intervals (15, 40, 90, 180 and 
360 minutes) in the presence and absence of agrin (1:800). 
Finally, in order to access the effects of NSC-87877 on MuSK phosphorylation 
in the presence of MuSK-Abs, 0.5 nM purified MuSK total IgG, IgG4 and IgG1-3 
 87 
 
were incubated with agrin (1:800) in the presence and absence of NSC-87877 100 
M for 40 minutes at 37°C.  
 
2.9) Immunoprecipitaion of MuSK and western blot analysis 
To detect and quantify MuSK phosphorylation levels, after incubation with the 
different compounds, myotubes were extracted in cold lysis buffer (10 mM Tris-
HCl, 1 mM EDTA, 100 mM NaCl, 1% Triton X-100, 1x protease inhibitor 
cocktail, 1x phosphatase inhibitor cocktail) followed by centrifugation. To 
precipitate endogenous MuSK, the whole cell lysate was incubated with an anti-
MuSK polyclonal antibody (AF562, R&D) at 4 ºC overnight. Bound antibody was 
captured with Dynabeads® protein G (Invitrogen). For the cells that were 
incubated with patient purified IgG or IgG subclasses, cell lysates were directly 
incubated with Dynabeads to immunoprecipitate MuSK with the antibodies from 
the patients. Bead-precipitated proteins were eluted into SDS sample buffer, 
subjected to SDS-PAGE and incubated with monoclonal mouse anti-
phosphotyrosine antibody (4G10, Upstate Biotechnology). The membrane was 
then harsh stripped (20 mL SDS 10%, 12.5 mL Tris HCl pH 6.8 0.5 M, 67.5 mL 
pure water, 0.8 ml β-mercaptoethanol) and reprobed for MuSK by incubating with 
anti-MuSK polyclonal antibody (AF562, R&D). Densitometry of bands was 
analysed using ImageJ software and the level of MuSK phosphorylation 
normalised to levels of immunoprecipitated MuSK. 
 
2.10) AChR cluster assay 
C2C12 myoblasts were seeded at a density of 1.5 x 105 per well into 6-wells 
plates and differentiated as described above. First, the myotubes were incubated 
for 12 hours with increasing concentration of NSC-87877 (1 µM, 10 µM, 100 µM, 
200 µM) in order to titrate its effect on AChR clustering. Secondly, the ability of 
NSC-87877 to reverse the effects of MuSK-Abs was tested. The cells were 
exposed to 0.5 nM purified MuSK total IgG, IgG4 and IgG1-3 for 30 minutes and 
then incubated overnight together with agrin (1:800) and in the presence and 
absence of NSC-87877 100 µM. the following day, AChR clusters were labeled 
using Alexa Flour 594-conjugated α-bungaratoxin (Invitrogen) diluted 1:1000 in 
differentiation media for 60 minutes at 37°C.  Myotubes were then washed 3 
times in differentiation media, fixed in 3% formaldehyde for 20 minutes, and 
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washed and stored in PBS at 4°C. Twenty fields containing myotubes were 
selected with bright field and red fluorescent images were captured using an 
Olympus IX71 fluorescence microscope and Simple PCI (Digital Pixel) software. 
Images were analyzed for AChR cluster number using Image J software.  
 
2.11) Statistical analysis 
All data were analysed using GraphPad Prism 7. Data from at least 3 experiments 
were pooled and analysed with one-way ANOVA test for multiple comparison.  
Error bars represent the standard deviation from the mean. 
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Chapter 3 
Results 
 
3.1) Developing the materials 
3.1.1) MuSK-MG samples 
The experiments used plasma samples from 3 patients with typical clinical 
myasthenic features who were positive for MuSK-Abs in the radioimmunoassay 
and negative for AChR and LRP4 antibodies. All the patients were female with an 
early onset of the disease (< 40 years). Patient 1, at the moment of the sampling, 
had a severe form of myasthenia (class IIIB) with mainly facial and bulbar 
involvement. During the course of the disease, she underwent several 
immunosuppressive treatments (including steroids, azathioprine, and 
cyclosporine) and plasmapheresis. She finally achieved full pharmacological 
remission with rituximab. Patient 2 had a bulbar onset (class IIIB) with proximal 
involvement of the limbs. Conversely to other cases, she responded well to the 
therapy and achieved pharmacological remission with azathioprine and 
prednisolone. Patient 3 was sampled during a myasthenic crisis (class IVB) with 
respiratory failure. Over the years, she has been treated with steroids, 
azathioprine, methotrexate and several administrations of IVIG and 
plasmapheresis. Although the different therapies allowed a remarkable 
improvement in her symptoms, she has never achieved a complete remission. 
 
3.1.2) Agrin titration 
Agrin is a fundamental component of all our experiments as it provides the 
physiological stimulation for the MuSK pathway. Therefore, agrin was used as a 
positive control to which to compare the effects of SHP2 inhibition and MuSK-
Abs. Agrin was produced by transfecting HEK 293 cells with a cDNA plasmid 
containing the full-length human neural protein together with a fluorescent tag 
(used to check the efficacy of cell transfection). Once harvested from the cell 
medium, agrin was tested at different dilutions on C2C12 myotubes in order to 
titrate its effects on AChR clustering. Myotubes were exposed to agrin for 12 
hours at 37ºC, then fixed in formaldehyde and finally labelled with fluorescent α-
bungarotoxin, a snake toxin that binds specifically to the acethylcholine receptors. 
Myotubes exposed to DMEM were used as negative controls. As expected, we 
 90 
 
observed a direct correlation between agrin concentration and the number of 
AChR clusters (Figure 4). At each dilution, agrin significantly increased AChR 
clustering compared to DMEM (p<0.0001 for 1:50, 1:100, 1:200, 1:400, 1:800 
and p<0.001 for 1:1600). We chose the 1:800 non-saturating agrin concentration 
for the following experiments in order to see the maximum effect of NSC-87877 
and MuSK-Abs on AChR clustering and MuSK phosphorylation. 
 
 
 
Figure 4. Effect of agrin on AChR clustering (titration curve). In A: AChR clusters labelled with 
α-bungarotoxin on C2C12 myotubes after incubation with agrin (1:50), agrin (1:800) and DMEM. 
(Olympus IX71 fluorescence microscope - 20x magnifications). In B: bar chart representing the 
average number of AChR clusters per microscopic field for different agrin dilutions. Each dilution 
of agrin significantly increased AChR clustering compared to DMEM (p<0.0001 for 1:50, 1:100, 
1:200, 1:400, 1:800 and p<0.001 for 1:1600; one-way ANOVA; n=3) 
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3.1.3) Purification of total IgG and IgG subclasses 
 Total IgG and IgG subclasses (IgG4 and IgG1-3) were purified from the 
plasma samples of three different MuSK-MG patients. The amount of plasma 
from patients 1 and 2 was sufficient to purify both total IgG and IgG subclasses, 
while sample from patient 3 was enough for the purification of IgG subclasses 
only. 
 IgG purification consists in an affinity matrix chromatography with protein G 
sepharose for the total IgG while a IgG4 matrix was used to bind specifically the 
IgG4 subclass and divide it from IgG1-3. A glycine acid solution (pH 2.3) was 
used to eluate IgG from the matrix. The first 5-6 fractions usually contain the 
highest amount of IgG whilst the concentration gradually decreases in the 
following fractions. In order to not waste precious IgG, the late elutions were 
pooled and further concentrated. In Figure 5 the elution profiles of the purification 
of MuSK plasma samples, divided according to the IgG subclasses, are shown. 
The final results and the efficacy of IgG purification are represented in Table 1. 
All the volumes from the different stages of purification are indicated (initial 
plasma amount, dilution with PBS, flow-through total IgG and IgG4 matrix) 
together with the relative protein concentrations measured with the nanodrop. 
After purification, the samples were pooled, dialysed against DMEM to provide a 
physiological solution for the experiments, sterile-filtered and heated in order to 
eliminate all residual complement fractions and eventual contamination. All these 
latter procedures could explain the partial loss of volume and concentration 
measured in the final purified samples. 
 
.  
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Figure 5. Elution profiles of purified fractions of total IgG (A), IgG4 (B) and IgG1-3 (C) from the 
three MuSK-MG patients (in red, blue and green respectively). Elution fractions are indicated on 
the X axis; protein concentrations are indicated on the Y axis. 
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Table 1. IgG purification from MuSK-MG patient’s samples: volumes and corresponding protein 
concentrations (OD280) collected during the different stages of IgG purification for each MuSK-
MG patient. 
 
 
 
 
3.1.4) Cell-based assay to access efficiency of MuSK subclasses purification 
 Once the purification of IgG4 and IgG1-3 was completed, it was important to 
determine the efficiency of the entire process and to test whether the samples were 
completely depleted from the complementary IgG subclasses. A MuSK cell-based 
assay was then performed on HEK 293 cells. The cells were transfected with a 
MuSK construct together with a fluorescent tag (mCherry) that gives a red 
coloration on the membrane were MuSK is expressed proving the efficacy of 
transfection. The cells were incubated with the samples containing IgG4 or IgG1-
3 in 1:20 dilution and then probed with specific secondary mouse antibodies 
directed against the different IgG subclasses. Finally, the samples were exposed to 
a tertiary green fluorescent antibody directed against mouseIgG. IgG1-3 samples 
resulted completely depleted from MuSK IgG4 (Figure 6). On the other hand, the 
IgG4 fraction still showed some positivity for MuSK IgG1-3 indicating that the 
IgG4 matrix is not completely selective (Figure 7). This should be taken into 
account in the interpretation of the results of the following experiments. 
 
 
Patient Sample Volume (ml) OD280 (µg/ml) 
1 Plasma 10 29860 
 Plasma + PBS (1:1) 20 14711 
 Flow-through IgG matrix 17.5 7842 
 Total IgG 5 6827 
 Flow-through IgG4 matrix 17.5 11378 
 IgG4 6.5 294 
 IgG1-3 5 6855 
 
2 Plasma 10 32781 
 Plasma + PBS (1:1) 20 15356 
 Flow-through IgG matrix 18 8245 
 Total IgG 7 4764 
 Flow-through IgG4 matrix 17.5 7629 
 IgG4 7 121 
 IgG1-3 5 7767 
    
3 Plasma 7.5 63617 
 Plasma + PBS (1:1) 15 36520 
 Flow-through IgG4 matrix 15 15441 
 IgG4 6 643 
 IgG1-3 7 3723 
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Figure 6. Cell-based assay of MuSK IgG1-3 antibody subclasses. HEK 293 cells were transfected 
with MuSK-mCherry (in red; A, D). Cells were exposed to MuSK IgG1-3 antibody purified from 
the three MuSK-MG patients and incubated with mouse anti-IgG1-3 (B) and anti-IgG4 (E) 
antibodies, and with a tertiary anti-mouse IgG antibody (Alexa Fluor 488 - in green). In C: merge 
picture showing a strong positivity for the presence of MuSK IgG1-3. In F: only not-specific 
binding is detectable when IgG1-3 were probed with anti-IgG4 antibody, confirming the 
effectiveness of IgG1-3 purification (Olympus IX71 fluorescence microscope - 40x 
magnifications). 
 
 
 
 
 
Figure 7. Cell-based assay of MuSK IgG4 antibody subclasses. HEK 293 cells were transfected 
with MuSK-mCherry (in red; A, D). Cells were exposed to MuSK IgG4 antibody purified from the 
three MuSK-MG patients and incubated with mouse anti-IgG4 (B) and anti-IgG1-3 (E) antibodies, 
and with a tertiary anti-mouse IgG antibody (Alexa Fluor 488 - in green). In C: merge picture 
showing a strong positivity for the presence of MuSK IgG4. In F: IgG4 fraction still showed some 
positivity for MuSK IgG1-3 indicating that the IgG4 matrix is not completely selective (Olympus 
IX71 fluorescence microscope - 40x magnifications). 
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3.1.5) Radioimmunoassay 
 Estimation of the titre of the MuSK-Ab fractions was obtained through 
radioimmunoassay (RIA) of different dilutions (from 1:10 up to 1:1280) of the 
samples from each patient, in order to determine and to standardise the amount of 
antibodies to use for the experiments. The purified IgG, IgG4 and IgG1-3 were 
incubated overnight with PTX buffer and 50 µl of MuSK labelled with 125I. 50 µl 
of anti-human IgG and 5 µl of plasma from a healthy control were then added to 
the solution to enhance immunoprecipitation. Antibody titration was performed 
also on the original plasma to evaluate the amount of antibodies lost during the 
purification process. The titre of MuSK-Abs was calculated according to the 
equation (see previous chapter “materials and methods”) using the dilution of the 
sample and the correspondent radioactive count. The reading of the negative 
control was deducted from the final count. Figure 8 shows the titration of MuSK-
Abs for each patient studied. The number of cpm reach a plateau with lower 
dilutions of the samples and this corresponds to the saturation level of the assay. 
The dilution at about half of the maximum cpm was considered the most 
appropriate point at which to estimate antibody titre. 
The titre of MuSK-Abs and the efficiency of IgG purification varied 
considerably among the patients. For example, patient 3 had a very high 
concentration of MuSK-Abs in the plasma and the counts decreased slowly as the 
dilutions increased. On the other hand, in patient 2, cpm dropped sharply after 
1:160 dilution indicating a significant lower titre of MuSK-Abs compared to the 
other patients. It is worth noting that patient 2 had the most efficient purification 
among the patients, in particular for the IgG4 subclass with a very low decrease in 
antibody titre. This could be related to the lower amount of antibodies in the 
original plasma. For the other two patients, IgG purification seemed to be much 
less efficient considering the loss of more than 10 folds of the initial antibody 
titre. Table 2 shows the summary of MuSK IgG purification of the three patients 
including the starting and final volumes, protein concentrations, and antibody 
titres. In Tables 3 and 4 all the samples’ dilutions with the corresponding cpm and 
estimation of MuSK-Abs amount (mmol) and titres (nM/ml) are shown. As 
expected, in all patients the titre of MuSK IgG4 was significantly high compared 
to IgG1-3, confirming that IgG4 is the most represented subclass in MuSK 
myasthenia. 
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Figure 8. Titration of MuSK antibodies on plasma (red), total IgG (green), IgG4 (blue) and IgG1-3 
(orange) samples from the three patients (A, B and C). Sample dilutions are indicated on the X 
axis; cpm (counts per minute) are indicated on the Y axis. 
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Table 2. Initial and final volumes with corresponding protein concentrations and estimated 
antibody titres of purified total IgG and IgG antibody subclasses for each MuSK-MG patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Titration of MuSK antibody from plasma, purified total IgG, IgG4 and IgG1-3 of patient 
#1. The dilution at about half of the maximum cpm was considered the most appropriate point at 
which to estimate antibody titre (highlighted in red). 
 
 
 
 
Patient 1 Patient 2 Patient 3 
Vol 
(ml) 
OD280 
[µg/ml] 
Titre 
(nmol/ml) 
Vol 
(ml) 
OD280 
[µg/ml] 
Titre 
(nmol/ml) 
Vol 
(ml) 
OD280 
[µg/ml] 
Titre 
(nmol/ml) 
Plasma 10 29860 11.82 10 32781 3.9 7.5 63617 27.7 
Tot IgG 5 6827 1.31 7 4764 0.84 - - - 
IgG1-3 5 6855 0.71 5 7767 0.53 7 3723 0.6 
IgG4 6.5 294 2.86 7 121 3.12 6 643 3.66 
Patient sample dilution cpm mmol Titre (nmol/ml) 
1 Plasma    1/10  22092 4.14 x 10-12 0.83 
     1/20  21924 4.11 x 10-12 1.65 
     1/40  20666 3.87 x 10-12 3.1 
     1/80  18010 3.38 x 10-12 5.4 
     1/160 15560 2.92 x 10-12 9.3 
     1/320 9843 1.84 x 10-12 11.82 
     1/640 6624 1.24 x 10-12 15.91 
  1/1280 3696 6.93 x 10-11 17.76 
 Tot IgG    1/10  12713 2.38 x 10-12 0.47 
     1/20  12243 2.29 x 10-12 0.92 
     1/40  8501 1.59 x 10-12 1.27 
     1/80  4365 8.19 x 10-11 1.31 
     1/160 2723 5.11 x 10-11 1.635 
     1/320 1183 2.22 x 10-11 1.421 
     1/640 818 1.53 x 10-11 1.965 
  1/1280 371 6.92 x 10-10 1.78 
 IgG4    1/10  6987 1.31 x 10-12 0.26 
     1/20  8844 1.65 x 10-12 0.66 
     1/40  7901 1.48 x 10-12 1.18 
     1/80  6688 1.25 x 10-12 2 
     1/160 4506 8.45 x 10-11 2.71 
     1/320 2385 4.47 x 10-11 2.86 
     1/640 1692 3.17 x 10-11 4.06 
  1/1280 999 1.87 x 10-11 4.8 
 IgG1-3    1/10  3686.2 6.91 x 10-11 0.14 
     1/20  6060.5 1.13 x 10-11 0.54 
     1/40  3792.1 7.11 x 10-11 0.56 
     1/80  2372.3 4.45 x 10-11 0.71 
     1/160 1432.3 2.68 x 10-11 0.85 
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Table 4. Titration of MuSK antibody from plasma, purified total IgG, IgG4 and IgG1-3 of patient 
#1 and #2. The dilution at about half of the maximum cpm was considered the most appropriate 
point at which to estimate antibody titre (highlighted in red). 
 
 
Patient sample dilution cpm mmol titre (nmol/ml) 
2 Plasma    1/10  19201 3.60 x 10-12 0.72 
     1/20  19465 3.65 x 10-12 1.46 
     1/40  16691 3.13 x 10-12 2.5 
     1/80  10347 1.94 x 10-12 3.1 
     1/160 6499 1.21 x 10-12 3.9 
     1/320 3643 6.83 x 10-11 4.37 
     1/640 2339 4.39 x 10-11 5.61 
  1/1280 1183 2.22 x 10-11 5.72 
 Tot IgG    1/10  12271 2.30 x 10-12 0.46 
     1/20  9209 1.72 x 10-12 0.68 
     1/40  5625 1.05 x 10-12 0.84 
     1/80  2943 5.52 x 10-11 0.88 
     1/160 1672 3.13 x 10-11 1 
     1/320 920 1.72 x 10-11 1.1 
     1/640 536 1.00 x 10-11 1.28 
  1/1280 288 5.40 x 10-10 1.38 
 IgG4 1/10 15456 6.01 x 10-12 0.58 
  1/20 16444 3.08 x 10-12 1.24 
  1/40 12572 2.35 x 10-12 1.88 
  1/80 6933 1.30 x 10-12 2.26 
  1/160 4161 7.81 x 10-11 3.12 
 IgG1-3    1/10  9138 1.71 x 10-12 0.34 
     1/20  5183 9.72 x 10-11 0.389 
     1/40  3531 6.62 x 10-11 0.53 
     1/80 1760 3.30 x 10-11 0.66 
     1/160 1252 2.34 x 10-11 0.94 
/////////////// /////////////// /////////////// /////////////// ////////////////////// //////////////////////// 
3 Plasma    1/10  22658 4.25  x 10-12 0.8 
     1/20  21298 3.99  x 10-12 1.6 
     1/40  22496 4.22 x 10-12 3.37 
     1/80  19531 3.66 x 10-12 5.8 
     1/160 18906 3.54 x 10-12 11.3 
     1/320 14306 2.68 x 10-12 17.18 
     1/640 11552 2.16 x 10-12 27.7 
  1/1280 7432 1.39 x 10-12 35.71 
 IgG4    1/10  11333 2.12 x 10-12 0.42 
     1/20  10440 1.95 x 10-12 0.78 
     1/40  9990 1.87 x 10-12 1.48 
     1/80  8646 1.62 x 10-12 2.59 
     1/160 6105 1.14 x 10-12 3.66 
     1/320 3318 6.22 x 10-12 3.98 
     1/640 1520 2.85 x 10-12 3.65 
  1/1280 971 1.82 x 10-12 4.6 
 IgG1-3    1/10  11299 2.12 x 10-12 0.42 
     1/20  7639 1.43 x 10-12 0.57 
     1/40  4485 8.41 x 10-11 0.67 
     1/80  2049 3.84 x 10-11 0.61 
     1/160 1082 2.03 x 10-11 0.64 
     1/320 253 4.74 x 10-10 0.47 
     1/640 202 3.79 x 10-10 0.48 
  1/1280 98 1.83 x 10-10 0.47 
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3.2) Experimental results 
3.2.1) SHP2 inhibition induced agrin-independent AChR clustering 
SHP2 inhibition by NSC-87877 has already been proven to induce AChR 
clustering on C2C12 myotubes independently by agrin (Zhao et al, 2007). For our 
experiments it was important to confirm these results and to titrate the effects of 
the drug on both AChR clustering and MuSK phosphorylation in order to identify 
the most efficient dose and incubation period to use in the experiments with 
MuSK-Abs. We studied first the effect of SHP2 inhibition on AChR clustering. 
Increasing concentrations of NSC-87877 were applied for 12 hours on C2C12 
myotubes and then the cells were fixed in formaldehyde and the AChR clusters 
labelled with α-bungarotoxin. The inhibition of SHP2 resulted in a dose-
dependent increase of AChR clustering (Figure 9) compared to medium alone. 
NSC-87877 had the maximal effect at around 100 µM (p<0.01 compared to 
DMEM) which was similar to that achieved by a non-saturating concentration of 
agrin (1:800). Higher concentrations of the drug did not correspond to a further 
increase in AChR clustering, indicating a saturation of the process. On the other 
hand, when myotubes were exposed to NSC-87877 100 µM together with agrin 
(1:800), the combined effect of the two compounds led to an increase in the 
number of clusters (p<0.001 against DMEM) compared to that observed after 
incubation with agrin or SHP2 inhibitor alone (Figure 10A, B). 
 
 
 
 
 
 
 
 
 
 
Figure 9. Dose-effect titration curve of NSC-87877 on AChR clustering performed on C2C12 
myotubes. The maximal effect was reached at a dose of 100 µM. On the X axis: increasing 
concentration of NSC-87877. On the Y axis: average number of AChR clusters per microscopic 
field. 
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Figure 10. Effects of NSC-87877 (100 µM) on AChR clustering, in the presence and absence of 
agrin. In A: AChR clusters after incubation with DMEM, agrin (1:800), NSC-87877 (100 µM), 
and agrin plus NSC-87877 on C2C12 myotubes (Olympus IX71 fluorescence microscope - 20x 
magnifications). In B: bar chart showing a significant increase of AChR clusters after incubation 
with NSC-87877 (100 µM) and with NSC-87877 (100 µM) combined with agrin (1:800) 
compared to DMEM only (p<0.01 and p<0.001 respectively; one-way ANOVA; n=3). No 
significant difference was observed between NSC-87877 and agrin alone.  
 
 
3.2.2) NSC-87877 increases MuSK phosphorylation  
To show that the SHP2 inhibitor was acting through MuSK phosphorylation, 
increasing concentrations of NSC-87877 (1 µM, 10 µM, 100 µM, 200 µM) were 
applied to C2C12 myotubes for 40 minutes. After incubation, myotubes were 
lysed in cold lysis buffer to preserve protein phosphorylation and MuSK was 
immunoprecipitated with Protein G magnetic beads pre-incubated with a 
commercial anti-MuSK-Ab. MuSK phosphorylation was determined by western 
blotting, probing the precipitate with a monoclonal antibody specific for 
phosphotyrosine. Phosphorylation level was normalised to MuSK expression, 
detected with a commercial anti-MuSK-Ab on the same blot. Agrin (1:800) was 
used as a positive control and results were compared with DMEM only. 
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Figure 11. Effects of NSC-87877 on MuSK phosphorylation. In A: example of western blot 
showing, in the first row, the level of phospho-tyrosine MuSK and, in the second row, the 
corresponding MuSK expression. Normalised densitometry values of phosphorylated MuSK, 
obtained by pooling the results of at least 3 different experiments, are represented in the bar charts 
(B and C). In B: dose-dependent increase of MuSK phosphorylation after incubation with NSC-
87877 with maximal effect at 100 µM (p<0.01; one-way ANOVA; n=6). In C: effects of NSC-
87877 (100 µM) in the presence and absence of agrin (1:800). The combined effect of NSC-87877 
(100 µM) and agrin (1:800) caused a significant increase of MuSK phosphorylation compared to 
DMEM (p<0.0001), agrin (p<0.01) and NSC-87877 (0<001) alone (one-way ANOVA: n=3).  
 
 
 
Consistently with the results observed on AChR clustering, a significant 
increase of MuSK phosphorylation (p<0.01) was observed after incubation with 
NSC-87877 at 100 µM and 200 µM in the absence of agrin (Figure 11A, B). 
There was no significant difference between the level of MuSK phosphorylation 
induced by the SHP2 inhibitor at 100 µM or agrin (1:800), but the combined 
exposure to both NSC-87877 and agrin caused an increase in MuSK 
phosphorylation significantly higher compared to each one of the two compounds 
alone (p<0.05 against agrin; p<0.01 against NSC-87877; p<0.0001 against 
DMEM) (Figure 11C). Thus, SHP2 inhibition increased MuSK phosphorylation 
both alone and in the presence of agrin as shown for AChR clustering. 
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3.2.3) MuSK phosphorylation time-course 
Once it was clear that NSC-87877 was able to induce its maximum effect on both 
AChR clustering and MuSK phosphorylation at a dose of 100 µM, we studied the 
variation of MuSK phosphorylation over time in order to identify the best 
temporal interval to perform the experiments with MuSK-Abs. 
C2C12 myotubes were exposed over 15 minutes to 6 hours to NSC-87877 100 
µM, in presence and absence of agrin (1:800). Myotubes were lysed and MuSK 
immunoprecipitated at the end of each time interval (15, 40, 90, 180 and 360 
minutes). MuSK phosphorylation levels were analyzed by western blotting as 
describe previously (Figure 12A). The maximum effect was consistently observed 
between 40 and 90 minutes (Figure 12B, in green) which was similar to the results 
of agrin alone (red) or both agrin and NSC-87877 (blue). The combined action of 
agrin and NSC-87877 did not make the MuSK phosphorylation process faster 
despite the overall increase in phosphorylation level. The submaximal incubation 
time of 40 minutes was chosen for the following experiments in order to allow the 
detection of subtle changes in MuSK phosphorylation caused by MuSK-Abs. 
 
 
Figure 12. MuSK phosphorylation time-course. In A: western blot examples showing phospho-
tyrosine bands and corresponding MuSK expression after incubation with agrin (1:800), in the 
presence and absence of NSC-87877 (100 µM) at different time intervals (from 15 minutes to 6 
hours). In B: variations over time of MuSK phosphorylation (normalised densitometry analysis 
from 3 different experiments) after exposure to agrin (1:800) (red), NSC-87877 (100 µM) (green) 
and agrin (1:800) combined with NSC-87877 (100 µM) (blue). All the different compounds 
showed a similar time-course reaching the maximum effect between 40 and 90 minutes and 
decreasing progressively after 180 and 360 minutes. The incubation with agrin and NSC-87877 
did not induce a faster phosphorylation of MuSK phosphorylation despite an overall increase in 
phosphorylation levels.  
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3.2.4) SHP2 inhibition counteracts the effects of MuSK-Abs on both MuSK 
phosphorylation and AChR clustering 
The main question was to ask whether SHP2 inhibition was able to increase 
MuSK phosphorylation and AChR clustering in the presence of MuSK-Abs and, 
therefore, to counteract their pathological effects. C2C12 myotubes were 
incubated with 0.5 nM of purified total MuSK-IgG, IgG1-3 and IgG4 form 
patients 1 and 2 together with agrin (1:800), in the presence and absence of NSC-
87877 100 µM. After 40 minutes of exposure, the cells were lysed and incubated 
with protein G magnetic beads in order to immunoprecipate MuSK using directly 
the antibodies from the patients. Levels of MuSK phosphorylation were analysed 
by western blotting as previously described. 
We observed that MuSK-IgG and IgG4 were able to prevent MuSK 
phosphorylation in the presence of agrin, consistently with that reported by 
Huijbers in 2013. Consequently, the level of MuSK phosphorylation was not 
significantly increased in the samples exposed to total IgG and IgG4 compared to 
DMEM. In both cases, the addition of NSC-87877 caused a dramatic increase in 
MuSK phosphorylation overwhelming the inhibitory effects of MuSK-Abs 
(p<0.0001) (Figure 13A, B). On the other hand, MuSK phosphorylation was not 
affected by IgG1-3 and, even more interestingly, the SHP inhibition did not show 
any effect on MuSK phosphorylation when incubated with IgG1-3 MuSK-Abs. In 
Table 5 are shown the densitometry results of each experiments divided 
accordingly to the patients’ sample used. 
 
To further confirm the pathogenic effects of the antibodies and the potential 
therapeutic properties of SHP2 inhibition observed in the MuSK phosphorylation 
experiments, an AChR clustering assay was performed incubating the myotubes 
with total IgG purified from patient 1 and the different IgG subclasses purified 
from patient 3. The myotubes were exposed to 0.5 nM of each IgG subclass (the 
same amount used for the phosphorylation assay) for 30 minutes. Then, agrin 
(1:800) and NSC-87877 100 µM were added to the medium. As described above, 
the cells were incubated overnight with the different compounds and then fixed in 
formaldehyde and labelled with fluorescent α-bungarotoxin. 
Total IgG, IgG1-3 and IgG4 all prevented the formation of AChR clusters 
despite the presence of agrin with a significant reduction of cluster numbers in the 
myotubes incubated with MuSK-Abs compared to agrin alone (p<0.0001). This 
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confirms the previous observation from Koneczny and colleagues in 2013 that all 
MuSK IgG subclasses have pathological effect including IgG1-3. Finally, and in 
contrast to the lack of effect on phosphorylation, SHP2 inhibition by NSC-87877 
increased AChR clustering in all the samples (p<0.01 compared to total IgG, 
p<0.05 to IgG1-3, p<0.001 to IgG4) further demonstrating its protective effect 
(Figure 14A, B). 
 
 
 
Figure 13. Effects of the different MuSK IgG antibody subclasses and NSC-87877 on MuSK 
phosphorylation. In A: western blot example showing, in the first row, the level of phospho-
tyrosine MuSK and, in the second row, the corresponding MuSK expression after incubation with 
0.5 nM of MuSK total IgG, IgG1-3, and IgG4, with agrin (1:800) and in the presence and absence 
of NSC-87877 (100 µM). In B: bar chart representing normalised densitometry values of 
phosphorylated MuSK, obtained by pooling the results of at least 3 different experiments. In the 
samples incubated with MuSK total IgG and IgG4, MuSK phosphorylation did not increase 
significantly compared to DMEM. However, once the myotubes were exposed to NSC-87877 (100 
µM), SHP2 inhibition induced a significant increase of MuSK phosphorylation despite the 
presence of MuSK antibodies (p<0.0001; one-way ANOVA; n≥3). IgG1-3 did not prevent MuSK 
phosphorylation in the presence of agrin stimulation and NSC-87877 did not show any effect (one-
way ANOVA; n=3). 
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Figure 14. Effects of the different MuSK IgG antibody subclasses and NSC-87877 on AChR 
clustering. In A: AChR clusters after overnight incubation with MuSK total IgG, IgG1-3, and 
IgG4, with agrin (1:800) and in the presence and absence of NSC-87877 (100 µM) on C2C12 
myotubes (Olympus IX71 fluorescence microscope - 20x magnifications). In B: bar chart 
representing AChR cluster counts per microscopic field, obtained by pooling the results of 3 
different experiments. MuSK total IgG, IgG1-3 and IgG4 inhibited the formation of AChR clusters 
in the presence of agrin. However, once the myotubes were exposed to NSC-87877 (100 µM), 
SHP2 inhibition induced a significant increase in AChR clustering despite the presence of MuSK 
antibodies (p<0.01 compared to total IgG, p<0.05 to IgG1-3, p<0.001 to IgG4; one-way ANOVA; 
n=3). 
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Patient 
Total IgG + 
agrin 
Total IgG + 
agrin + 
NSC-87877 
IgG1-3 + 
agrin 
IgG1-3 + 
agrin + 
NSC-87877 
IgG4 + 
agrin 
IgG4 + 
agrin + 
NSC-87877 
1 
0.38 1.87 - - 0.12 1.7 
0.39 1.68 1.01 1.02 0.25 2.35 
0.65 1.44 1.07 0.75 0.6 1.31 
2 
0.46 0.96 1.24 0.79 0.28 1.3 
0.35 1.5 - - 0.35 2.5 
- - - - 0.25 1.08 
 
Table 5. Normalised level of MuSK phosphorylation in western blot analysis after incubation with 
MuSK total IgG, IgG1-3 and IgG4 from patient #1 and #2 in the presence and absence of NSC-
87877 (100 µM). The results represent the ratio between the densitometry values of phospho-
tyrosine-MuSK and MuSK expression of each experiment conducted on the two different MuSK-
MG patients. 
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Chapter 4 
Discussion 
 
Within the different forms of myasthenia gravis, the one associated with 
MuSK-Abs often represents a difficult clinical challenge for its correct 
management and treatment. MuSK patients are generally more severe compared 
to those affected by AChR-myasthenia as they present more frequently bulbar 
involvement and with a higher incidence of life-threatening respiratory crises. 
Moreover, they often do not respond well to symptomatic therapy with 
cholinesterase inhibitors while high dose of steroids and other immunosuppressant 
drugs are required for long-term treatment. Therefore, the development of a 
therapy that acts specifically on the pathological mechanisms of the disease would 
be important in order to achieve a better and stable control of the symptoms and to 
decrease the risk of side effects. 
Targeting the intracellular regulators of the AChR clustering pathway 
represents a novel and specific therapeutic strategy in myasthenic syndromes with 
either autoimmune or genetic pathogenesis. There are several proteins in the 
pathway downstream of MuSK that could be potential pharmacological targets 
including Abl tyrosine kinases and GTPases of the Rho family. However, 
increasing the activity of these regulators in order to enhance AChR clustering 
could lead to the development of tumours as many of them play an important role 
in favouring cell-growth signalling. On the other hand, SH2 domain-containing 
phosphatase (SHP2) seems to be a safer target. In physiological conditions, 
through a negative-feedback loop, SHP2 reduces the phosphorylation of MuSK, 
helping to control the formation of AChR clusters at the neuromuscular synapses. 
SHP2 also activates cell replication through different pathways such as Ras/Erk, 
PI3K, AKT, and JAK-STAT. For these reasons, inhibition of SHP2 would have 
the combined positive effect to increase AChR clustering/density and, at the same 
time, to reduce the risk of tumorigenesis. In fact, pharmacological inhibition of 
SHP2 has already demonstrated efficacy in the treatment of mouse tumour 
xenograft models and a glioma mouse model (Bunda et al, 2015). 
With respect to MuSK myasthenia, MuSK-Abs, that are mainly of the IgG4 
subclass, inhibit MuSK activation by blocking its interaction with LRP4. This 
leads to a reduced MuSK phosphorylation and to the inhibition of downstream 
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signalling which is essential for maintaining the high density of acetylcholine 
receptors at the neuromuscular junction. The selective inhibition of SHP2 by the 
drug NSC-87877 has been previously shown to increase AChR clustering in 
C2C12 myotubes in either the presence or absence of agrin (Zhao et al 2007). 
Therefore, SHP2 inhibition would be able to activate MuSK, independently by 
agrin, removing the negative restraint of its physiological regulator and to 
overcome the effects of MuSK-Abs. 
In the first part of our study, we analysed the effect of NSC-87877 on MuSK 
phosphorylation and AChR clustering in order to determine which concentrations 
and incubation times were the most appropriate to use in the experiments with 
MuSK-Abs. We consistently observed that NSC-87877 showed a dose-dependent 
increase of both MuSK phosphorylation and AChR clustering reaching the 
maximal effect at a concentration of 100 µM. A further increase of the dose did 
not correspond to any additional responses suggesting that a saturation of the 
effect was reached. Furthermore, once we looked at the phosphorylation time-
course, we observed that both NSC-87877 and agrin determined a similar MuSK 
phosphorylation pattern activating MuSK early after the beginning of stimulation 
(between 15 and 40 minutes), reaching the peak level after 90 minutes and then 
decreasing progressively to the basal condition during the following 6 hours. It is 
worth noting that NSC-87877 and agrin, when incubated together on the 
myotubes, induced a combined and more powerful effect on both MuSK 
phosphorylation and AChR clustering. This is not surprising considering that 
agrin and SHP2 inhibition stimulate MuSK in two different and complementary 
ways to create a cooperative effect in the activation of AChR clustering pathway. 
NSC-87877 was then tested on C2C12 myotubes in the presence of purified 
MuSK total IgG and IgG subclasses. SHP2 inhibition significantly increased 
MuSK phosphorylation despite the presence of MuSK total IgG and IgG4, and 
prevented the dispersal of AChR clusters in all the samples. Our experiments 
further confirmed that inhibition of MuSK activation represents the main 
pathogenic mechanism of the IgG4 subclass as they block agrin-LRP4 interaction 
with MuSK. The removal of the physiologic inhibition of SHP2 by NSC-87877 is 
sufficient to activate the autophosphorylation loop of MuSK directly on its 
intracytoplasmic domain and, therefore, initiates the phosphorylation cascade 
resulting in AChR clustering (Figure 15). 
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Figure 15. Representation of the effects of SHP2 inhibition by NSC-87877 on the AChR clustering 
pathway. In A: MuSK antibodies block LRP4-MuSK interaction preventing MuSK 
phosphorylation and causing the dispersal of AChR clusters. In B: SHP2 physiologically 
downregulates MuSK activation inducing dispersal of AChR clusters in extrasynaptic sites. In C: 
NSC-87877 inhibits SHP2 and increases MuSK phosphorylation activating AChR pathway despite 
the presence of MuSK antibodies. 
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Consistently with the finding of Koneczny and colleagues, MuSK IgG1-3 also 
showed pathogenic potential although the mechanism by which they work is still 
unclear. According to our results, IgG1-3 did to not reduce MuSK 
phosphorylation although they were still able to disperse AChR clusters. The 
reliability of these observations on MuSK phosphorylation, however, has to be 
verified as MuSK immunoprecipitation with IgG1-3 was very difficult to obtain 
compared to total IgG and IgG4, and only worked well in a minority of the 
experiments. This could be due in part to a minor affinity of IgG1-3 to MuSK 
leading to a less stable binding during the immunoprecipitation process. 
Nevertheless, if IgG1-3 are pathogenic without reducing MuSK phosphorylation, 
one possible explanation is that, due to their divalent binding, IgG1-3 could 
restrain MuSK in an abnormal dimer configuration resulting in a pathologically 
phosphorylated state. This could lead to an abnormal interaction with the 
downstream players of the AChR pathway, in particular Dok7. Interestingly, a 
congenital myasthenic syndrome associated with a missense mutation 
(p.Met835Val) in the MuSK kinase domain has been reported (Ammar et al, 
2013). This mutation increases basal MuSK phosphorylation and impaired co-
immunoprecipitation of MuSK and Dok7 when both proteins were transfected in 
HEK 293 cells. Although NSC-87877 did not modify significantly MuSK 
phosphorylation in the myotubes incubated with MuSK IgG1-3, the drug was still 
able to prevent the dispersal of AChR clusters induced by the antibodies. It is 
possible that the inhibition of SHP2 restores a more physiological phosphorylation 
of MuSK and, therefore, favouring binding and activation of Dok7 with the 
reactivation of the downstream clustering pathway. Thus, regardless of the IgG 
subclass of the antibodies, or the mechanisms by which they work, SHP2 
inhibition could provide a novel pharmacological treatment for MuSK-MG. 
Finally, would NSC-87877 have other “off target” effects that might be 
detrimental? NSC-87877 represents currently the most specific compound to 
inhibit selectively SHP2 activity through the binding to its catalytic cleft. 
However, NSC-87877 inhibits other phosphatases, in particular SHP1 and, with 
less affinity, DUSP26 (Chen et al, 2006; Song et al, 2009). Nevertheless, it is 
worth noting that SHP2 expression is readily detected in C2C12 myotubes and its 
role in AChR clustering is well established (Madhavan et al, 2005; Zhao et al, 
2007) whilst neither SHP1 nor DUSP26 have been reported to be involved in 
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AChR clustering, suggesting that the effects we observed were specific to SHP2 
inhibition.  The use of this drug in animal models of MuSK-MG is justified as a 
proof of principle that inhibition of this phosphatase can provide a 
pharmacological, relatively rapid treatment for MuSK-MG. 
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Conclusions 
 
MuSK-MG is a treatable disease but, despite the progress of our understanding 
on its pathogenesis and the advanced multiple ways of treatment, we still lack of a 
specific therapy able to counteract directly the mechanisms that cause the 
symptoms. Modulating the activity of the intracellular regulators of AChR 
clustering pathway could represent an important first step in the development of a 
specific treatment. In particular, the phosphatase SHP2, that physiologically 
reduce MuSK activation, could be an effective and potentially safe protein to 
target.  
Our in vitro results suggest that inhibition of SHP2 by the drug NSC-87877 is 
able to cause a dose-dependent increase of both MuSK phosphorylation and 
AChR clustering. More importantly, these effects are maintained in the presence 
of MuSK-Abs providing an initial but solid evidence of the potential efficacy of 
this strategy in the treatment of MuSK-MG. 
Our findings open a wide range of possibilities for the future developments of 
our research. First, it would be important to test SHP2 inhibition in an animal 
model of MuSK myasthenia in order to verify its efficacy and reliability in vivo. 
Moreover, SHP2 inhibition could be effective also in other disorders that impair 
neuromuscular transmission (in particular congenital myasthenic syndromes) and 
therefore its efficacy in models of different diseases should be studied. These 
steps are fundamental in order to develop specific and safe therapies for use in 
clinical practice. 
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